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ABSTRACT 
The ability to identify melanoma patients with progressive disease is central to efficient management. 
The challenge therefore, is to develop prognostic markers and techniques which will allow the 
identification of those patients whom, at the time of primary tumor diagnosis, already have 
micrometastases (occult or clinically undetectable metastases). 
The use of the reverse transcription-PCR (RT-PCR) technique for the detection of circulating 
melanoma cells (CMCs) is potentially a powerful tool for identifying those patients at risk for 
developing metastases. The first aim of this study was to develop a more sensitive, reproducible, cost 
effective and clinically applicable assay and to eliminate the problem of false positives. A combined 
RT-PCR assay for tyrosinase mRNA, a marker specific for melanoma cells, was developed and 
. 
tested. It was shown that the assay can reproducibly detect a single, viable melanoma cell in 10-15 ml 
of peripheral blood. Furthermore, a simple but effective procedure was developed to prevent carry-
over contamination. It was found that the chance of obtaining normal melanocyte contamination with 
the needle prick during blood sampling was only 2% and that illegitimate transcription does not 
contribute to sporadic false positives. 
The second aim of this study was to determine whether the early detection of CMCs is of any clinical 
value to monitor melanoma progression. Peripheral blood samples from 143 patients with primary 
melanoma (PM) were analysed by RT-PCR for the presence of tyrosinase mRNA. Seven percent 
( 10/143) of the patients with PM had detectable CMCs. The percentage of PCR-positive patients was 
higher for stage II patients (9.0%) compared to stage I (5.3%) but the difference was not significant. A 
significantly higher percentage (P < 0.05) PCR-positive patients were found to have tumors greater 
than 1.5 mm thick and with ulceration present. Although this finding supports the notion that tumor 
thickness and ulceration are the two most significant prognostic factors, it was not possible at this 
stage, to link this directly to a poor prognosis since the majority of the PCR-positive patients have not 
yet (within four years) developed metastatic disease. However, the data does indicate that cells from 
tumors greater than 1.5 mm thick and with ulceration have a greater propensity to enter the circulation 
but that these cells do not necessarily have the ability to establish metastases. The results suggest 
that the detection rate of 9% for patients with stage II disease is much lower than would be expected, 
since 23.9% (16/67) of the stage II patients subsequently developed metastases. Of these 16 patients, 
only one was PCR-positive, one week before the metastases became clinically evident. Thus, the 
current technique fails to predict the likelihood of developing metastatic disease (P = 0.3485). The 
other nine PCR-positive patients had not yet developed metastases after a median follow-up period of 
xvi 
four years. It is concluded that the current technique for the detection of CMCs is of limited clinical 
value to predict the likelihood of metastasis in patients with PM. It is suggested that other anatomic 
compartments, such as sentinel lymph nodes, should be explored for the identification of patients at 
risk for developing metastases. 
The third aim of this study was to determine whether high or low plasma levels and/or activity of 
plasminogen activator inhibitor type 1 (PAI 1) correlate with the presence of metastatic disease in 
patients with melanoma. PAI 1 is considered to be the main regulator of fibrinolytic activity in blood and 
has been identified as a key enzyme in the metastasis and vascularization of solid tumors. A unique 
enzyme-linked immunosorbant assay was developed to measure both the total amount of PA11 in 
plasma as well as the active fraction of the inhibitor. This novel assay was then used to analyse and 
compare the plasmatic PAl1 levels and activity of a group of patients with advanced melanoma (AM) 
with a group of patients with primary disease and a control population. There was no statistical 
. 
difference in the total plasmatic PAl1 levels between the controls and patients with PM and AM 
(P = 0.6199). In contrast, there was a significant difference in the active fraction of PAl1 between the 
controls and patients with PM or AM (P = 0.0076). A value of less than 44% active PAl1 was shown to 
be clinically meaningful by linear discriminant analysis. This means that a melanoma patient with a 
plasmatic PAI 1 activity value less than 44% will have a 50% chance of harbouring metastases. Of the 
patients with PM, 19% had PAI 1 activity values less than 44%, which strongly supports further 
investigations to determine whether plasmatic PAl1 activity levels might be predictive of metastatic 
disease. The false positive rate was 2.6%. It is speculated that this reduction in the active fraction of 
PAI 1 for patients with AM might be attributed to tumor-derived tissue plasminogen activator and/or 
other melanoma-derived proteases or factors. 
The last section of this study describes several monoclonal antibodies (Mabs) that were developed 
against PAl1 in order to obtain useful reagents to study the regulatory functions of PAl1 in the 
metastasis and vascularization of solid tumors. The baculovirus expression system was used to 
express human PAl1 in insect cells and the crude infected cell population was used as the 
immunogen in mice. This approach was followed since the Escherichia coli-derived recombinant 
molecule elicited a poor immune response. A unique panel of anti-PAl1 Mabs was developed that 
were characterized with regard to their use for immunoblotting, immunofluorescence and 
immunocytochemistry. One of these antibodies blocked the binding of PAI 1 to vitronectin and inhibited 
the activity of the inhibitor. Finally, two of these Mabs turned out to be extremely valuable and were 
used to develop a novel microtiter plate assay for measuring the active fraction of PAl1 in biological 
fluids by making use of Mabs against different epitopes of PAI 1. 
!SECTION Aj 
CHAPTER 1: LITERATURE REVIEW 
MOLECULAR DETECTION OF CIRCULATING MELANOMA CELLS 
1.1 Introduction 
Cutaneous melanoma is a potentially lethal tumor that arises from epidermal melanocyte 
transformation. The main factor involved in the etiology of melanoma is environmental exposure to 
ultraviolet B-range (280-320 nm) irradiation (reviewed by Koh, 1991) although genetic components 
have also been implicated (reviewed by Chin et al., 1998; Kraehn et al., 1995). Data from the 
United States show a consistent 6% annual increase in the incidence of melanoma and a 2% 
annual increase in mortality since the 1950's (reviewed by Rigel, 1997). It has been speculated 
that the depletion of the earth's ozone layer and the consequent increase in UV radiation may 
contribute to the increased incidence of melanoma (Fitzpatrick, 1996; Moan & Dahlback, 1992). 
The lifetime risk for developing melanoma in the United States has increased from 1 in 250 in 1980 
to 1 in 87 in 1996 and is estimated to be 1 in 75 by the year 2000. In Cape Town (South Africa) the 
overall incidence is 24.4 per 100 000 per annum which is almost as high as in Australia (Saxe et 
al., 1998). These alarming figures emphasise the need for more effective prevention, detection and 
treatment strategies. 
The thickness of the primary tumor is currently the most important parameter for predicting the 
metastatic phenotype (reviewed by Garrison & Nathanson, 1996). The 5-year survival rate for 
patients with thin tumors (less than 1.5 mm) is 85%, whereas for patients with thick tumors (greater 
than 4 mm), it is only 46% (Morton et al., 1993). Various other clinico-pathological parameters have 
been implicated as prognostic factors for melanoma namely, in descending order of significance, 
ulceration, anatomical site of the primary tumor and the pathological stage (reviewed by Balch et 
al., 1992; Beahrs et al., 1992). However, these factors do not provide the clinician with sufficient 
prognostic information, especially during the advanced stages of the disease. Patients with thin 
tumors may nevertheless die of melanoma and patients with thick tumors may experience long-
term disease-free survival. Those patients with tumors of intermediate thickness (1.5 ~ ::s; 4.0) 
present the greatest prognostic challenge since surgical excision will cure some while others will 
die of metastates in spite of complete excision of the primary tumor. 
Current techniques for the detection of metastatic disease rely on clinical manifestations (reviewed 
by Rigel et al., 1986; Romero et al., 1994), imaging studies (reviewed by Berman & Reintgen, 
1993; Neal & Hoskin, 1997) and serum marker assays (reviewed by Provost et al., 1997; Weiss et 
al., 1995). The success of these techniques is dependant on a critical minimum tumor mass. The 
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clinical reality reveals that widespread systemic metastasis may be well underway long before the 
tumor is detectable with these techniques (Crowley & Seigler, 1992). The challenge therefore, is to 
develop prognostic markers and techniques which will allow the identification of those patients 
whom, at the time of primary tumor diagnosis, already have micrometastases. Such markers and 
techniques will have the potential to identify those patients at risk for developing widespread 
macrometastatic disease. It will also justify more expensive adjuvant therapies and more intensive 
surveillance. Most importantly, it will permit therapeutic intervention (surgical, radiation and/or 
systemic) prior to the appearance of macrometastases. The development of a successful 
melanoma vaccine (reviewed by Pardall, 1998; Sakai et al., 1997) would benefit from techniques 
which could identify micrometastases, since it is unlikely that immunotherapy will have much 
success in patients with a large tumor burden (McNamara et al., 1998; Staveley et al., 1998). In 
addition, the economic implications of new treatment modalities such as tumor vaccines and 
chemotherapy, are likely to dictate that they be offered primarily to those patients at high risk. 
The ability to identify patients with progressive disease is central to efficient management. This 
section of the thesis reviews the literature with regard to the use of reverse transcription-
polymerase chain reaction (RT-PCR) technology for the detection of micrometastatic disease 
(occult or clinically undetectable metastases) in patients with primary melanoma (PM). The clinical 
value of applying this technology on tissue from different secondary sites, including peripheral 
blood (PB), bone marrow (BM) and lymph nodes (LNs), will be discussed. 
1.2 The detection of metastatic cells in peripheral blood (PB) 
The detection of circulating tumor cells (CTCs) in PB using RT-PCR technology was initially 
described for hematopoietic malignancies (Kawasaki et al., 1988). The detection of CTCs has been 
associated with poor outcome in malignant lymphoma (Gribben et al., 1994) and in chronic 
myelogenous leukemia (Roth et al., 1992). The use of PCR technology for the detection of CTCs 
has been recently reviewed for various carcinomas, including colorectal, abdominal, urinary tract, 
prostate and breast cancers (Raj et al., 1998) as well as melanoma (Jung et al., 1996; Keilholz, 
1998; Pelkey et al., 1996). 
In general, the blood vessels and the lymphatics are the main routes whereby tumor cells 
metastasize to distant organs (Hart & Saini, 1992; Morton et al., 1993). The detection of circulating 
melanoma cells (CMCs) by the amplification of tyrosinase mRNA was initially proposed by Smith et 
al. (1991). In view of the fact that RT-PCR is so highly specific and sensitive, the detection of 
CMCs by RT-PCR has the potential for being superior to conventional serum marker assays 
(Provost et al., 1997) for the prediction of metastatic disease. This is because serum markers are 
dependant on a critical minimum tumor mass and not necessarily the metastatic potential of the 
melanoma cells. 
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Tyrosinase, the key enzyme in melanin biosynthesis, catalyzes the hydroxylation of tyrosine to 3,4-
dihydroxy-phenylalanine (DOPA) and ultimately to DOPAquinone. It is one of the most specific 
markers of melanocytic differentiation and is only expressed by melanocytes, Schwann cells and 
melanoma cells (Battyani et al., 1993). The detection of CMCs by RT-PCR relies on the fact that 
melanocytes and Schwann cells are not normally present in the blood, that peripheral blood 
lymphocytes (PBL) do not express tyrosinase and that the majority of melanoma tumors express 
tyrosinase. The procedure involves 30 PCR amplification rounds with external oligonucleotide 
primer pairs, followed by another 30 amplification rounds with internal primer pairs (Smith et al., 
1991). A sensitivity of one melanoma cell (most often SK-Mel-28 melanoma cell line) in a 
background of 106 (Kunter et al., 1996) to 107 (Glaser et al., 1997) PBL is obtained with this 
protocol. The PCR primers are placed within different exons of the tyrosinase gene to eliminate the 
amplification of contaminating genomic DNA in the RNA sample. Van der Velde-Zimmermann et al. 
(1996) reported a modified pair of internal primers to improve the specificity of the assay. 
The initial experiments on the detection of CMCs by RT-PCR for tyrosinase mRNA raised 
somewhat false hopes for using the technique to predict metastatic disease. The detection rates 
varied between 17% (Brossart et al., 1993) and 91% (Hoon et al., 1995) for patients with stage II 
melanoma, between 35% (Brossart et al., 1993) and 86% (Hoon et al., 1995) with stage Ill 
melanoma and between 50% (Battayani et al., 1995) and almost 100% (Brossart et al., 1993; Hoon 
et al., 1995; Mellado et al., 1996) with stage IV melanoma. In contrast, other research groups 
reported that the assay was of limited or no clinical value in the prediction of metastatic disease. 
Their detection rates were considerably lower than reported earlier and varied between 0% 
(Reinhold et al., 1997) and 13% (Farthmann et al., 1998) for patients with stage II melanoma, 
between 0% (Reinhold et al., 1997) and 17% (Farthmann et al., 1998) with stage Ill melanoma and 
between 13% (Pittman et al., 1996) and 44% (Farthmann et al., 1998) with stage IV melanoma. 
Several factors could have contributed to these highly contradictory results. First, the number of 
patients studied within each stage was often too low and could have biased the results. For 
example, Hoon et al. (1995) reported 10 of 11 (91 %) stage II patients to be positive for CMCs, 
compared to 6 of 46 (13%) stage II patients as reported by Farthmann et al. (1998). 
Secondly, the assay technique used by the different investigators differed substantially. This has 
resulted in different sensitivities (varying from one to ten melanoma cells per 10 ml blood) and 
emphasizes the need for quality standards between laboratories (Keilholz et al., 1998). 
Thirdly, unrecognized carry-over PCR contamination might be the main culprit in producing these 
contradictory results. A high level of contamination will raise the baseline detection rate and mask 
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the true results. The introduction of effective procedures to prevent carry-over contamination 
should be of high priority, since the generation of false positive tests could result in confusing and 
potentially harmful information. Carry-over contamination which is often associated with nested-
PCR reactions, seems to be a major stumbling block for successful clinical application. To reduce 
the contamination risk, Pittmann et al. (1996) developed a single 50-cycle PCR reaction which was 
as sensitive as the previously described nested-PCR method (Smith et al., 1991). This was also 
the rationale of a 40-cycle PCR-ECL system recently described (0' Connell et al., 1998). General 
guidelines to limit the contamination risk have been reviewed extensively elsewhere (Belak & 
Ballagi-Pordany, 1993; Kwok & Higuchi, 1989; Sarkar & Sommer, 1990; Verkaik et al., 1997; 
Walder et al., 1993). 
A fourth possible reason for the contradictory results is the phenomenon of illegitimate transcription 
- the fact that any gene may be transcribed at a very low level in any cell type (Chelly et al., 1989). 
This implies that a positive RT-PCR reaction could be the result of very low-level ubiquitous 
tyrosinase transcription from PBL. In fact, Smith et al. (1991) have suggested that increasing the 
number of nested-PCR cycles from 30 to 40 could contribute to false positive results. Sufficient 
evidence for this phenomenon has been obtained from a study where RT-PCR for CK19 mRNA 
was used to detect breast cancer micrometastases in lymph nodes (Schoenfeld et al., 1994). It 
was concluded that the optimal cut-off point to distinguish involved nodes from metastasis-free 
nodes remained at the level of 40 PCR cycles when compared to a two-stage amplification (total of 
60 cycles) with nested primers. 
A fifth possible reason for the contradictory results from different studies is that there might also be 
false positives arising from the existence of melanocyte-specific pseudogenes (Oetting et al., 1993; 
Takeda et al., 1991). The tyrosinase pseudogene contains sequences that correspond to exons 4 
and 5 of the tyrosinase gene (Giebel et al., 1991). However, the oligonucleotides used for 
amplification of tyrosinase mRNA overlap exons 1, 2 and 3 of the tyrosinase gene (Smith et al., 
1991) and theoretically could therefore not create a false positive result. The possibility of false 
GAPDH signals as a result of the presence of GAPDH pseudogenes (Keilholz, 1998; Willhauck et 
al., 1998) could also contribute to discrepant results. If the PCR is generated off pseudogene 
genomic DNA, this would give a false impression of good RNA quality, leading to incorrect 
deductions regarding the tyrosinase detection rate. The omission of reverse transcriptase from a 
control RT-PCR reaction should determine the contribution of pseudogenes in creating false 
positive results. 
The last possible cause of false positives could be contamination with normal melanocytes 
obtained from a skin plug during blood sampling. To circumvent this problem it was suggested that 
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the first vacutainer containing a few millilitres of blood should be discarded to avoid skin plug 
contamination when venipuncture is performed (Foss et al., 1995). 
5 
Besides the potential value of the RT-PCR assay to predict metastasis, the quantitation of CMCs 
has also been proposed as a possible means to monitor the efficacy of immunotherapy in patients 
with AM (Brossart et al., 1995). This was conducted by comparing the amplified tyrosinase signal 
with a corresponding signal of diluted SK-Mel-28 cells. In 50 patients with AM, the strength of the 
amplified tyrosinase signal in PB correlated with the tumor burden. In patients that responded to 
immunotherapy a statistically significant decrease of the tyrosinase signal was observed, whereas 
in patients with stable disease the signal was unchanged. However, the results obtained with this 
approach were based on the assumption that an equivalent level of tyrosinase expression in tumor 
cells (in vivo) compared to tested SK-Mel-28 cells (in vitro) rather than a precise number of an 
individual patient's tumor cells. As a result of this study, different assay systems for the quantitation 
of CMCs have been proposed. In one such system, a competitive RT-PCR assay for tyrosinase 
mRNA was developed with heterologous DNA as an internal standard (Curry et al., 1996). In 
another, an electrochemiluminescence (ECL) system was developed to verify the specificity and to 
improve quantitation of tyrosinase PCR product in PB (0' Connell et al., 1998). This system 
involves the use of rTth (Juhasz et al., 1996) for reverse transcription and PCR, followed by 
hybridization of the biotinylated PCR product to a tris (2,2'-bipyridine) ruthenium (II) (TBR) chelate-
labeled oligonucleotide probe. The resulting hybrid is captured on magnetic beads for activation of 
the TBR and quantitation by ECL. A sensitivity of one to ten melanoma cells in a background of 107 
B231 breast cancer cells was obtained with a single 40-cycle PCR reaction. In their pilot study, 
they could detect tyrosinase mRNA in the PB from 7 of 16 melanoma patients, whereas none of 
the 5 normal controls were positive. 
A number of investigators have attempted to correlate the presence of CMCs to histological 
criteria, but the results from these studies reveal a number of contradictions. Whereas some 
groups found that the presence of CMCs seemed to correlate with the clinical stage (Curry et al., 
1998; Farthmann et al., 1998; Mellado et al., 1996) and the thickness of the primary tumor (Curry 
et al., 1998; Farthmann et al., 1998), other groups found no correlation between the presence of 
CMCs and the clinical stage (Ghossein et al., 1998) or the thickness of the primary tumor (Hoon et 
al., 1995; Mellado et al., 1996). In a recent comprehensive study by Farthmann et al. (1998), 
CMCs were detected in 13% (6/46) of patients with stage II disease, 17% (7/41) with stage Ill 
disease and 44% (16/36) with stage IV disease. Positive results were obtained more frequently in 
(a) men compared with women, (b) patients with thick primary melanomas(> 4 mm, 38%) 
compared with those with thinner tumors (1.1 to 4 mm, 22%; ~ 1 mm, 5%), and (c) patients with 
non-classifiable (38%), nodular (34%), and occult primary melanomas (30%) compared with those 
with acrolentiginous (17%), superficial spreading (9%), or lentigo maligna melanoma (0%). 
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In terms of the predictive value of the assay, Curry et al. (1998) assessed the value of tyrosinase 
and Mart-1 as mRNA markers for the detection of CMCs in 276 stages I, II and Ill melanoma 
patients. The presence of CMCs was assessed in relation to multiple time periods before and after 
surgical removal of the primary tumor. Fourteen percent of the patients who were negative before 
surgery became positive in the 3 months after surgery. From this finding it was concluded that the 
surgical manipulation itself may cause shedding of melanoma cells into the circulation. Sixty-five 
percent of the patients who were positive before surgery became negative in tests conducted in the 
first 3 months after surgery. The tests were most frequently positive in the first 3 months after 
surgery and declined in frequency thereafter. It was therefore concluded that tests conducted in the 
first 3 months after surgery may have the best chance of detecting patients who might 
subsequently develop recurrent disease. Of the 276 patients with stages I, II and Ill disease 
studied, 123 were followed up for 18 months of which 47 (38.2%) recurred. Of these with recurrent 
disease, 66% were positive within 3 months of surgery so that 34% of the recurrences were not 
predicted by the tests. Assays for tyrosinase alone predicted recurrence in 51% of patients and 
Mart-1 alone in 21 %. For patients with stage Ill disease, the tests were positive in 73% of those 
with a recurrence. The false-negative results led the authors to question the reliability of the assay 
for selection of patients for adjuvant therapy. Approximately 35% of 76 patients who had not had a 
recurrence, had positive tests in samples taken within 3 months of surgery and more than 60% in 
tests conducted over the 12-month period. However, it was too early to assess whether these 
represent false-positive results. It was therefore concluded that it seems most likely that a large 
proportion of patients with PM in whom CMCs are detected, is the result of sporadic shedding of 
melanoma cells into the circulation. 
In this regard, it is imperative to understand that various factors play essential roles in the 
successful establishment of metastases (reviewed by Fidler, 1996). These include, the capability of 
melanoma cells to survive the flow forces of the blood (Fidler, 1990), their proteolytic capacity to 
cross anatomic barriers (reviewed by Andreasen et al., 1997; Mignatti & Rifkin, 1993), expression 
of cell adhesion molecules (reviewed by Albelda, 1993; Pignatelli & Stamp, 1995), increased cell 
motility (reviewed by Danen et al., 1995), growth and colonization potential (reviewed by Fidler, 
1990; Halaban, 1996), induction of angiogenesis (reviewed by Fidler & Ellis, 1994; Hanahan & 
Folkman, 1996) and the host immune response (reviewed by Cella et al., 1997; Shresta et al., 
1998). In addition, animal studies have demonstrated that between 102 to 106 tumor cells need to 
be introduced into the circulation to obtain a 50-100% chance of forming a single metastasis and 
that the formation of tumor emboli is an equally important factor promoting the formation of 
metastases (Glaves, 1983). Animal studies also indicate that less than 0.01 % of circulating tumor 
cells eventually survive to produce metastases (Liotta & Stetler-Stevenson, 1991 ). Thus, although 
the presence of CMCs seems to correlate with the clinical stage and the thickness of the primary 
tumor (Curry et al., 1998; Farthmann et al., 1998), its value to predict metastatic spread before 
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clinically detectable metastases are evident, remains elusive and needs to be assessed more 
extensively. 
1.3 The detection of metastatic cells in bone marrow (BM) 
7 
The BM, like the lymph nodes (LNs), could act as clearing sites for normal and tumorigenic cells 
(Raj et al., 1998). Brossart el al. (1994) made the first attempt to analyse PB samples and BM 
aspirates from 28 patients with AM for the presence of metastatic cells prior to and after therapy 
with interferon alpha-2b and interleukin-2. All 28 patients, including those with no clinical evidence 
of disease after treatment, were RT-PCR positivite for tyrosinase mRNA in their blood and BMs, 
prior to and after immunotherapy. Recently, a more comprehensive study evaluated the prognostic 
value of the RT-PCR assay for the detection of metastatic melanoma cells in PB and BMs of 
patients with stages II to IV melanoma (Ghossein et al., 1998). Overall, 19% of the 123 patients 
had tyrosinase mRNA in their blood and/or BMs. The PCR-positivity was slightly higher for BMs 
(16.5%) than for PB (12%) and neither correlated with the clinical stage. Within stage 11, BM PCR-
positive patients had a shorter median survival than BM PCR-negative patients. However, BM 
PCR-positivity was not predictive of overall survival in the whole population studied. In contrast, 
blood PCR-positivity showed a statistically significant correlation with decreased overall survival in 
stages II and Ill, but was not a predictor of overall survival in stage IV. Multivariate analysis showed 
that blood PCR-positivity was independent of clinical stage in predicting overall survival. The PCR-
positivity for stage II patients was twice as high for BM aspirates (25%) as for PB (12.5%). Thus it 
seems, that BM aspirates are more useful than small blood samples for predicting metastasis in 
patients with PM. 
1.4 The detection of metastatic cells in lymph nodes (LNs) 
The LNs may act as clearing sites for normal and tumorigenic cells. Therefore, the presence of 
micrometastases in LNs may signal the functional effectiveness of the immune system in filtering 
and clearing the CTCs (Raj et al., 1998). The presence of clinically evident LN metastases is 
currently the most powerful prognostic factor for predicting survival (Drepper et al., 1993; Reintgen 
et al., 1983). If metastases are present, the 5-year survival rate decreases by 50% and other 
variables based on the primary tumor are of little prognostic value. Approximately 20% of clinically 
node-negative patients harbour micrometastases in regional draining lymph nodes (Reintgen et al., 
1994). These patients will have an 85% risk of harbouring micrometastases at distant visceral 
sites, which will most likely develop into fatal metastases. Thus, the molecular detection of 
micrometastases in LNs seems to be potentially useful in the clinical setting. 
Until now, routine examination of LNs has been done using standard histopathology with 
hematoxylin-eosin staining and/or immunohistochemistry (IHC) with S100 and HMB45 antibodies 
(Cochran et al., 1988). However, IHC (especially serial sectioning) is a time-consuming and 
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expensive technique, prone to human errors, subject to individual interpretation and is not 
particularly sensitive. In addition, standard clinical and pathological evaluations of the regional LNs 
underestimate the number of patients with micrometastases by 25-30% (reviewed by Cochran, 
1997). Wang et al. (1994) investigated the use of the RT-PCR technique for the detection of 
micrometastases in LN biopsies. They analysed the LNs of 29 patients with intermediate thickness 
PM that underwent elective LN dissections, by standard pathological staining and RT-PCR for 
tyrosinase mRNA. Thirty eight percent of the samples were pathologically positive and 66% were 
RT-PCR positive and these included all of the pathologically positive samples, so that the false-
negative rate was zero (Wang et al., 1994). However, elective LN dissection is a controversial 
procedure because the majority of dissected LNs are reported to be tumor free (Drepper et al., 
1993). Morton et al. (1992) introduced an intra-operative mapping procedure to identify the sentinel 
lymph node (SLN). The SLN is the first node in the lymphatic basin that drains the primary tumor 
and is known to be the first possible site of metastatic disease (Morton et al., 1992). The rationale 
is that if the SLN is negative for metastatic cells, then the remainder of the nodes are also 
expected to be negative and the patient will most likely be free of metastatic disease (Godellas et 
al., 1995; Reintgen et al., 1994). Therefore, only those patients with positive SLNs would require a 
complete LN dissection, sparing those with negative SLNs the morbidity associated with this 
procedure. A 98% success rate has now been obtained for the SLN mapping technique by using a 
combination of a vital blue dye and 99mTechnetium-sulfur colloid (reviewed by Brady & Coit, 1997; 
Karakousis et al., 1997; Leong et al., 1997; Morton, 1997; Reintgen, 1997; Ross, 1997; Thompson, 
1997). 
In a pilot study (Van der Velde-Zimmermann et al., 1996), 28 LNs derived from 4 patients after 
lymphadenectomy and 12 patients after SLN resection, were evaluated for micrometastases using 
RT-PCR for tyrosinase mRNA. lmmunohistochemistry revealed positivity in 10 LNs from the 4 
patients with lymphadenectomy. RT-PCR analysis detected an additional 6 positive SLNs which 
were otherwise histologically negative. The 5 LNs from patients with other diseases, were RT-PCR 
negative. In a more recent study (Joseph et al., 1997), the SLNs of 583 patients, having primary 
melanoma but no evidence of regional or systemic disease, were analysed for micrometastases 
over a 4-year period. Micrometastases was detected in the SLNs of 64 patients (11 %). Of these, 
73.8% was identified by routine histological staining, 7.8% with serial sectioning and the additional 
18.4% with IHC. SLNs from a subset of 29 patients were analysed with RT-PCR for tyrosinase 
mRNA and compared with routine histology. Of these patients, 38% of the SLNs were histologically 
positive compared to a 66% RT-PCR positivity, which included all pathologically positive samples. 
In a similar study among 48 patients negative by immunohistochemical assessment, 21 (44%) had 
nodal micrometastases using RT-PCR analysis for tyrosinase mRNA (Blaheta et al., 1998). All 68 
LNs from 46 non-melanoma patients serving as negative controls, were tyrosinase RT-PCR 
negative. Additional support for the detection of micrometastases in SLNs by molecular analysis 
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was recently obtained (Shivers et al., 1998). They also show a recurrence rate among 13% of the 
patients that were upstaged by RT-PCR analysis after a relative short average follow-up period of 
28 months. 
Peripheral support for the SLN-mapping technique and the use of RT-PCR analysis to improve 
disease staging and the detection rate of micrometastases was recently provided by Gershenwald 
et al. (1998). Of 243 patients with histologically negative SLNs, 27 (11%) developed nodal and/or 
distant metastases after a median follow-up time of 35 months. Ten of these patients developed 
nodal recurrences in the previously mapped basins which were histologically negative. Detailed 
analysis of the SLNs by serial sectioning demonstrated evidence of occult metastases in 80% of 
the cases (Gershenwald et al., 1998). In addition, since node dissection offers increased survival 
for patients with node metastases only, Cascinelli et al. (1998) support SLN biopsy as a tool to 
identify patients with occult node metastases, who could then undergo node dissection (Cascinelli 
eta/., 1998). 
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Thus, SLN mapping and RT-PCR analysis are potentially powerful tools to identify micrometastatic 
disease in patients with PM that are otherwise clinically free of metastases. Patients with a positive 
SLN would then be eligible for a complete LN dissection and interferon alpha-2b therapy. In 
combination with adjuvant therapy, this strategy has the potential to provide more accurate staging 
for the melanoma patient, at lower costs for the health care system and a lower morbidity for the 
patient (Joseph et al., 1997). However, tyrosinase transcripts have been reported to be present in 
normal LNs, possibly from Schwann cell origin (Battyani et al., 1993) although a recent and more 
thorough study reported the controversy (Blaheta et al., 1998). Therefore, large clinical studies with 
appropriate and sufficient negative controls and with additional melanocytic and/or tumor-specific 
markers, must be pursued before clinical application. 
1.5 General and specific aims of study 
As described in the literature review, the early detection of CMCs in patients with PM using 
molecular techniques, is potentially a powerful tool for identifying those patients at risk for 
developing metastases. The original method, as described by Smith et al. (1991), is based on the 
amplification of the mRNA for tyrosinase, an enzyme specific to melanocytes. Unfortunately, the 
assay is laborious, expensive, not reproducible and not sensitive enough. The extraction of RNA 
from large quantities of blood (more than 1 ml) with potent, but costly, RNase inhibitory reagents 
such as guanidine isothiocyanate, and the separation of reverse transcriptase and PCR reactions 
in separate tubes, makes it an extremely laborious and expensive assay. In addition, the problem 
of false positives, either due to contamination with amplicons (Foss et al., 1995), illegitimate 
transcription (Chelly et al., 1989; Smith et al., 1991) or contamination with normal melanocytes 
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obtained by the needle prick during blood collection (Foss et al., 1995), are potential stumbling 
blocks for successful clinical application. 
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The broad aim of the present study was to develop a more sensitive, reproducible, cost effective 
and clinically applicable assay and to eliminate the problem of false positives. The second broad 
aim was to make use of this assay to test blood samples from patients with PM and to evaluate the 
results in relation to various clinical and histological criteria. 
The specific aims of the study were: 
• to eliminate the possibility that the needle prick during blood collection could result in false 
positives due to contamination of the blood sample with normal skin melanocytes. A large 
number of controls were screened to determine the false positive rate. 
• to address the problem of illegitimate transcription. Blood samples from controls were 
subjected to increasing numbers of first-round and second-round (nested) PCR cycles and 
analysed for the presence of false positives. 
• to develop a simple and effective procedure to prevent carry-over contamination. 
• to determine whether the early detection of CMCs will allow the identification of patients at 
risk for developing metastases. A large number of patients that presented with PM were 
screened for the presence of CMCs (using the "in-house" standardized RT-PCR assay for 
tyrosinase mRNA) and the findings were correlated with the outcome of the disease. 
• to established whether there was a correlation between the presence of CMCs and various 
histological criteria, including tumor thickness, ulceration and Clark's level of invasion. 
• to establish whether blood sampling at different time points would improve the detection rate. 
Multiple blood samples were collected with intervals from two to twelve months and analysed 
in terms of number of times tested. 
11 
CHAPTER 2: MATERIALS AND METHODS 
2.1 Tissue culture 
The melanoma cell lines UCT-Mel-1 to 6 were established in the Department of Clinical Science 
and Immunology from patient tumors as described before (Hoal-Van Heiden et al., 1986). The 
human melanoma cell lines SK-Mel-1 and SK-Mel-28 were obtained from the American Type 
Culture Collection. The cells were maintained in RPMI 1640 medium supplemented with 10% 
fetal calf serum, 50 U/ml penicillin and 20 µg/ml streptomycin at 37°C under 5% C02'95% air and 
90% humidity (see A.1 -A.5 for details). UCT-Mel-1 and -2, and SK-Mel-1 and -28 were 
classified as pigmented cell lines, while UCT-Mel-3, -4, -5 and -6 were classified as non-
pigmented cell lines according to the visual detection of pigment. 
2.2 Sample preparation 
Duplicate 10-15 ml samples of heparinized blood from a normal control, were combined with 100, 
10 or one human melanoma cell(s) from the different pigmented or non-pigmented cell lines. The 
introduction of one melanoma cell to the blood sample was achieved by plating approximately 
two cells per well of a microtiter plate. The cells were allowed to settle for one hour at 37°C. Each 
well was viewed with phase contrast microscopy (100x) and those containing a single, viable cell 
were marked and the cell transferred with a Pasteur pipette to the blood sample. The well was 
then viewed again to confirm that the cell had been transferred. 
2.3 RNA extraction 
Efficient erythrocyte lysis of each 10-15 ml blood sample was obtained by the addition of 35-
40 ml cold TE-buffer (10 mM Tris, pH 7.5 and 1 mM EDTA, pH 8) for 3-5 min on ice. The 
lymphocytes(+/- melanoma cells) were centrifuged at 700 g for 5 min and the total RNA was 
extracted from the cell pellet according to a rapid extraction method described before (Xie & 
Rothblum, 1991 ). The average yield per 10 ml blood was 30 µg total RNA and the 002601280 ratio 
was >1.5 and <1.8. Each sample was stored in 5 µg aliquots in 10 µI diethyl pyrocarbonate 
(DEPC)-treated water (under mineral oil) at -80°C. Samples were thawed only once for RT-PCR. 
(see A.6 -A.11 for details) 
2.4 RT-PCR 
All RNA samples were incubated at 90°C for 5 mins and then snap-cooled on ice to eliminate 
mRNA secondary structure. Combined RT-PCR was achieved by adding 40 µI RT-PCR mix 
containing 1 x PCR-buffer (10 mM Tris, pH 8.3 and 50 mM KCI), 1.5 mM MgCl2, 250 µM of each 
deoxynucleotide triphosphate (dNTP, Baeringer and Mannheim, Germany), 30 pmol sense 
(HTYR1) and anti-sense (HTYR2) outer primers for human tyrosinase, 20 U RNase inhibitor 
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(Baeringer and Mannheim, Germany), 10 U Moloney-murine leukemia virus reverse transcriptase 
(MMLV-RTase, Superscript II RNase H- from Gibco, Grand Island, NY) and 2.5 U 
ThermoprimePLus DNA polymerase (Advanced Biotechnologies, Surrey, UK). Synthesis of 
complimentary DNA (cDNA) was completed at 37°C for one hour. This was directly followed by 
30 PCR cycles with an initial denaturation at 94 °C for 60 sec. All subsequent cycles were carried 
out at 94°c for 15 sec (denaturation), 55°C for 30 sec (annealing) and 72°C for 30 sec 
(extention). The PCR was performed with a water-based cycler fitted with a 3000 Watt element. 
The second round of amplification was carried out by adding 5 µI of a 1/100 dilution (opening only 
one tube at a time) from the first 30 cycles of amplification to 20 µI PCR mix containing 1x PCR-
buffer, 1.5 mM MgCl2, 200 µM of each dNTP, 30 pmol sense (HTYR3) and anti-sense (HTYR4) 
nested primers for human tyrosinase and 1 U ThermoprimePLus DNA polymerase as final 
concentrations. The previous step was carried out by using aerosol resistant tips (Molecular Bio-
Products, USA) only. Thirty PCR cycles were performed as described above, except that the 
initial extended denaturation was omitted. The final reaction product (207 bp fragment) was 
visualized on a 1.5% agarose gel with ethidium bromide (0.5 µg/ml) staining (see A.12 - A.14 for 
details). 
The integrity of the RNA of each sample was verified by RT-PCR with primers (Battyani et al., 
1993) for human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The RT-PCR mix 
(40 µI), as described above for the first-round of amplification but with sense and anti-sense 
GAP DH primers, was added to 1 µg total RNA in 10 µI DE PC-treated water and subjected to 
cDNA synthesis and 30 PCR cycles as described above for the first PCR profile. 
2.5 Oligonucleotide primers 
The outer and nested primers for human tyrosinase were synthesized by the department of 
Biochemistry (University of Cape Town) using an automated process. The sequences were as 
previously described (Smith et al., 1991 ). They included: 
outer sense HTYR1 (5' TTGGCAGATTGTCTGTAGCC 3'); 
outer anti-sense HTYR2 (5' AGGCATTGTGCATGCTGCTT 3'); 
inner sense HTYR3 (5' GTCTTTATGCAATGGAACGC 3') and 
inner anti-sense HTYR4 (5' GCTATCCCAGT AAGTGGACT 3') primers. 
The primers for human GAPDH were a modification of those as described before (Battyani et al., 
1993). They included the sense GAPDH (5' ACGGATTTGGTCGTATTGGG 3') and anti-sense 
GAP DH (5' AGGGATGA TGTTCTGGAGAG 3') primers. GAPDH was the choice for the internal 
control since it is expressed in almost all types of cells and tissues (Battyani et al., 1993; Taylor & 
Heasman, 1994). 
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2.6 Laboratory precautions 
Gloves were worn at all times, disposable tubes were used where possible, a separate set of 
Gilson pipettes were designated to each separate area, all solutions were treated with 0.01 % 
DEPC or prepared with DEPC-treated water and all chemicals were of the finest grade available. 
Blood samples were processed for erythrocyte lysis in a vertical laminar flow in 50 ml conical 
polypropylene disposable tubes. The tubes with the lymphocyte pellets were then transferred to a 
separate "RNase-free" area for the extraction of total RNA. The preparation of RT-PCR reaction 
mixtures were carried out in a separate room fitted with a glass cabinet and ultra violet 
sterilization. After the first 30 PCR cycles, the reaction products were cooled to 4 °C and the 
diluted products were then transferred to the nested reaction mix in a separate room fitted with a 
fume hood. The final PCR products were cooled to 4 °C and analysed by electrophoresis in a 
separate room also fitted with a fume hood. 
2. 7 Patients 
A total of 410 blood samples from 181 melanoma patients attending the Groote Schuur Hospital 
Melanoma Clinic were examined for the presence of metastatic cells. Control blood samples were 
collected from 50 South Africans with no history of skin cancer. The study was approved by the 
Ethics and Research Committee of the University of Cape Town. Written and informed consent 
was obtained from all patients before they entered into the study. 
The clinical staging was based on the TNM classification system as agreed upon by the 
International Union Against Cancer and the American Joint Committee on Cancer (reviewed by 
Garrison & Nathanson, 1996). There were 10 patients with stage O (in situ melanomas), 76 
patients with stage I (pT1 and pT2), 67 patients with stage II (pT3 and pT4), 10 patients with stage 
Ill (regional nodal involvement), 12 patients with stage IV (distant metastasis) and 6 patients with 
uveal melanoma. Standard histological criteria were recorded, including: Location of primary and 
secondary tumors, number of lesions per site, morphological type, tumor length and width, 
Breslow's tumor thickness, Clark's level of invasion, ulceration, pigmentation, evidence of 
regression, presence of satellites, invasion of vascular and/or lymphatic spaces, symptoms 
suggestive of metastasis and evidence of metastasis on the chest radiograph. 
2.8 Blood preparation 
Blood samples were drawn at the time of primary tumor diagnosis and thereafter, if possible, at two 
to 12 month intervals. Ten to 15 ml samples of heparinized blood were collected from each patient. 
The first few milliliters of each blood sample was discarded to avoid possible contamination by 
normal skin melanocytes. Blood samples were processed within 2 to 3 hours after collection. The 
RNA extraction, yield and RT-PCR procedures were as described and all neccesary steps were 
taken to prevent carry-over contamination. For each reaction, 5 µg of total RNA was analysed in a 
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50 µI combined RT-PCR reaction mix, followed by the second round nested PCR. A negative 
(normal blood RNA) and a positive control (RNA from normal blood containing one SK-Mel-28 
melanoma cell) were included with each batch of samples to verify a contamination-free 
environment and a faultless RT-PCR operating system. The integrity of the RNA for each sample 
was verified by RT-PCR with primers for GAPDH as described before (see 2.4 and 2.5). 
2.9 Statistical analysis 
14 
Fisher's exact test for 2 x 2 tables was used to assess the significance (P < 0.05) between RT-
PCR results (coded as positive or negative) and disease stage (stage I versus stage II), tumor 
thickness(:=; 1.5 mm versus> 1.5 mm), ulceration (present versus absent), Clark's level of vertical 
invasion (Clark IV versus Clark V) and metastases (present versus absent). Pearson's Chi-analysis 
was used to assess the significance between disease stage (I versus II) and metastases (present 
versus absent). All data analyses were performed with the Epi Info Version 6.01 software (USO, 
Inc., Stone Mountain, GA). 
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CHAPTER 3 
3.1 TECHNICAL RES UL TS AND DISCUSSION 
3.1.1 Sensitivity and reproducibility 
The primary aim of the first part of this study was to develop a sensitive, reproducible, cost 
effective and clinically applicable RT-PCR assay for tyrosinase mRNA. Duplicate 10-15 ml blood 
samples from controls were combined with 100, 10 or one melanoma cell(s) from different 
pigmented or non-pigmented melanoma cell lines. The RT-PCR assay enabled the detection of 
seven out of eight melanoma cell lines but with different degrees of sensitivity (Figure 3.1, 207 bp 
fragment). All four of the pigmented melanoma cell lines, SK-Mel-1 and -28, UCT-Mel-1 and -2 
(Figure 3.1A and 3.18), as well as one of the non-pigmented cell lines UCT-Mel-3 (Figure 3.1 C), 
could be detected at one cell per 10-15 ml blood. This is equivalent to one melanoma cell in a 
background of 1 to 5 x 107 lymphocytes. A lower level of sensitivity was obtained with the non-
pigmented cell lines, UCT-Mel-4, -5 and -6 (Figure 3.1 C and 3.1 D). This is most likely the result 
of reduced tyrosinase mRNA levels in these cell lines. Only 100 and 10 UCT-Mel-5 cells and 100 
UCT-Mel-6 cells could be detected per blood sample. UCT-Mel-4 was completely negative at 100 
cells per blood sample. Similar results were obtained in two independent experiments. 
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Figure 3.1. Combined RT-PCR for tyrosinase mRNA of eight melanoma cell lines. A, SK-Mel-1 
and SK-Mel-28. B, UCT-Mel-1 and UCT-Mel-2. C, UCT-Mel-3 and UCT-Mel-4. D, UCT-Mel-5 and 
UCT-Mel-6. Lane m, plasmid pKT279 digested with Hinf I. Lane a and b, one melanoma cell per 
10-15 ml blood. Lane c, ten melanoma cells per 10-15 ml blood. Lane d, one hundred melanoma 
cells per 10-15 ml blood. Lane n, control blood sample containing no melanoma cells. Each 
sample tested positive for the presence of intact RNA using combined RT-PCR for GAPDH (results not shown). 
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These results suggest that this assay is superior to previously described methods in the following 
respects: First, a single melanoma cell could be detected in 10-15 ml blood, while previous 
publications (Brossart et al., 1993; Foss et al., 1995; Kunter et al., 1996; Mellado et al., 1996; 
Pittman et al., 1996; Smith et al., 1991) reported a sensitivity of 2 to 10 SK-Mel-28 cells in 10 ml 
blood. Secondly, the assay is highly reproducible, since a single, viable melanoma cell could be 
detected in duplicate blood samples in five out of eight melanoma cell lines tested. Thirdly, 
efficient erythrocyte lysis eliminates the use of large volumes of RNA extraction buffer and it 
would appear that the lysis step does not significantly reduce the survival of the melanoma cells 
in the blood samples. The assay is therefore more economical and clinically applicable since less 
reagents and consumables are used. Fourthly, rapid total RNA extraction with multiple sample 
processing (up to 12 samples) are easily performed within 2-3 hours. Lastly, combining reverse 
transcription and PCR in one reaction tube simplifies the technique, minimizes the unnecessary 
handling of samples and is more economical since less reagents and consumables are used. 
The results obtained with a number of thermocyclers suggest that PCR profiles should be 
optimized for every individual thermocycler. In general, shorter denaturation times, will extend the 
half-life of the DNA polymerase and consequently increase the product yield. The RoboCycler of 
Stratagene was found to be not suitable for obtaining a sensitive RT-PCR assay for tyrosinase. 
Water-cyclers produce a temperature gradient with cooling and heating of the water. The 
annealing efficiency of primer pairs with different melting temperatures will be favoured by the 
temperature gradient and therefore produce greater sensitivity. In contrast, the RoboCycler of 
Stratagene, which operates with static heat-blocks and a robot arm, transfer samples quickly from 
one temperature to another. The shorter temperature gradient generated by the RoboCycler most 
likely reduces the efficiency of primer annealing. 
3.1.2 Contamination with normal melanocytes 
One of the specific aims of the present study was to investigate the possibility that the needle 
prick during blood collection could result in the contamination of blood samples with normal 
melanocytes. Fifty controls were screened for the presence of false tyrosinase signals. One of the 
50 controls was positive for tyrosinase mRNA. Subsequent blood samples from this control was 
negative for tyrosinase mRNA and no clinical evidence of the disease could be found. The results 
therefore indicate a 2% chance of obtaining normal melanocyte contamination among all skin 
categories. This 2% risk factor could most likely be eliminated by rejecting the first few milliliters 
of blood taken from the patient. 
To confirm that the above failure to detect false positives was not due to poor quality RNA, each 
normal control sample was also subjected to combined RT-PCR for GAPDH. Figure 3.2 
represents nine of the 50 controls. A specific 600 bp fragment for GAP DH was obtained for each 
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control after cDNA synthesis and 30 cycles of PCR. These results therefore indicate that the 
rapid total RNA extraction method used in this study (Xie & Rothblum, 1991) is sufficient to obtain 
good quality, intact RNA for RT-PCR. 
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Figure 3.2. Combined RT-PCR for GAPDH mRNA. Fourty-nine of the 50 controls were negative for tyrosinase mRNA, indicating that there was a 2% chance of obtaining normal melanocytes 
contamination during blood sampling (results not shown). Therefore each control was tested for 
the presence of intact RNA by combined RT-PCR for GAPDH (600 bp fragment) of which nine (lanes a-i) are shown here. Lane m, plasmid pKT279 digested with Hinf I. 
3.1.3 Illegitimate transcription 
Because of the phenomenon of illegitimate transcription (Chelly et al., 1989; Smith et al., 1991) 
that is, that any gene may be transcribed at a very low level in any cell type, it is possible that a 
positive RT-PCR reaction could be the result of very low-level ubiquitous tyrosinase transcription 
from the different blood cell types. In order to investigate this phenomenon, RNA from ten 
controls (10-15 ml blood samples) were subjected to 30 or 40 first-round PCR cycles followed by 
either 30 or 40 second-round (nested) PCR cycles. Figure 3.3 demonstrates that every control 
was still negative after 30 or 40 first-round and 30 or 40 second-round PCR cycles. A gradual 
increase in the non-specific background was obtained after 40 cycles, but no specific product was 
generated. The positive control generated a specific tyrosinase product (207 bp fragment) with a 
slight increase in the yield after 40 nested PCR cycles (Figure 3.3.A, lane a). It was therefore 
concluded that the phenomenon of illegitimate transcription mentioned by Smith et al. (1991) 
obtained after 40 nested PCR cycles for tyrosinase, was most likely the consequence of carry-
over contamination resulting from long-term amplicon accumulation in the laboratory atmosphere. 
Detection of CMCs: Technical results and discussion 
m a b C a b C a b C 
Figure 3.3. Combined RT-PCR for tyrosinase mRNA of ten controls to test for illegitimate transcription. A, forty first-round and 40 second-round PCR cycles. B, forty first-round and 30 
second-round PCR cycles. C, thirty first-round and 40 second-round PCR cycles. Lane m, plasmid pKT279 digested with Hint I. Lane a, ten to 15 ml blood combined with a single SK-Mel-28 cell as a positive control. Lane b and c, two of the ten controls. 
3.1.4 Carry-over contamination 
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Various methods and tools have been tested to prevent and to eliminate false positive results that 
can arise from carry-over contamination (Belak & Ballagi-Pordany, 1993; Kwok & Higuchi, 1989; 
Sarkar & Sommer, 1990; Walder et al., 1993). It was found that the pre-cooling of the PCR 
reaction product and the use of fume hoods, before and after the nested PCR reaction, will 
induce condensation of volatile amplicons and will prevent the release of amplicons in the 
laboratory atmosphere, respectively. In addition, the use of aerosol-resistant tips before the 
nested PCR reaction and application of the general precautions as outlined in Materials and 
Methods (see 2.6) will prevent carry-over contamination. Not a single false positive in more than 
200 reactions was obtained after applying strict contamination precautions as described and by 
following the optimized PCR profile. However, some false positives was obtained when the 
general precautions were not applied. Therefore, it is imperative to include a negative and a 
positive control with each batch of patient samples to verify a contamination-free environment 
and a faultless RT-PCR operating system. 
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3.1.5 Reverse transcriptase activity 
The efficiency of reverse transcription was tested by titrating the concentration of MMLV-RTase 
from 80 to 5 Units (two-fold dilutions) in a 50 µI reaction (results not shown). As little as 5 Units of 
the Superscript II RNase H- MMLV-RTase was sufficient to obtain complete reverse transcription 
after one hour at 37°C. A ratio of four parts RTase (10 Units) to one part DNA polymerase (2.5 
Units) was found to be the most effective combination. The RTase from Gibco was chosen 
among other MMLV-RTases, since it carries a point mutation to remove endogeneous RNase H 
activity which doesn't affect the reverse transcriptase activity. In addition, it was found to be the 
most cost effective RTase, since 1 Ox more units of RTase had to be used with those enzymes 
which carry the deletion to remove endogeneous RNase H activity. 
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3.2 CLINICAL RESULTS 
3.2.1 Correlation between the presence of CMCs and clinical stage 
It was first determined whether there was a correlation between clinical stage of disease and the 
presence of CMCs. Overall , 11 of 181 patients (6.0%) had detectable melanoma cells in their blood 
as measured by RT-PCR for tyrosinase mRNA. This included four patients (5.3%) with stage I 
disease, six (9.0%) with stage II disease and one (16.7%) with uveal melanoma (Figure 3.4). The 
difference between the number of PCR-positive patients for stages I and II was not statistically 
significant (P = 0.2958). Surprisingly, none of the 22 stage Ill and IV patients were PCR-positive. 
Negative and positive controls confirmed a contamination-free environment and faultless RT-PCR 
reactions respectively. RNA integrity was confirmed in each sample with GAPDH amplification. 
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Figure 3.4. RT-PCR results in relation to clinical stage and metastases. (D) The number of patients studied within each stage; ( ) the number of PCR-positive patients 
within each stage (P = 0.2958 for stages I and II); (•) the number of patients that subsequently developed metastatic disease (P = 0.0004 for stages I and II); (•) the number of patients that 
tested PCR-positive in relation to those that subsequently developed metastatic disease. 
3.2.2 Correlation between the presence of CMCs and metastases 
Correlations between patients with PM and those that subsequently developed metastases 
(regional nodal and systemic) were carried out (Figure 3.4). It was found that two (2.6%) of the 
stage I patients, 16 (23.9%) of the stage II patients and two (33.3%) of the uveal melanoma 
patients subsequently developed metastatic disease (P = 0.0004 for stage I versus stage II). The 
mean intervals between primary tumor diagnosis and clinically detectable disease were as follows: 
Detection of CMCs: Clinical results 21 
Twenty-eight months for the two stage I patients, 13 months for 15 of the 16 stage II patients (with 
the exception of one stage II patient which had an interval of six years) and four months for the two 
uveal melanoma patients. Surprisingly, only one (tumor thickness= 5 mm, Clark= IV and 
ulcerated) of the 16 stage II patients and one of the two uveal melanoma patients were PCR-
positive before clinically detectable metastases became evident. Both these patients had visceral 
metastases, implying haematogenous rather than lymphatic metastasis. Both patients (Table 3.2: 
patients no's 9 and 6) tested positive shortly before (one week and three months respectively) the 
metastases became clinically evident and both died of metastases within three months after the 
positive PCR tests were obtained. There was no correlation between the PCR-positive patients 
and the development of metastases (P = 0.3485). Each of the other nine PCR-positive patients 
have been followed-up for a median period of 4 years without clinical evidence of metastases to 
date (Table 3.2). 
3.2.3 Correlation between the presence of CMCs and histological parameters 
It was next determined whether the presence of CMCs correlated with any histological parameters. 
Correlation to tumor thickness (Figure 3.5) revealed that a higher percentage of PCR-positive 
patients (11 .9%) had tumors greater than 1.5 mm thick compared to 3.3% with tumors less than 
1.5 mm thick. The difference was statistically significant (P = 0.0442). This correlates with our 
finding (Figure 3.1) that a significantly higher percentage (23.9%, P = 0.0004) of stage II patients 
(tumor thickness > 1.5 mm) subsequently developed metastases compared to only 2.6% of stage I 
patients (tumor thickness < 1.5 mm). 
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Figure 3.5. Correlation between PCR-positive patients and Breslow's tumor thickness. (D) The 
number of patients studied for the two main tumor thickness categories; (•) The number of PCR-
positive patients for each category with the line graph (-A-) representing the percentages. The 
difference between the two tumor thickness categories was statistically significant (P = 0.0442). 
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The percentage of PCR-positive patients was approximately 5% for Clark's levels II , Ill and IV with 
a higher frequency (21.4%) for Clark's level V (Figure 3.6). The difference between Clark's levels 
IV and V approached significance (P = 0.06) . A statistically significant relationship (P = 0.0252) 
was found between patients with ulcerated tumors and the presence of CMCs (Table 3.1 ). Fifty 
percent (5/10) of the PCR-positive patients with cutaneous melanoma had ulcerated tumors 
compared to only 19.4% of the total population studied. All five patients with ulcerated tumors had 
tumor thicknesses greater than 1.5 mm. There was no correlation between PCR-positive patients 
and other histological parameters such as the presence of satellites, invasion of vascular and/or 
lymphatic spaces, signs of regression, symptoms suggestive of metastasis or the presence of 
metastases on chest radiographs. 
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Figure 3.6. Correlation between PCR-positive patients and Clark's level of invasion. (D) The 
number of patients studied for each level of invasion; <•) The number of PCR-positive patients for 
each level of invasion with the line graph (-.._-) representing the percentages. The difference 
between Clark's level IV and V approached significance (P = 0.06). 
Table 3.1. RT-PCR results in relation to histological criteria. 
Histological criteria 1PCR-positive 2Group totals 
5 (14.7) 
1 (25.0) 
1 (9.1) 
2 (7.1) 
10 
34 (19.4) 
4 (2.3) 
11 (6.3) 
28 (16.0) 
175 
1 The PCR-positive patients as a percentage of the 
group totals given in brackets. 
2 The group totals as a percentage of the total 
population given in brackets. 
* Invasion of vascular and/or lymphatic spaces. 
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3.2.4 Sample analysis 
The final aim was to establish whether blood sampling at different time points would improve the 
detection rate. Fifty percent (91/181) of the total population was tested once, 23% (41/181) twice 
and 27% ( 49/181) three to seven times. The intervals between tests for patients that underwent 
multiple testing, was two to twelve months. Six PCR-positive patients were tested only once, two 
were tested twice and three were tested four to five times (Table 3.2). Each of these patients 
tested positive only once. For example, patient number 10 tested negative at the time that the 
primary tumor was diagnosed (T1). Two months later the patient tested positive (T2) but three times 
subsequently again tested negative (T3-T5). The majority of the 18 stage I and II patients that 
subsequently developed metastatic disease were tested at least three times with 3 to 6 month 
intervals, yet only one of these (patient no. 9) was PCR-positive. Thus, the data supports the 
general view that the shedding of melanoma cells into the circulation is sporadic and that the 
detection rate could be improved with sampling at different time points. 
+ 
+ 
+ 
+ 
+ 
+ 
9 
2 
2 
2 
4 
Table 3.2. RT-PCR results and temporal sample analysis 
II N 
I N 
I N 
II y HF 
I N 
u IV 3.0 y MM 
I N 
+ II N 
2 2 + II IV 0.2 y MM 
+ 2 3 2 II N 
11 2 3 II N 
47 
46 
45 
11 
27 
3 
45 
41 
3 
46 
40 
Abbreviations: N°, patient number; T1, T2, etc., RT-PCR test one, two, etc.; ln1, ln2, etc. , interval 
one, two, etc. in months between tests; IS, initial clinical stage; SS, sub-sequent clinical stage; In+, interval in months between first positive RT-PCR test and clinical detectable metastases; D, died; C, cause of death; FP, follow-up period in months after a positive RT-PCR test had been 
obtained; +, RT-PCR positive;-, RT-PCR negative; U, uveal melanoma; N, no; Y, yes; HF, heart failure; MM, metastatic melanoma. 
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CHAPTER 4: CLINICAL DISCUSSION 
In this study, a combined RT-PCR assay for tyrosinase mRNA was developed and tested. It was 
shown that the assay can reproducibly detect a single, viable melanoma cell in 10-15 ml of 
peripheral blood. The assay was then used to test blood samples from patients with melanoma 
(primarily stages I and II) and the results were evaluated in relation to various clinical and 
histological criteria. The results confirm the recent doubts raised by other investigators that the 
current technique for the detection of CMCs by RT-PCR is of limited or no clinical value for 
monitoring melanoma progression (Farthmann et al., 1998; Glaser et al., 1997; Reinhold et al., 
1997). It was found that 7% (10/143) of the patients with PM had detectable melanoma cells in 
their blood (Figure 3.4). As would be predicted, the percentage of PCR-positive patients was 
higher for stage II patients (9.0%) than for stage I patients (5.3%) but the difference was not 
statistically significant (P = 0.2958). The detection rate of 9% observed for patients with stage II 
disease is in concordance with two recent groups who reported detection rates of 12-13% 
(Farthmann et al., 1998; Ghossein et al., 1998). However, none of the stage Ill and IV patients 
were PCR-positive. There are a number of possible explanations for this. First, it is possible that 
the number of stage Ill and IV patients studied, was simply too low. Alternatively, it was known that 
one third of the stage Ill and IV patients underwent chemotherapy at the time of blood sampling 
and it is possible that effective chemotherapy could have contributed to a more stabilized disease 
and thus a lower detection rate. 
The data in this study supports the notion that tumor thickness and ulceration are the two most 
significant prognostic factors for predicting the likelyhood of developing metastases. A significantly 
higher percentage PCR-positive patients (±12%) was found to have tumors greater than 1.5 mm 
thick (Figure 3.5) compared to 3.3% with tumors less than 1.5 mm thick (P = 0.0442). Furthermore, 
50% of the PCR-positive patients had ulcerated tumors (Table 3.1) compared to 19.4% of the total 
population studied (P = 0.0252). It should be cautioned that although a higher percentage PCR-
positive patients had ulcerated tumors greater than 1.5 mm thick, it was not possible at this stage, 
to link this directly to a poor prognosis since the majority of the PCR-positive patients have not yet 
(within four years) developed metastatic disease. However, the data does indicate that cells from 
tumors greater than 1.5 mm thick and with ulceration have a greater propensity to enter the 
circulation but that these cells do not necessarily have the ability to establish metastases. It was 
also found that a higher percentage (21.4%) of Clark's level V patients were PCR-positive 
compared to patients with Clark's levels IV (3.8%) with a P value (0.06) approaching significance 
(Figure 3.6). This indicates that the shedding of tumor cells into the circulation is associated with a 
deeper tumor penetration (vertical growth) and supports the observations that a deeper tumor 
penetration correlates with a poorer prognosis (reviewed by Garrison & Nathanson, 1996). 
Detection of CMCs: Clinical discussion 25 
The results suggest that the detection rate of 9% for patients with stage II disease is much lower 
than would be expected, since 23.9% (16/67) of the stage II patients subsequently developed 
metastases (Figure 3.4). Of these 16 patients, only one was PCR-positive. Thus, the current 
technique fails to predict the likelihood of developing metastatic disease (P = 0.3485). None of the 
PM patients received any form of therapy (besides surgery of the primary tumor) which might have 
influenced the low detection rate observed. The risk of recurrence after a 4 year follow-up period 
for stage I patients (tumors < 1.5 mm thick) is approximately 3-6% and for stage II patients with 
intermediate thickness melanoma (1.5 > < 4 mm) the risk is 12-20% (Delaunay, 1992). Recurrence 
rates of 2.6 and 23.9% were obtained for the stage I and II patients respectively after a median 
follow-up period of 4 years. It is therefore clear, at least for the stage I patients, that follow-up 
periods longer than 4 years will be necessary to establish whether the presence of CMCs will 
ultimately result in metastatic disease. 
The presence of tumor cells in the circulation will not necessarily result in the establishment of 
secondary tumors, as most circulating tumor cells die rapidly and the establishment of metastases 
is an inefficient process involving multiple factors (reviewed by Fidler, 1996). Animal studies 
indicate that less than 0.01% of circulating tumor cells eventually survive to produce metastases 
(Glaves, 1983; Liotta & Stetler-Stevenson, 1991 ). Thus, this study support this animal model 
observation. The strong correlation between the presence of CMCs and important prognostic 
factors (ie. tumor thickness and ulceration) but not between CMCs and metastasis is not 
necessarily a contradiction. It is most likely that this lack of correlation is indicative of a 
subpopulation of metastatic cells from the primary tumor that has the enzymatic capability of 
entering the circulation but which do not have the ability to survive the immune surveillance 
system, nor extravasate into target organ interstitium, proliferate or induce angiogenesis at 
secondary sites. In contrast to the findings of this study, Ghossein et al. (1998) reported that blood 
PCR-positivity was associated with a significantly decreased overall survival for stage II patients 
and Curry et al. (1998) reported that 66% of recurrences were predicted by PCR analysis in the 
early postoperative period. 
To address the question of whether multiple sampling would increase the positive detection rate, 
the RT-PCR results were examined in terms of number of times tested. Fifty percent of the total 
population studied underwent a single test of which six tested positive (Table 3.2: patient numbers 
1-6) and the other 50% underwent two or more tests of which five patients tested positive only 
once (Table 3.2: patient numbers 7-11 ). This suggests that sampling at different time points will 
increase the detection rate, as was suggested previously (Battayani et al., 1995; Pittman et al., 
1996) and that some of the PCR-negative patients could in fact be positive if they were tested 
more than once. However, of the 18 PM patients that developed metastases, only one was PCR-
positive even though these patients underwent multiple tests at different time points. This strongly 
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supports the concept of sporadic shedding of melanoma cells into the circulation and that the 
number of cells that circulate at any given moment is very low. Thus, sampling the large blood 
compartment seems to have severe limitations: First, the time of blood sampling may not coincide 
with the shedding process, leading to sampling errors. Secondly, sampling small blood volumes 
(10-20 ml) from the large blood pool seems to be statistically insufficient for obtaining a positive 
RT-PCR test due to the low numbers of CMCs. It was suspected that in addition to sampling at 
different time points, multiple sampling at each time point will also increase the detection rate. 
However, this was not tested. Lastly, the presence of CMCs will not necessarily be indicative of 
metastasis for reasons as discussed previously. 
In conclusion, the results indicate that the current technique for the detection of CMCs is of limited 
clinical value for the identification of patients with PM at risk for developing metastases. However, 
the presence of CM Cs does seem to correlate with the clinical stage (Curry et al., 1998; Farthmann 
et al., 1998; Mellado et al., 1996) and the tumor thickness (Curry et al., 1998; Farthmann et al., 
1998) although some groups found no correlation with the clinical stage (Ghossein et al., 1998) or 
the tumor thickness (Hoon et al., 1995; Mellado et al., 1996). In agreement with Verkaik et al. 
(1997) it is advised that clinical decisions should not be based on the presence of circulating tumor 
cells in small blood volumes. It is suggested that other options should be explored to predict the 
presence of micrometastates. One option is to enrich melanoma cells from larger blood volumes 
(ie. 50 to 500 ml for PM patients) with immunomagnetic technology (Hardingham et al., 1993), 
although this option might not be practical or feasible. Another option is to make use of a 
multimarker approach to compensate for the heterogeneity of tumor cells or lack of expression of 
tyrosinase. Various mRNA markers, such as p97, Muc-18 and Mage-3 (Hoon eta/., 1995) (3-
human chorionic gonadotropin (Doi et al., 1996) Pmel17/gp100, Mart-1/Melan-A, Trp-1 and Trp-2 
(Sarantou et al., 1997) and more recently (31-+4-N-acetylgalactosaminyl-transferase (Kuo et al., 
1998) and ganglioside GM3 (Zhang et al., 1998) are potentially suitable markers for the detection 
of CMCs. However, Curry et al. (1998) reported that gp100, p97, and Muc-18 were not suitable 
markers because the mRNAs were detected in normal blood samples. They also provided 
evidence that the use of Mart-1 in combination with tyrosinase allows the detection of CMCs in a 
larger percentage of patients and increases the potential utility of the assay by reducing the false-
negative rate. 
Other options that should be explored to predict the presence of micrometastases, is to make use 
of biopsies from anatomic compartments other than blood, such as bone marrow (Brossart et al., 
1994), lymph nodes (Schwurzer-Voit et al., 1996; Van der Velde-Zimmermann et al., 1996; Wang 
et al., 1994) and subcutaneous fat of the primary tumor (Proebstle et al., 1996). The sampling error 
associated with the detection of CMCs, will then be obviated. The only comprehensive study (to 
the best knowledge of the investigator) on the use of bone marrow aspirates for the prediction of 
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metastatic disease was reported by Ghossein et al. ( 1998) who found that the PCR-positivity for 
stage II patients was twice as high for bone marrow aspirates (25%) as for blood (12.5%). This 
suggests that sampling the smaller bone marrow compartment is more informative than sampling 
the larger blood compartment. However, it is the opinion of the investigator that the detection of 
micrometastases in sentinel lymph nodes (SLNs) with RT-PCR analysis will most likely prove to be 
of more clinical value since the SLN (identified by radio-guided surgery; reviewed by Brady & Coit, 
1997) is the first node in the lymphatic basin to receive metastases from the primary tumor 
(Gershenwald et al., 1998; Reintgen et al., 1994). Several recent reports (Blaheta et al., 1998; 
Goydos et al., 1998; Joseph et al., 1997; Shivers et al., 1998) indicate that the SLNs of patients 
with PM that were negative by immunohistochemical assessment, could be upstaged by 
approximately 50% using RT-PCR analysis for tyrosinase alone. Moreover, Shivers et al. (1998) 
have shown a recurrence rate amongst 13% of the patients that were upstaged by RT-PCR 
analysis after a relative short average follow-up period of 28 months. The SLN mapping technique 
together with a multimarker/RT-PCR approach could therefore prove to be a more powerful tool to 
predict metastatic disease. 
FUTURE CONSIDERATIONS 
A very challenging and potentially viable research prospect would be to use RT-PCR analysis for 
the identification of SLN micrometastases in patients with PM and to offer these patients a 
potentially effective immunotherapy approach. The rationale is that patients with a small metastatic 
tumor burden are more likely to respond to immunotherapy since dormant micrometastases are 
more susceptible to cell-mediated immunological attack (McNamara et al., 1998; Staveley et al., 
1998). Amongst the various immunotherapy strategies that have been investigated, dendritic cell 
(DC)-based immunotherapy is currently the most promising (reviewed by Pardoll, 1998). DCs are 
potent antigen presenting cells (APCs) which play a central role in the induction of an antigen-
specific cytotoxic T-lymphocyte (CTL) response. APCs express costimulatory molecules (eg. 87) in 
response to certain inflammatory cytokines which promote T-cell activation. It was recently 
demonstrated that the interaction of mouse DCs with mouse melanoma or lung tumor cells will 
result in effective CTL-mediated tumor-specific lytic activity, either by conferring sufficient APC 
function to tumor cells for T-cell activation or by facilitating the delivery of tumor antigens to DCs for 
processing and presentation (Celluzzi & Falo, 1998). Mice immunised with irradiated DC-816 
tumor cell aggregates were completely protected from lethal challenge with 816 tumor cells. Mice 
with established tumors demonstrated complete regression when challenged with the immunogen 
and demonstrated long-lasting antitumor immunity. 
Thus, DC-melanoma cell aggregates seem to be potentially effective immunogens that could be 
used to eradicate dormant micrometastases before the onset of tumor vascularization and 
progression to macrometastatic disease. The tumor cells of a patient that is positive for 
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micrometastases (using SLN biopsy and RT-PCR analysis) could be cultured and selected from 
the primary tumor or from a portion of the SLN (Reinhold et al., 1997; Thompson & Ioli, 1997). The 
patients DCs could be expanded from blood precursors with the addition of GM-CSF, SCF, Flt-3 
ligand, TGF-a and TGF-~ (Seliga et al., 1998). Once melanoma cells and DCs have been 
established successfully in vitro from a patient with proven SLN micrometastases, such a patient 
becomes eligible for autologous immunotherapy. The patients DCs could then be co-cultured with 
its own melanoma cells for 24 hrs and irradiated (Celluzzi & Fala, 1998). The immunogen 
(irradiated DC-melanoma cell aggregate) could then be given to the patient during the early stages 
of tumor progression. 
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CHAPTER 5: LITERATURE REVIEW 
SERUM MARKERS FOR CUTANEOUS MELANOMA 
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The dramatic improvements in the survival of patients with cutaneous melanoma over the past 
decades are mainly the result of earlier diagnosis and surgical intervention of primary disease 
(Halpern & Schuchter, 1997). The ability to predict micrometastatic disease is therefore of utmost 
clinical importance for making rational therapeutic decisions. Although a number of clinico-
pathological parameters (reviewed by Cochran, 1997; Garrison & Nathanson, 1996) have been 
implicated as prognostic factors for melanoma, little progress has been made in the identification of 
reliable serum markers for monitoring the progression of PM or AM (Guo et al., 1995; Provost et 
al., 1997; Weiss et al., 1995). 
The detection of substances secreted or shed by tumor cells into the PB may have value in the 
diagnosis of cancer. In addition, it could also be used to monitor the progression from localised to 
metastatic disease and the response to therapy in patients with metastatic disease or the 
possibility of recurrence. Substances secreted into the PB by the normal host tissue in response to 
invading malignant cells could possibly also serve as prognostic markers. A brief evaluation of 
serum markers and their potential use for monitoring tumor progression and response to therapy 
follows: 
5.2 Liver function tests 
The liver function tests are usually used to obtain prognostic information (reviewed by Provost et 
al., 1997; Weiss et al., 1995) and to monitor treatment (Bedikian et al., 1995; Huang et al., 1990; 
Miller et al., 1989) in patients with AM. These tests include the determination of aspartate 
aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase 
(LOH), alkaline phosphatase, creatine kinase, total bilirubin and direct bilirubin levels in serum. In 
addition, the serum levels of creatinine and urea nitrogen may be used to monitor renal function 
(Huang et al., 1990). A survey (Provost et al., 1997) amongst 30 experienced physicians indicated 
that the majority of them routinely order chest X-rays with or without liver function tests (mostly 
LOH) for stages I, 11 and Ill and during follow-up for stages 18, II and 111, and baseline computed 
tomographic or magnetic resonance imaging scans of the chest, abdomen, pelvis and brain for 
stage Ill patients. It was concluded from this survey that complete liver function tests and blood cell 
counts are justified only for patients with clinically established metastases. The value of the liver 
function tests as indicators of melanoma progression is controversial. In 12.5% (11/88) of stage II 
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patients, a persistent increase in serum LOH was the first indicator of recurrent visceral metastatic 
disease (Finck et al., 1983), but others reported that routine liver function tests have no (Kersey et 
al., 1985) or limited value (Weiss et al., 1995) in the prediction of metastatic disease. The pre-
treatment values of LOH and albumin, dichotomized as high and low, have been reported to be 
independent prognostic factors for survival in patients with AM (Sirott et al., 1993). Because LOH is 
metabolized at a fairly constant rate, elevated levels are believed to represent tumor cell turnover 
(growth and necrosis) and tumor burden but it does not necessarily indicate tumor involvement of 
the liver as reported initially (Garg et al., 1979). In this study, the median survival was 11.8 months 
in patients in whom both the LOH and serum albumin were normal versus 3.6 months in patients 
with a low albumin and a LOH that was greater than or equal to two times the upper limit of normal. 
Elevated LOH levels have been found to be an independent prognostic parameter for response to 
treatment and survival in patients with AM treated with interferon-a and interleukin-2 (Keilholz et 
al., 1996). A more recent study indicates that by using only serum LOH and disease site as 
prognostic parameters, patients with both favorable factors had a median survival time of 12 
months, whereas patients with neither had a median survival time of 5 months (Eton et al., 1998). 
5.3 Melanin-related metabolites 
The use of melanin-related metabolites to monitor the progression of melanoma were reported to 
be of some promise. In particular, serum levels of 5-S-cysteinyldopa seem to reflect melanoma 
progression better than urine levels, whereas the serum or urine levels of 6-hydroxy-5-
methoxyindole-2-carboxylic acid was of little value (Horikoshi et al., 1994). It was proposed that the 
measurement of tyrosinase activity in the serum of melanoma patients could be a possible 
progression marker (Sonesson et al., 1995b). However the method, which measures stereospecific 
dopa oxidation, was found to be of little value and was troubled by seasonal variation in tyrosinase 
activity. The mean tyrosinase activity values in 30 normal individuals was 0.4 ±0.2 nkatal/1 and for 
1 O patients with AM the mean value was 3.1 nkatal/1 (Sonesson et al., 1995a). 
5.4 Soluble adhesion molecules 
Elevated serum levels of adhesion molecules may be indicative of an enhanced host cell-mediated 
immune response to a primary tumor or may reflect a passive shedding of adhesion molecules by 
tumor cells (Harning et al., 1991; Miller et al., 1997). Adhesion molecules that have been studied in 
melanoma as possible progression markers, include soluble isoforms of intercellular adhesion 
molecule 1 (ICAM-1, CD54), vascular cell adhesion molecule 1 (VCAM-1, CD106) and E-selectin 
(CD62e). A number of studies have suggested a positive correlation between melanoma 
progression and elevated serum levels of soluble ICAM-1 (Altomonte et al., 1992; Denton et al., 
1992; Harning et al., 1991; Miller et al., 1997; Viac et al., 1993) although not all studies agree with 
this finding (Bosserhoff et al., 1997; Kageshita et al., 1993; Kageshita et al., 1992). A more recent 
study (Franzke et al., 1998) compared the pre-treatment serum levels of sVCAM-1, slCAM-1, sE-
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selectin and LOH to determine their prognostic value in 97 patients with AM. Multivariate analysis 
showed that elevated serum levels of sVCAM-1 and LOH were dominant independent prognostic 
variables and correlated with poor outcome in metastatic melanoma, while slCAM-1 and sE-
selectin were of no prognostic value. Combining elevated sVCAM-1 and LOH serum levels, 
identified a subgroup of patients at high risk, all of who died of metastatic disease within one year. 
5.5 S100 protein 
S 100 protein has received considerable attention as a possible prognostic serum marker for 
melanoma (Bosserhoff et al., 1997; Fagnart et al., 1988; Guo et al., 1995; Hansson et al., 1997; 
von Schoultz et al., 1996). It is a 21 kD acidic, intracellular calcium-binding protein originally 
isolated from the central nervous system (Dannies & Levine, 1969; Moore, 1965). Although the 
biological functions have not been elucidated, it has been shown to affect the assembly and 
disassembly of microtubules (Baudier et al., 1982; lsobe & Okuyama, 1978). S100 is a dimeric 
protein composed of a- (10.4 kD) and (3- (10.5 kD) subunits, with the possible combinations aa, a(3 
and (3(3 (reviewed by Donato, 1991; Kligman & Hilt, 1988). High concentrations of the (3-subunit are 
present in glial and Schwann cells of the central nervous system (Takahashi et al., 1984) but have 
also been found in epidermal Langerhan's cells (Nakajima et al., 1982). Melanocytes, 
macrophages and monocytes contain only the a-subunit (Nakajima et al., 1982; Takahashi et al., 
1984). 
Polyclonal and monoclonal antibodies against protein S100 and in conjunction with HMB-45 
antibodies (Chiamenti et al., 1996; Walts et al., 1988) are now being used routinely in the 
histopathological diagnosis of melanoma and its differential diagnosis from other solid tumors 
(Carrel & Rimoldi, 1993; Cho et al., 1990; Gatter et al., 1985). The a- and (3-subunits are rarely 
found in ordinary nevi, with dysplastic nevi expressing only the a-subunit. The expression of the (3-
subunit is strongly associated with vertical growth and invasiveness of superficial spreading 
melanomas. The majority of nodular melanomas express both subunits. It was therefore suggested 
that the expression of the (3-subunit might be related to vertical progression (Cho et al., 1990; Paul 
et al., 1987; Smeller, 1991). 
The levels of protein S100 in serum and cerobrospinal fluid have been shown to increase after 
damage to the central nervous system and is now being used to monitor brain damage in stroke 
patients (Aurel! et al., 1989; Persson et al., 1987). Fagnart et al. (1988) initially suggested that the 
serum levels of protein S100 might be a useful marker to monitor melanoma progression. The 
clinical significance of serum S100 was demonstrated by Guo et al. (1994) using an 
immunoradiometric assay, which measures the (3-subunit. They found that a persistent rise in 
serum S 100 indicated progression of the disease, whereas a decline indicated response to 
therapy. A sensitivity of 1.3% for stages I and II patients versus 41.3% for stages Ill and IV patients 
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indicated clearly that serum S100 levels was of no value for the early detection of metastatic 
disease. In addition, serum S100 showed a better discrimination between patients with distant 
metastases and those without it, than neurone-specific enolase serum levels (41.3% versus 23.9% 
respectively). Similar studies (Karnell et al., 1997; van Schoultz et al., 1996) show a strong 
association between overall survival rate and serum S100(3 levels. The observed/expected death 
ratio was markedly increased with increasing S 100(3 levels. These data strongly suggest that 
serum S 100(3 is an independent prognostic marker that may be useful in identifying high-risk cases 
and to monitor response to therapy in patients with AM. 
5.6 Melanoma-inhibiting activity (MIA) 
MIA has been identified initially as an 11 kD soluble protein secreted from melanoma cell lines in 
vitro (Apfel et al., 1992; Bogdahn et al., 1989). More recently, it has been identified independently 
by a differential display approach and has been referred to as CD-RAP (Dietz & Sandell, 1996). It 
is speculated that the function of this growth-regulatory protein is to slow tumor progression in vivo 
by an autocrine mechanism (Graeven & Herlyh, 1992; Weilbach et al., 1990). High MIA mRNA 
levels have been detected in almost 100% of malignant melanoma biopsies and at low levels from 
benign melanocytic nevi but not from normal skin melanocytes (Bosserhoff et al., 1996; van 
Groningen et al., 1995). Bosserhoff et al. (1997) investigated whether MIA was a clinically useful 
progression marker in patients with melanoma. They reported enhanced MIA serum levels in 13 
and 23% of patients with stage I and II disease, respectively, and in 100% with stage Ill or IV 
disease. MIA was the most sensitive marker when compared with S100 and soluble ICAM-1 serum 
levels in these patients. Response to therapy in stage IV disease correlated with changes in MIA 
serum levels. Thirty-two of 350 stage I and II patients developed enhanced MIA serum levels. 
Fifteen of the 32 patients developed metastases at the time of a raised MIA serum level and one 
presented with metastatic disease 6 months later. None of the patients with normal MIA serum 
levels developed metastases during a 6-12 month follow-up period. An extended follow-up period 
will be necessary to determine whether the 16 patients who developed enhanced MIA serum 
values, but had no clinical signs of disease progression, will develop metastases at a later stage. 
5.7 Plasminogen activators and inhibitors 
The plasminogen activator (PA) cascade plays a fundamental role in tumor cell migration and 
invasion processes which require the coordinated and temporal regulation of a series of adhesive, 
proteolytic and migratory events (reviewed by Andreasen et al., 1997; Blasi, 1997). High levels of 
urokinase plasminogen activator (uPA) and its receptor (uPAR) (Duffy, 1996; Duffy et al., 1998), 
but paradoxically also plasminogen activator inhibitor type 1 (PAI 1 ), have been correlated with a 
poor prognosis for a variety of solid tumors (reviewed by Pappot et al., 1995). The regulatory role 
of PAl1 in uPAR-mediated cell adhesion and release may explain why high tumor PAl1 levels 
correlate with a poor prognosis for many cancers (Deng et al., 1996a). In support of this model, de 
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Vries et al. ( 1994) demonstrated by immunohistochemistry and in situ hybridization that uPA, 
uPAR, PA11 and PAl2 could not be detected in benign and in early stages of PM but appeared 
frequently in advanced PM and melanoma metastasis lesions (de Vries et al., 1994). Convincing 
experimental evidence for the role of host-produced PAl1 in cancer cell invasion and angiogenesis 
was recently provided by Bajou et al. (1998). PAI 1-deficient mice failed to support local invasion 
and tumor vascularization of transplanted malignant keratinocytes. When this PAI 1 deficiency was 
circumvented by intravenous injection of a replication-defective adenoviral vector expressing 
human PAl1, invasion and associated angiogenesis were restored (Bajou et al., 1998). 
Although the high levels of tumor PAl1 in breast (Grondahl-Hansen eta/., 1993; Janicke eta/., 
1994; Kim et al., 1998; Knoop et al., 1998), lung (Pappot et al., 1997; Pedersen et al., 1994), 
gastric (Allgayer et al., 1997; Nekarda et al., 1994), colorectal (Sier et al., 1994) and ovarian 
cancers (Chambers et al., 1998; Kuhn et al., 1994) appear to be independent predictors of short 
survival, the use of tumor extracts to obtain prognostic information is usually not clinically 
practicable. It has been suggested that plasma PA11 levels may provide the same prognostic 
information as when measuring tumor PAl1 (reviewed by Pappot et al., 1995). Some patients with 
ovarian cancer have been shown to have raised plasma levels of PA11 (Casslen et al., 1994). In 
patients with colorectal cancer (Nielsen et al., 1998), high preoperative plasma concentrations of 
PAl1 have been associated with a shorter survival and increasing severity of the disease and in 
gastric cancer, the plasma levels of PAI 1 were significantly higher than in benign gastric disease 
(Ho et al., 1998). In breast cancer patients, plasmatic PAI activity was significantly higher for 
patients with metastasis compared to patients whose cancer did not recur (von Tempelhoff et al., 
1997). 
5.8 Specific aims of study 
Despite the correlation between high tumor or plasma levels of PAI 1 and a poor prognosis in 
patients with various solid tumors, the role of PAI 1 in cancer progression and invasion is still poorly 
understood. In this section of the thesis, the specific aim was to investigate whether high or low 
plasma levels and/or activity of PAI 1 correlate with the presence of metastatic disease in patients 
with melanoma. To the best knowledge of the investigator, the plasma levels or activity of PAI 1 for 
patients with AM has not previously been reported. A unique enzyme-linked immunosorbent assay 
(ELISA) was developed to measure both the total amount of PAl1 in plasma as well as the active 
fraction of the inhibitor. (The production of these antibodies and their uses are fully described in 
section C of this thesis.) This novel Mab-based immunofunctional assay was then used to analyse 
and compare the plasmatic PAl1 levels and activity of a group of patients with AM (stages Ill and 
IV disease) with a group of patients with primary disease (stages I and II) and a control population. 
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CHAPTER 6: MATERIALS AND METHODS 
6.1 Reagents 
Latent and active Escherichia coli-derived human recombinant PAl1 (rPA11) was obtained and 
prepared as described in section C of this thesis (see 10.1 ). The concentration of latent and active 
rPAl1 was determined with the BCA protein assay (Pierce Chemical Company, Rockford, USA) 
using the 60°C protocol and with bovine serum albumin (BSA) as a standard according to the 
instructions of the manufacturer. The rabbit anti-PAl1 polyclononal antibody (RaPAl1 Pab, see 
10.2) and the mouse anti-PAl1 monoclonal antibodies, clones 6 and 11 (maPAl1/C6 and -C11 
Mabs, see 10.4, 11.4 and 11.11) were prepared as described in section C of this thesis. 
6.2 Calibration curves for PA11 
A 96-well polypropylene MaxiSorb ELISA plate (NUNC NS, Roskilde, Denmark) was coated with 
the RaPAl1 Pab at 50 µg/ml in PBS for 16 hours at 4°C and then blocked with 0.1% BSA in PBS 
for 30 mins at RT. The reagents used by the ELISA procedure were added to the plates at 50 µI 
per well (unless otherwise stated) and all steps were followed by five washes with TST-buffer (see 
A.27 for details) except for the last wash which was done ten times. All incubation steps were for 
30 mins at RT (except if mentioned differently). Calibration curves were constructed with latent or 
active rPAl1 as follows: The rPAl1, prepared by serial dilutions from 12 ng/ml down to 2 ng/ml in 
blocking solution, was added to the plate for 1 hour at RT. The maPAl1/C6 and -C11 Mabs were 
tested for their ability to detect the bound latent or active PAl1 and were added at 1 µg/ml. The 
bound antibody was detected with goat anti-mouse lgG conjugated with alkaline phosphatase 
(Dako, Glostrup, Denmark, diluted 1 in 2000). p-Nitrophenyl phosphate (PNPP, 100 µI per well) 
was used as a substrate for alkaline phosphatase (see A.57 for details). The plate was incubated 
for 6 hrs at RT and the absorbance was read at 405 nm. 
6.3 Patients 
Blood samples were collected from 39 melanoma patients attending the Melanoma Clinics of 
Groote Schuur and Kingsbury Hospitals in Cape Town. There were 21 patients with PM (7 stage I 
and 14 stage II patients) and 18 patients with AM (10 stage Ill and 8 stage IV patients). The clinical 
staging was based on the TNM classification system as agreed upon by the International Union 
Against Cancer and the American Joint Committee on Cancer. There were 38 controls, which 
included South Africans working in the Groote Schuur Hospital and University of Cape Town 
academic institutions. The controls were selected on the basis of no history of skin cancers and 
cardiovascular diseases. The study was approved by the Ethics and Research Committee of the 
University of Cape Town. Written and informed consent was obtained from all patients before they 
entered into the study. 
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6.4 Sample preparation and PAl1 measurements 
Blood from control and melanoma patients was collected from a steadily flowing venipuncture 
between 2:00 and 4:00 p.m. into 0.1 volume of 0.1 M sodium citrate at pH 4.5 (Declerck et al., 
1988a; Kruithof et al., 1987). Blood samples for control and patient groups were collected within 
the same time period to minimise the effect of diurnal variation in plasma PAl1 (Andreotti et al., 
1988; Juhan-Vague et al., 1992; Macy et al., 1993). The first 5 ml of blood was discarded, as was 
any tube that collected non-free-flowing blood or plasma contaminated with erythrocytes. The 
blood were mixed three times by inversion and kept on ice. The tubes were centrifuged at 700 g for 
1 O mins at RT within one to two hours of collection. These restrictions imposed on blood collection 
were carried out at all times to minimise the release of platelet-containing PAl1 into the plasma 
(Macy et al., 1993). Platelet-free plasma (PFP) was prepared by filtering the citrated-plasma 
through a 0.45 µm acetate membrane filter, fitted with a 1.0 µm borosilicate glass prefilter (Micron 
Separations Inc., Westborough, USA). The PFP was stored in suitable aliquots at -70°C. 
PFP samples were thawed only once and were diluted 1/2 to 1/80 in 0.1 %BSA/PBS for PAl1 
measurements. ELISA's were carried out as described in 6.2 above. The plasmatic PAI 1 levels for 
the samples were estimated from the calibration curves using the linear function, y = mx + c. Two 
measurements were carried out for each sample (in duplicate): The first measurement (with 
maPAl1/C11) is used to calculate the total amount of PAl1 (latent plus active PAl1). The second 
measurement (with maPAl1/C6) is used to calculate the amount of latent PAl1. The two 
measurements are then subtracted from each other to obtain the amount of active PAl1. The 
percentage active PA11 is then calculated as (ng/ml active PAl1) / (ng/ml total PAl1) x 100. 
6.5 Statistical analysis 
Since the variances were not homogeneous, differences between controls and patients with PM 
and AM were tested with the Kruskal-Wallis ANOVA test using the Statistica Version 5.1 software 
(StatSoft, Inc., Tulsa, OK). A p-value less than 0.05 was considered as being statistically 
significant. The Linear Discriminant Function test was used to determine the cut off values for the 
active fraction of plasmatic PAl1 between groups using the StatGraph Version 6.0 software 
(Manugistics, Inc.). 
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CHAPTER7:RESULTS 
7.1 Calibration curves for PAl-1 
Calibration curves for active and latent PAI 1 were constructed for each of the Mabs maPAI 1 /C6 
and -C11 in order to quantitate active and latent PAl1 in plasma samples (see Materials and 
Methods, 6.2). Figure 7.1 illustrates the calibration curves obtained for both maPAl1/C6 and -C11 . 
The maPAl1/C11 allows the quantitation of free latent (open square) and active (solid square) 
PAl1 with an equal affinity. In contrast, maPAl1/C6 showed a high affinity for latent (open triangle) 
PAl1 but failed to detect active (solid triangle) PAl1 within the concentration range of the standard 
curve. Thus, maPAl1/C6 allows the quantitation of active PAl1 by subtracting the amount of latent 
PAl1 (detected by maPAl1/C6) from the amount of total PAl1 (detected by maPAl1/C11). The 
lower limit of sensitivity for the assay was 2 ng/ml PAl1 in blocking buffer. 
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Figure 7.1. Calibration curves for PAl1. 
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Decreasing concentrations of latent (open symbols) or active (solid symbols) rPAl1 from 12 ng/ml 
down to 2 ng/ml were used to construct calibration curves. The maPAl1/C11 (squares) detected 
latent (D) and active(•) PAl1 with equal affinity. The maPAl1/C6 (triangles) showed a high affinity 
for latent (Ll) PAI 1 but failed to detect active (A) PAI 1 within the concentration range of the 
standard curve. The background 405 nm readings were less than 0. 7 after 6 hours at RT and were 
subtracted from each reading to construct standard curves (r > 0.98). Each value represents the 
mean from duplicate readings. 
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7.2 PAl1 quantity and activity for controls and patients with melanoma 
The total plasmatic PAl1 levels for patients with PM and AM were compared with the controls to 
determine whether there are any statistical differences between the three groups. The data are 
summarised in Table 7.1 (see also Appendixes 58 to 60 for raw data). The mean concentration of 
total PAl1 was 57 ±66 ng/ml for the controls (n = 38), 139 ±295 ng/ml for patients with PM (n = 21) 
and 88 ±124 ng/ml for patients with AM (n = 18). There were two PM patients (see A.59, patient 
numbers 13 and 15) and one AM patient (see A.60, patient number 1) with total PAI 1 values 
greater than 500 ng/ml . These outliers have contributed significantly to the large standard 
deviations of 295 and 124 ng/ml that were obtained for PM and AM patients respectively. However, 
the differences in total PAI 1 between the three groups were not statistically significant (P = 0.6199) 
with the Kruskal-Wallis ANOVA test (Figure 7.2). 
In the following analysis, the active fraction of plasmatic PAl1 (percentage active PAl1) for patients 
with PM and AM were compared with the controls to determine whether there are any statistical 
differences between the three groups. The data are summarised in Table 7.1 (see also A.58 -A.60 
for raw data). The mean percentage of active PAl1 was 62 ±10.5% for the controls, 55 ±12.4% for 
patients with PM and 46 ±15.1 % for patients with AM. The differences in the percentage active 
PAl1 between the three groups was statistically significant (P = 0.0076) with the Kruskal-Wallis 
ANOVA test (Figure 7.3). The difference between the control and AM groups was highly significant 
(P = 0.0042). Surprisingly, the difference between the control and PM groups was also significant -
although borderline (P = 0.0488), while the difference between PM and AM groups was not 
statistically significant (P = 0.2556). Overall, there was a definite order of linearity between the 
three groups with a correlation coefficient of 0.49 (P < 0.0005) using multiple regression analysis. 
TABLE 7.1. Number of samples, median and range of plasmatic PAl1 levels. 
Patients n Total PA11 Active PA11 
(ng/ml) (%) 
Median Mean (range) Median Mean (range) 
Controls 38 34 57 (10-326) 64 62 (38-84) 
PM 21 43 139 (15-1257) 55 *55 (28-76) 
AM 18 39 88 (9-528) 44 *46 (23-73) 
* Differs significantly from controls. 
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Figure 7.2. Box plots of total PAl1 in controls versus patients with PM and AM. The boxes 
encompass the 25th to 75th percentiles of the data with the median values (34, 43 and 39 ng/ml 
respectively) as the solid squares within the boxes. 
90 
.,.... 
~ 
a.. 
80 
Q) 
.2: 70 u >·· 
Cl) 
Q) 
• Cl 60 Cl) 
c 
Q) 
• e 50 Q) 
a.. 
• 40 
30 
20 
I Min-Max 
10 D 25%-75% 
Controls (n=38) PM (n=21) AM (n=18) • Median value 
38 
Figure 7.3. Box plots of percentage active PA11 in controls versus patients with PM and AM. The boxes encompass the 25th to 75th percentiles of the data with the median values (64, 55 and 44% respectively) as the solid squares within the boxes. 
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7.3 Linear discriminant function analysis 
The data were analysed according to the linear discriminant function in order to determine a 
clinically meaningful value for the percentage active PAl1 in plasma. The centroid values for the 
controls, PM and AM patients were 0.4820, -0.1378 and -0.8787 respectively. The midpoints 
between these centroid values were substituted into the linear discriminant function equation 
(0.0818 x % active PAl1 - 4.6106) to obtain the relevant cut off values. The cut off values for the 
controls was greater than 61 % active PAI 1, for the PM patients it was between 44 and 61 % and for 
the AM patients it was less than 44%. A value of less than 44% active PAl1 was considered to be 
clinically meaningful. The data are summarised in Table 7.2. 
For the controls, 55.3% (21/38) had active plasmatic PAl1 values greater than 61 %, 42.1 % (16/38) 
had values between 44 and 61% whereas only 2.6% (1/38) had values smaller than 44%. This 
represents a false positive rate of less than 3%. For patients with PM, there was a shift in the 
active fraction of plasmatic PAl1 predominantly (52.4%) towards the 44 to 61% range. For patients 
with AM, there was a shift in the active fraction of plasmatic PAl1 predominantly (50%) towards the 
less than 44% range. Overall, 2.6% (1/38) of the controls, 19% (4/21) of the patients with PM and 
50% (9/18) of the patients with AM had values less than 44% active PAl1. 
Table 7.2. Summary of the linear discriminant function analysis. 
Groups Percentage active PAl1 
> 61 44 ~ ~ 61 <44 Total 
cc 21 (~5.3)* 16 (42.1) 1 (2.6) 38 
-PM 6 (28.6) 11 (52.4),· 4 (19.0) 21 
. ·," .. 
AM 4 (22.2) 5 (27.8) 9 .(50.0) 18 
Total 31 32 14 77 
* Percentage of the total in brackets. 
40 
CHAPTER 8: DISCUSSION 
PAI 1 is considered to be the main regulator of fibrinolytic activity in blood (reviewed by Loskutoff et 
al., 1989). Elevated plasma levels and/or activity of PAl1 have been implicated in a large number 
of disease conditions. These include, an increased risk for cardiovascular diseases (reviewed by 
Vaughan, 1998), obesity and insulin resistance (Juhan-Vague & Alessi, 1997), acute inflammatory 
syndrome (D' Angelo et al., 1985), survival in cancer patients (Ho et al., 1998; Nielsen et al., 1998), 
aging (Aillaud et al., 1986), pregnancy (Kruithof et al., 1987), rheumatoid arthritis (Kopeikina et al., 
1997), pancreatitis and liver diseases (Juhan-Vague et al., 1984). It has been suggested that PAl1 
is an acute-phase reactant since plasmatic PA11 levels frequently increases after major surgery 
(Aillaud et al., 1985), in response to acute myocardial infarction (Almer & Ohlin, 1987) and with 
severe trauma (Kluft et al., 1985). Deficiency of PAl1 is a rare phenomenon associated with 
significant clinical bleeding. Only a single patient with complete deficiency of PAl1 has been 
reported and is associated with life-threatening haemorrhage (reviewed by Eitzman & Ginsburg, 
1997). 
Due to this wide clinical relevance of PAI 1, a number of anti-PAI 1 Mabs have been developed for 
measuring it in plasma (Declerck et al., 1988a; MacGregor & Booth, 1988; Nielsen et al., 1986). 
However, at least four molecular forms (active, latent, substrate and cleaved) of PAl1 can occur in 
blood (reviewed by Pappot et al., 1995) which makes it difficult to obtain an accurate measure of 
the total molecular concentration of plasmatic PAl1. Of the several immunoassays that have been 
developed to measure plasmatic PAl1, the lnnotest PAl1 antigen assay appears to be the only 
assay which can detect all molecular forms of plasmatic PAl1 to a similar degree (Meijer et al., 
1994). By convention, PAI activity is measured with functional assays which are based on the 
neutralisation of tPA added to samples and measurement of residual tPA activity on fibrin plates 
(Chmielewska & Wiman, 1986) or with spectrophotometric methods (Eriksson et al., 1988). A Mab-
based immunofunctional assay, based on the measurement of PAl1/tPA complexes, has been 
described for human PAl1 (Declerck et al., 1988b) and recently for rat PAl1 (Ngo et al., 1998). To 
the best knowledge of the investigator these are the only two alternative assays for PAI activity. 
However, there are several limitations to these functional assays: For example, interference by 
competing protease inhibitors, the non-parallelism of calibration curves in buffer and in plasma and 
the fact that functional assays cannot distinguish between the different PAis. These factors have 
undoubtedly contributed significantly to the variability in results reported between different 
laboratories (Samama et al., 1985; Speiser et al., 1986). To overcome these limitations, a novel 
Mab-based immunofunctional assay specific for PAI 1 activity was developed. 
This novel immunoassay allows the user to quantitate the total plasmatic PAl1 level (latent plus 
active) as well as the active fraction of the inhibitor. The latter is obtained by subtracting the 
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amount of latent PAl1 (quantified with maPAl1/C6) from the amount of total PAl1 (quantified with 
maPAl1/C11). A possible way to explain the principle of the ELISA is illustrated in Figure 8.1. A 
RaPA11 Pab is used to capture latent and active PAl1 from the biological sample on a microtiter 
plate. The maPAl1/C11 would allow the quantitation of latent and active PAl1 since the 
recognisable epitope (A) is available for binding with both molecular forms captured on the plate. 
The results show that this Mab detects both molecular forms with an equal affinity across the 
dilution range of the calibration curve (see Figure 7.1). The maPAl1/C6 would allow the 
quantitation of only latent PAl1 since the recognisable epitope (t) would only be available for 
binding with the latent molecule captured on the plate. The epitope is most likely hidden when the 
active molecule, due to its conformational change, is captured on the plate. The fact that 
maPAl1/C11 detects both molecular forms with an equal affinity across the dilution range of the 
calibration curve is important, since it will ensure an accurate estimation of the active fraction of 
PAl1 after subtracting the quantity for latent PAl1 obtained with maPAl1/C6. It is also important to 
note that although maPAl1/C6 detects only latent PAl1 on the plate, it does in fact bind to active 
PAl1 in the fluid phase since it inhibits the activity of PAl1 in the 1251-fibrin plate assay (see 
Section C, 11.10 and Figure 11.9 for details). 
C6 C6 
C11 1 C11 1 1~ 1 ~ntPAl1 Active PAl1 
r!dri r!dri • 
H R.1bbit-ani·PAl1 
Figure 8.1. Hypothetical principle of the PAI 1 ELISA. 
Besides the free latent and active PAl1 found in blood, it is also present in complex with tPA, uPA 
and VN (reviewed by Loskutoff et al., 1989). In terms of the total molecular concentration of PA11, it 
would be of value to determine whether this novel assay is also able to detect the above 
mentioned complexes of PAI 1. However, no definite investigations were undertaken to determine 
this. In spite of this, there is some peripheral evidence that suggests that maPAl1/C11 is most 
likely also able to quantitate PNPAl1 complexes. For example, the western blotting results 
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presented in section C of this thesis (see 11.5 and Figure 11.4) reveals two bands (lane 5) which 
might correspond to tPNPAl1 and uPNPAl1 complexes. Additional support was obtained from a 
modified PAl1 ELISA procedure that was carried out as follows: tPNPA11 complexes were 
generated and captured on a microtiter plate with the RaPAl1 Pab. Both maPAl1/C11 and a 
mouse anti-tPA Mab recognised the tPNPAl1 complexes on the plate (data not shown). However, 
these experiments do not provide conclusive evidence that the assay can detect PNPAI 1 
complexes since the presence of free PAI 1 could not be ruled out in the latter experiment. There is 
also some peripheral evidence to suggest that maPAI 1/C11 is most likely also able to quantitate 
VN/PAI 1 complexes. For example, the results presented in section C of this thesis (see 11.9 and 
Figure 11.8) show that the Mab can detect VN/PAl1 complexes bound on a microtiter plate. Since 
maPAl1/C6 blocks the binding of PAl1 to VN, it may be assumed that this Mab is not able to detect 
VN/PAl1 complexes in this assay. Overall, it can be concluded that maPAl1/C11 can measure free 
latent and active PAl1 and most likely also PNPAl1 and VN/PAl1 complexes. In contrast, 
maPAl1/C6 seems to measure only free latent PAl1. However, future investigations will address 
these aspects more thoroughly. 
In order to measure plasmatic PAl1, it is essential to remove the platelet-fraction which constitutes 
92% of the blood PAI 1 (Macy et al., 1993). Failure to remove the platelets will result in a significant 
rise in plasmatic PAl1 and consequent false values. Until now investigators have made use of 
centrifugation to remove the platelet fraction from the blood. A minimum centrifugation speed of 
30 000 g has been reported to be essential in removing the platelets effectively from the blood 
(Macy et al., 1993). In order to simplify the technique, additional options were explored. It was 
found that membrane (1.0 µm followed by 0.45 µm) filtration is an effective alternative to remove 
the platelets, which are approximately 2-4 µm in diameter (Hutton, 1989), from plasma. Three 
control samples were analysed before and after cryopreservation for total PAl1 to test the 
efficiency of the filtering procedure (results not shown). The rationale being that freezing and 
thawing of the sample will release any platelet-PAI 1 due to platelet lysis (Macy et al., 1993). Since 
there were no differences in the PAl1 levels of the samples before and after cryopreservation, it 
was concluded that the filtering procedure was effective in removing the platelets from the plasma. 
In order to verify the reliability of the PAl1 antigen levels obtained for the controls with this novel 
PAl1 assay, data from other investigators were compared with the findings from this study. Most 
investigators have reported a wide variation in the PAl1 antigen levels for normal human plasma 
which varied from nearly undetectable levels to values greater than 200 ng/ml (reviewed by 
Vaughan, 1998). The majority of normal individuals have PA11 antigen levels that vary between 
0 and 60 ng/ml, with a mean level around 20 ng/ml (Declerck et al., 1988a). In this study, the mean 
concentration of total PAI 1 for the controls was 57 ±66 ng/ml (mean age of 41 years). The median 
value, which is more representative of the normal range than the mean, was 34 ng/ml. When 
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population and/or assay differences (eg. calibration curves for PAl1) are taken into account, it may 
be concluded that the mean, median and range for plasmatic PAI 1 obtained with this novel assay 
is reliable and is a true reflection of the normal population studied. There were only two outliers 
(greater than 200 ng/ml) amongst the 38 controls (see A.58, patient numbers 15 and 28). To 
ensure that these high PAl1 levels were not due to technical errors, one of the patients (number 
28) was tested three times. Since approximately the same PAl1 value was obtained with all three 
samples, it could be concluded that the elevated PAl1 levels of these two control individuals is not 
due to experimental error or artefacts but rather due to some unknown pathological condition. 
In order to verify the ability of the assay to quantitate the active fraction of PAl1 in plasma, data 
from other investigators were compared with the findings from this study. Previous studies have 
shown that approximately two thirds of plasmatic PAI 1 is in the active conformation (Booth et al., 
1988; Declerck et al., 1988a). In this study, a mean value of 62 ±10.5% for the active fraction of 
PAl1 was observed for the controls (median was 64%). Thus, it was concluded that the values 
obtained with this novel assay are reliable and is representative of the active fraction of plasmatic 
PAl1 for a normal population. It was important to ensure that the blood collection and storing 
procedures used in this study would not contribute to artefacts in determining the active fraction of 
plasmatic PAl1. To test this, three control samples were collected as described in Materials and 
Methods (6.4) and were analysed after various time points (0-3 hours). There were no differences 
in the active fraction of PAl1 between the different time points when samples were stored at 4°C 
(results not shown). Thus, it was concluded that processing the patient samples within 1-2 hours 
of blood collection provided reliable and reproducible measurements. 
The primary aim of this study was to determine whether high or low plasma levels and/or activity of 
PAl1 correlates with the presence of metastatic disease in patients with melanoma. It is important 
to note that all comparative analyses excluded gender as a parameter, since there was no 
statistical difference in plasmatic PAI 1 antigen or activity levels between male and female control 
subjects (results not shown). The results of this study did not reveal a statistical difference in total 
plasmatic PAl1 levels between the controls and patients with PM or AM (see Figure 7.2). In order 
to interpret these results, it is important to note that a number of factors have been shown to 
stimulate PAI 1 synthesis by endothelial cells (reviewed by Loskutoff et al., 1989). These include 
growth factors like transforming growth factor beta (TGFp), basic fibroblast growth factor (bFGF), 
interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFa). The involvement of steroids in 
stimulating PAl1 biosynthesis have also been described. It could therefore be concluded that the 
above mentioned factors that are known to upregulate PAl1 biosynthesis are unlikely to contribute 
significantly to an alteration in the fibrinolytic balance of the blood for the patients in this study. In 
contrast to the findings of this study, a rise in the plasmatic PAI 1 level has been reported 
previously for patients with advanced ovarian (Casslen et al., 1994), colorectal (Nielsen et al., 
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1998) and gastric cancer (Ho et al., 1998) and a rise in plasmatic PAI activity (total inhibitory 
activity) has also been described for patients with advanced breast cancer (van Tempelhoff et al., 
1997). However, at this stage it is unclear why the plasmatic PAI 1 levels for patients with AM was 
not significantly elevated compared to the controls, as reported for the above mentioned 
carcinomas. It could be that elevated plasmatic PAl1 levels is a late event in the disease 
progression and that it is strongly linked to liver metastases (Leiper et al., 1994). The data of this 
study supports this theory, since none of the eight stage IV patients had any clinical evidence of 
liver metastases. 
Although there was no difference in plasmatic PAl1 levels between the controls and patients with 
PM or AM, there was a significant difference (P = 0.0042) in the percentage active PAl1 (see 
Figure 7.3). The data for the active fraction of plasmatic PAl1 was subsequently analysed by the 
linear discriminant function to determine a clinically meaningful value for the percentage active 
PAI 1. A cut off value of less than 44% active PAI 1 was obtained: This means, that a melanoma 
patient with a plasmatic PAl1 activity value of~ess than 44% will have a 50% chance of harbouring 
metastases (see Table 7.2). A false positive rate of 2.6% was obtained with this analysis. Only 
4 out of 18 (22.2%) patients with AM had PAl1 activity values greater than 61% and another five 
(27.8%) had values between 44 and 61 %. This may indicate a more stabilised or less aggressive 
disease amongst the other 50% of the patients with AM. Of the nine patients with AM having a 
PAl1 activity value of less than 44%, 6/10 were stage Ill and 4/8 were stage IV patients. There 
were four (19%) patients with PM having PAl1 activity values of less than 44%. Of these four 
patients, 1/7 were stage I and 3/14 were stage II patients. It is therefore possible that the plasmatic 
PAI 1 activity level could be predictive of metastatic disease for patients with PM. A follow-up period 
of three to five years should be sufficient to determine whether these four patients will ultimately 
develop metastases (Delaunay, 1992). The active fraction of PAl1 for patients with PM differed 
also significantly (although borderline, P = 0.0488) from the controls. The data therefore strongly 
supports further investigations to determine whether plasmatic PAl1 activity levels might be 
predictive of metastatic disease. 
In conclusion, in this study it was found that the plasmatic PAI 1 levels for patients with AM was not 
significantly elevated compared to the controls, but a significant reduction in the active fraction of 
plasmatic PA11 was found. This last section of the discussion attempts to explain the biological 
basis of this reduction of the active fraction of PA11 in PM and AM patients. It is possible that 
certain individuals with PM are genetically predisposed to develop metastases. Lower levels of 
PAl1 activity would provide a biological basis for such a predisposition. However, if this was the 
case then one would predict that in a normal population one would find some patients with levels of 
PAI 1 activity as low as those patients with AM. The data of this study does not support this theory: 
The lowest percentage active PAl1 for the controls was 38% (which is an outlier). Seven of the 
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nine patient with AM (see A.60) had percentage active PAl1 below 38%. This means that there is 
no overlap between the lowest range of the controls and the lowest range of patients with AM (see 
Figure 7.3). Thus, from this it can be deduced that there is not a genetic predisposition for lower 
levels of PAl1 activity in the normal population. Instead, it suggests a causative link between the 
development of metastases and a reduction in the active fraction of plasmatic PAl1. 
There are a number of factors that have the potential to influence the overall fibrinolytic activity 
through their effects on PAl1 (reviewed by Edelberg et al., 1994; Loskutoff et al., 1989) and these 
are summarized in Figure 8.2. The first group of factors includes molecules, like vitronectin (VN), 
that stabilize plasma PAl1 against spontaneous inactivation. The second group of factors includes 
a number of agents that may inactivate PAl1 directly, including oxidants liberated by activated 
inflammatory cells and proteases. There are two classes of proteases that have the potential to 
inactivate PAI 1: Those that inactivate it through the formation of an enzyme-inhibitor complex, for 
example PAs and activated protein C and those that directly cleave PA11 as a substrate, for 
example thrombin and neutrophil elastase. The third group of factors includes molecules that may 
convert latent PAl1 into its active conformation, for example negatively charged phospholipids on 
cell surfaces (eg. platelets) that could provide the site for activation of latent PAl1. This is unlikely, 
since in this study a reduction in the active fraction of PA11 was observed and not an increase. 
The reduction in the active fraction of plasmatic PAl1 in patients with AM could possibly be 
explained in the light of the above mentioned information. The first possibility is that there could be 
a functional defect with VN or factors that might interfere with the binding of VN to PAl1. This would 
ultimately affect PA11 activity since VN is known to stabilize the activity of PAl1. It has been shown 
that heparin (an endothelial matrix component like VN) can block the interaction between VN and 
PAl1 and that this competition between heparin and VN may decrease the overall PAl1 inhibitory 
capacity due to displacement of the inhibitor from VN (Preissner et al., 1990). It is possible that 
elevated proteolytic activity in the blood could cause a release of endothelial matrix-bound heparin 
into the blood. The elevated heparin levels may compete with VN for binding to PAl1, thus 
destabilizing the activity of PAl1. Plasmin, in turn, could proteolytically digest VN, destroying its 
PAl1- and heparin-binding capacity (Sane et al., 1991). 
The second option, that is, that there are agents that may inactivate PAI 1, seems to be an equally 
possible option. Tissue PA is the most likely candidate from all the proteases mentioned, since it is 
commonly upregulated in melanoma tumors (Hoal-Van Heiden et al., 1986) and it plays a key role 
in the metastasis of melanoma (reviewed by de Vries et al., 1996). It is possible that the presence 
of melanoma metastases (regional or systemic) could result in elevated plasmatic tPA antigen 
and/or activity levels. Since PAI 1 is known to be the main regulator of fibrinolytic activity in blood, it 
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Figure 8.2. A model of the factors involve in the regulation of PAI 1 activity. 
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EC, endothelial cell; SMC, vascular smooth muscle cell; BM, basement membrane; PAs, 
plasminogen activators; PAl1, plasminogen activator inhibitor type 1; VN, vitronectin. The factors 
that might play a role in the modulation of PAl1 activity have been boxed. 
can be speculated that the tumor-derived tPA will bind to the free or VN-bound active plasmatic 
PAl1. This could result in a reduction of the active fraction of plasmatic PAl1 due to tPNPAl1 
complex formation. Another candidate could be tumor-derived neutrophil elastase which has been 
shown to inactivate PA11 by proteolytic cleavage (Urano et al., 1996; Wu et al., 1995). Similarly, 
thrombin has been shown to efficiently inactivate PAl1 in the presence of either VN or heparin, 
unless a sufficient excess of the inhibitor is present (van Meijer et al., 1997a; van Meijer et al., 
1997b). Thrombin, in turn, can activate protein C which in turn can inactivate PA11 by complex 
formation (Sakata et al., 1985). In addition, PAl1 may also bind to fibrin to inhibit tPA-mediated 
fibrin dissolution (Reilly & Hutzelmann, 1992). However, the role of the fibrin clot in altering the 
specificity of PAl1 is poorly understood. The end effect of the above mentioned proteases will be 
an increase in the overall fibrinolytic activity since more plasmin is generated. It should be possible 
to test these hypotheses by monitoring the antigen and/or activity levels of these candidate factors. 
In summary, this study shows for the first time that there is a reduction in the active fraction of 
plasmatic PA11 in patients with AM and that a value of less than 44% seems to be indicative of 
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metastatic melanoma. Furthermore, it is speculated that this reduction might be attributed to tumor-
derived tPA and/or other melanoma-derived proteases or factors which may disturb the fibrinolytic 
balance of the blood and which might reflect the progression of the disease towards a more severe 
condition. As mentioned earlier, it is possible that elevated plasmatic PAl1 levels could be a late 
event in melanoma progression and that this is strongly linked to liver metastases. In contrast, it 
seems that a reduction in the active fraction of plasmatic PAl1 could be an early event in 
melanoma progression that is related to an alteration of the fibrinolytic balance brought about by 
the proliferation and metastasis of melanoma. It is generally accepted that the ability of serum 
markers to predict metastatic disease is dependent on a critical minimum tumor mass. It would 
therefore be of enormous value to determine to what extent the active fraction of plasmatic PAI 1 
could be used to monitor the progression of primary and/or metastatic melanoma. 
FUTURE CONSIDERATIONS 
There are several technical issues that need to be addressed before larger clinical studies are 
pursued. lmmunoassays that make use of Pabs are often troubled with calibration problems and 
suffer from a lack of reproducibility and availability of reagents. It would therefore be imperative to 
develop a mouse or rat Mab to PAl1, which could replace the rabbit anti-PAl1 Pab that was used 
as a capture antibody in this study. This would allow the development of a standardised assay that 
could be used by other investigators. Furthermore, it would be advisable to calibrate the rPAl1 
standard by amino acid analyses or to obtain an international standard for PAl1. Another aspect to 
consider is to make use of calibration curves that were constructed in PAl1-depleted, pooled 
normal human plasma (Declerck et al., 1988a). This would ensure more accurate PAl1 
measurements since the plasma components might interfere with the linearity of the calibration 
curves when plasma dilutions smaller than one in ten are used. Special attention should be given 
to determine the ability of the assay to measure with accuracy the active fraction of PAl1 in 
plasma. 
Once these technical issues have been addressed thoroughly, a larger number of melanoma 
patients with primary and advanced disease should be studied. It would be interesting to follow-up 
patients with AM who have plasmatic PAl1 activity values less than 44%. Will the prognosis of 
these patients be worse? Conversely, will the prognosis of patients diagnosed with regional or 
systemic metastases and with normal plasmatic PAI 1 activity values be better? Moreover, could 
plasmatic PAl1 activity be used as a predictor of metastasis for patients diagnosed with PM? Long 
follow-up periods (3-5 years) would be necessary to determine whether patients with PM that 
develop plasmatic PAl1 activity values less than 44%, would be indicative of metastatic 
progression. Finally, factors that might cause false positives (eg. medication) is another important 
aspect to investigate. 
~ECTION Cj 
CHAPTER 9: THE DEVELOPMENT AND CHARACTERIZATION OF MONOCLONAL 
ANTIBODIES AGAINST PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 
9.1 Introduction 
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Tumor cell invasion and metastasis depends on the ability of tumor cells to degrade and to 
migrate through connective tissue barriers by modulating cell-to-cell or cell-to-matrix adhesive 
interactions (reviewed by Andreasen et al., 1997; Chen, 1992; Mignatti & Rifkin, 1993). The 
plasminogen-plasmin system (reviewed by Kwaan, 1992; Plow et al., 1995) is prominently 
involved in these processes. The activation of plasminogen (Pig) yields the important extracellular 
proteinase, plasmin, which may degrade specific extracellular matrix (ECM) components directly 
or indirectly by the activation of metalloproteinases and growth factors (reviewed by Keski-Oja et 
al., 1991; Mignatti & Rifkin, 1993). The generation of plasmin is strictly controlled by the action of 
the plasminogen activators (PAs). Of the two types, tissue plasminogen activator (tPA) has a 
predominant fibrinolytic function (Edel berg et al., 1991 ), while urokinase (uPA) is believed to be 
principally responsible for extracellular proteolysis (reviewed by Blasi, 1993). The activity of the 
PAs is regulated at the transcriptional level by hormones, cytokines and growth factors (reviewed 
by Keski-Oja et al., 1991; Laiho & Keski-Oja, 1989), at the processing level by plasmin, which 
converts the single-chain form to the proteolytically active two-chain form (de Serrano & 
Castellino, 1990) and at the functional level by inhibitors (Potempa et al., 1994), of which PAl1 is 
considered to be the most important (reviewed by Loskutoff et al., 1989; Reilly et al., 1994). 
Pig and uPA bind to specific receptors and thereby direct plasmin activity to the migrating tumor 
cell surface (reviewed by Andreasen et al., 1997; Bu et al., 1994; Plow et al., 1995). 
Active two-chain uPA and its single-chain pro-enzyme bind with high specificity to the 
glycosylphosphatidylinositol (GPl)-anchored cell surface receptor, uPAR (Ploug et al., 1991 ). This 
interaction alters the conformation of the uPAR (Ploug et al., 1994), thereby increasing its affinity 
for the somatomedin B (SMB) domain (Seiffert et al., 1994) of vitronectin (VN) in the ECM. The 
induction of the uPAR promotes cell adhesion through its interaction with VN and facilitates cell 
migration and invasion by localizing uPA to the cell surface. Active PAl1 binds with a higher 
affinity to the SMB domain of VN (Deng et al., 1996b) than uPAR and competes with the receptor 
for binding to SMB (Deng et al., 1996a). This interaction detaches U937 myeloid cells from their 
VN substratum and appears to occur independently of its ability to function as a protease inhibitor 
(Waltz et al., 1997). An excess uPA will reverse the anti-adhesive effect of PAl1. Stahl and 
Mueller (1997) have demonstrated that PA11 can stimulate M24met melanoma cell migration on 
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VN, presumably by inhibiting uPA/uPAR-mediated cell adhesion to VN and thereby releasing the 
inhibition of cell migration induced by uPA (Stahl & Mueller, 1994; Stahl & Mueller, 1997). 
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Solid tumors are typically composed of transformed cancer cells which display some form of 
genetic instability and normal stromal cells (eg. fibroblasts, inflammatory and endothelial cells) 
which are thought to be genetically stable but which may become activated during tumor 
progression to produce proteases, inhibitors and other regulatory factors (reviewed by Edwards & 
Murphy, 1998; Hanahan, 1998; Lochter et al., 1997). In several human cancers only stromal cells 
produce PAl1 (eg. colon adenocarcinomas; Pyke et al., 1991) while in others only cancer cells 
make PAl1 (eg. squamous cell carcinomas of the skin; Sappino et al., 1991). The presence of 
ECM-associated PAl1 inside the tumor could serve to protect neovascularized tissues from the 
uPA-mediated proteolysis the tumor imposes on itself. PAl1 might also be of importance for 
reimplantion of circulating tumor cells, since formation of new stroma at the metastatic site would 
require the blocking of uPA-mediated degradation of ECM-components (Pappot et al., 1995). 
The uPA/uPAR/Plg system may provide surface-associated protease activity to promote tumor 
cell invasion and simultaneously promote tumor cell adhesion through the interaction of cell-
bound uPA with matrix-bound VN (reviewed by Blasi, 1997). Considerable evidence indicates 
that PAl1 is the molecular switch that controls tumor cell adhesion and migration through the 
uPA/uPAR system (Deng et al., 1996a). PAl1 acts as a cell detachment factor by competing with 
the uPAR for binding to VN (Stahl & Mueller, 1997; Waltz et al., 1997). These findings may 
explain why increased tumor levels of PA11 correlate with a poor prognosis (Allgayer et al., 1997; 
Foekens et al., 1994; Kim et al., 1998; Knoop et al., 1998; Sier et al., 1994) and why PAl1-
deficient mice show reduced invasion and vascularization of malignant keratinocytes compared 
with wild-type mice (Bajou et al., 1998). 
9.2 Specific aim of study 
The specific aim of this study was to develop Mabs against a variety of diverse epitopes 
of PAl1 in an attempt to obtain useful reagents to study the role of PA11 in the metastasis 
and vascularization of human melanoma. Such antibodies would for example, be useful 
reagents for studying the interaction of PAl1 with ECM and PA components, for blocking 
its activity in tissue culture experiments, for immunoblotting, for immunofluorescence or 
immunocytochemistry and for the measurement of PAl1 in biological fluids. In a previous 
attempt to produce murine Mabs against Escherichia coli-derived rPAl1, it was found that 
the compound was a poor immunogen (C. Heussen-Schemmer: personal 
communication). This was possibly due to inappropriate or inadequate post-translational 
modification of the molecule. However, it was then decided to investigate the baculovirus 
expression system (Webb & Summers, 1990) as a means of expressing PAl1 in insect 
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cells and to follow then the recommendations of de Boer et al. (1992) using the crude 
infected cell population as the immunogen (de Boer et al., 1992). 
50 
This section of the thesis describes the success that was obtained with this approach and the 
characteristics of the Mabs that it provided. During the course of this study it became clear to the 
investigator that studies concerning the role of PAl1 in tumor cell invasion and vascularization will 
fall outside the main theme of this thesis. Therefore, the potential value of these Mabs in the 
study of metastasis was not pursued but will most likely form part of future studies. However, two 
of the Mabs that were obtained with this approach turned out to be extremely valuable and were 
used in the study described in section B of this thesis. 
51 
CHAPTER 10: MATERIALS AND METHODS 
10.1 Cell lines and reagents 
The complementary DNA (cDNA) for human PAl1 (clone PAIB6, 1.9 kb) was obtained as a gift 
from Dr. David Ginsburg from the Department of Internal Medicine and Human Genetics, Howard 
Hughes Medical Institute, Medical School of the University of Michigan. The pBlueBac-2 vector, 
wild-type Autographa californica multiple nuclear polyhedrosis virus (WT-AcMNPV) DNA and 
Spodoptera frugiperda insect cells (Sf9 strain) were purchased from lnvitrogen Corporation (San 
Diego, CA). Sf9 cells were maintained as a monolayer in TNMFH medium supplemented with 
10% FCS and 50 µg/ml gentamycin sulphate at 27°C under 100% air and 90% humidity (see 
A.15 - A.16 for details). Suspension cultures were grown under the same conditions in 
Erlenmeyer tissue culture flasks (Corning, Acton, MA) on a horizontal platform with orbital 
shaking. 
The PAl1 ELISA kit was obtained from American Diagnostica Inc. (New York, NY). Escherichia 
coli-derived human recombinant PAI 1 (rPAI 1) in the latent form was obtained as a gift from 
Dr. E.J. Goldsmith from the Department of Biochemistry, University of Texas, South-West 
Medical Centre, Dallas. Latent rPAl1 was activated with 4M guanidine.HCI for 30 mins at 37°C 
and then dialysed extensively at 4°C against PBS (Hekman & Loskutoff, 1985). The activated 
PAl1 was stored at -80°C and thawed once for experiments. Recombinant tPA was a generous 
gift from Dr. 0. Safriel, Technifin, South Africa. The enzyme was converted to the two-chain form 
by treatment with plasmin linked to Sepharose 48 (see A.56 for details). The SP-2 and PA-1 
mouse myeloma cell lines and the HT1080 fibrosarcoma cell line were purchased from the 
American Type Culture Collection. The cells were maintained in RPMI medium supplemented 
with 10% fetal calf serum (FCS), 50 U/ml penicillin and 20 µg/ml streptomycin at 37°C under 5% 
C02/95% air and 90% humidity (see A.20 for details). 
10.2 Production of polyclonal antibodies to PAl1 
The polyclonal antibodies to PAl1 were prepared by Dr. Christa Heussen-Schemmer previously 
from the Department of Clinical Science and Immunology at the University of Cape Town. Briefly, 
two New Zealand rabbits each received 100 µg E. coli.-derived rPAl1 in Complete Freund's 
Adjuvant (Difeo) subcutaneously (s.c.) at several sites. Subsequent immunizations were 
performed on days 30, 38, 88 and 255 with 50 µg rPAl1 in Incomplete Freund's Adjuvant. High 
titre anti-sera were pooled and shown to be specific by ELISA and immunoblotting (results not 
shown). The antibodies were purified by caprylic acid and ammoniumsulphate (Reik et al., 1987) 
precipitations (see A.33 for details). 
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10.3 Expression of PA11 in insect cells 
I am greatly indebted to Mrs. Debby Clarke who has carried out the cloning of the PAl1 cDNA into 
the baculovirus vector and subsequent plaque purifications. Briefly, the 1.46 kb coding sequence 
for the mature PAl1 protein (Ginsburg et al., 1986) was removed from the vector pUC13 by 
digestion with EcoR-1 and Bgl-11, blunt-ended and attached to Nhe-1 linkers for insertion into the 
pBlueBac-2 vector (Figure 10.1 ). This construct was cloned and amplified in Top1 Of competent 
bacterial cells (after verification of the correct orientation by Pst-1 and Barn-HI restriction analysis) 
and used to co-transfect Sf9 cells with WT-AcMNPV DNA (Figure 10.2). Recombinant plaques 
were selected for expression of beta-galactosidase after one round of plaque purification and 
screened by dot blotting with a digoxigenin-dUTP labelled PAl1 cDNA probe to verify stable 
insertion of PAI 1. A positive plaque was subjected to four rounds of plaque purification until no 
occlusion bodies were visible and until the plaque was PCR-negative for WT virus contamination. 
PAl1 recombinant virus stock was prepared and the virus titre (plaque forming units per ml) was 
calculated. Monolayer and suspension cultures were infected with the PA11 recombinant virus at 
a multiplicity of infection (MOI) of three. Aliquots of the conditioned medium (CM) were removed 
every 24 hours and quantitated for PAl1 antigen using a commercial PAl1 ELISA. PAl1 levels of 
more than 10 µg/ml was measured after 4 days in culture. Details of the procedures used are 
described elsewhere (Summers & Smith, 1987; Webb & Summers, 1990). 
10.4 Monoclonal antibody production 
The titre of the PAI 1 recombinant virus stock preparation was determined by a standard 
protocol ( see A.17 for details). A suspension culture of Sf9 cells ( see A.15 for details) 
was infected with the purified PAI 1 recombinant virus at a MOI of five (see A.18 for 
details). After 3 days in culture a sample of cells was removed and multi-well slides 
(Veenstra & Dowdle, 1992) were prepared for immunofluorescence (see A.45 for details) 
to confirm the expression of PAl1 using the anti-PAl1 Mab supplied by American 
Diagnostica Inc. as the primary antibody (approximately 10 µg/ml) and fluorescein-
conjugated goat anti-mouse lgG (Cappel, 50 µg/ml) as the secondary antibody. 
lntraperitoneal (i.p.) injections of 4-6 x 106 PAl1 expressing Sf9 cells in PBS were used 
to immunize Balb/c female mice. Three immunizations were carried out at two week 
intervals. Two weeks after the second immunization, the sera (see A.19 for details) were 
tested for anti-PAI 1 antibodies using a capture ELISA as described below under 
Screening assay. A final booster was given three days before the fusion. The spleen 
cells from an immune mouse were fused with SP2 mouse myeloma cells (see A.20-A.26 
for details) according to published methods (Harlow & Lane, 1988; Pontecorvo, 1975). 
The resulting hybridomas were screened with the capture ELISA as described below 
under Screening assay (see 10.5) and cloned once by limiting dilution. 
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Xbal 
Hindlll 
Figure 10.1. Construction of pBlueBac2/PAI 1 vector. 
AmpR, ampicillin resistance; lacZ, beta-galactosidase; 
RS, recombination sequences; pPH, polyhedrin promoter; 
pETL, ETL promoter. 
(Bglll) Nhel 
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5:1: homologous 
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p Al-1 pPH pETL lacZ 
PAl-1 recombinant virus 
Figure 10.2. Construction of PAl1 recombinant baculovirus. 
AmpR, ampicillin resistance; lacZ, beta-galactosidase; 
RS, recombination sequences; pPH, polyhedrin promoter; 
pETL, ETL promoter. 
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10.5 Screening assay 
Coating an antigen directly on an ELISA plate for screening purposes could result in a 
preferential orientation of the antigen on the plastic surface. Consequently, some epitopes of the 
antigen might be hidden and would not be available for antibody binding. The use of a polyclonal 
antibody will minimise this problem by capturing the antigen in different spatial orientations on the 
ELISA plate. A round-bottom polyvinylchloride (PVC) ELISA plate (Dynatech) was coated with 
rabbit anti-PAl1 (RaPAl1, immunoglobulin fraction) at 20 µg/ml in PBS for 2 hours at room 
temparature (RT). The reagents used by all the ELISA procedures were added to the plates at 
50 µI per well (unless otherwise stated) and all steps were followed with five washes TST-buffer 
(see A.27 for details) except for the last wash which was done ten times. All incubation steps 
were for 30 mins at RT (except if mentioned differently). The plate was blocked with 0.1 % bovine 
serum albumin (BSA) in PBS. This was followed by 1 µg/ml latent rPAl1 in blocking solution and 
then the antibody-containing hybridoma CM (100 µI/well) to duplicate wells. An anti-PA11 Mab 
from American Diagnostica was included as a positive control. Mouse anti-beta galactosidase 
Mab (see A.28 for details), normal mouse serum and sheep serum were included as negative 
controls. Bound antibody was revealed with the peroxidase anti-peroxidase (PAP) method (De 
Blas & Cherwinski, 1983). The sheep anti-mouse lgG antibody (SAM) and the PAP were 
prepared (see A.28-A.29 for details) as described previously (Heussen-Schemmer et al., 1993). 
2,2-Azino-di (3-ethyl-benzthiazoline) sulphonic acid (ABTS) was used as a substrate (see A.30 
for details). The absorbance at 405 nm was read after 15 mins on an Organon Teknika Microwell 
ELISA Plate Reader. 
10.6 Additivity assay 
The epitope specificity of 20 selected anti-PAI 1 clones was determined by a standard additivity 
assay (Friguet et al., 1985). Saturating amounts of each antibody alone, and in all possible paired 
combinations, were added to duplicate wells (50 µI each) of an ELISA plate prepared with 
RaPAl1 capture antibody and 1 µg/ml rPAl1. This concentration of PAl1 gave a 405 nm reading 
of approximately 1.0 after 15 mins of substrate addition. The total amount of bound antibody was 
determined by the PAP method as described under Screening assay (see 10.5). The additivity 
index (Al) for each combination of antibodies was calculated as 
[A1+2 - (A1+A2)/2] I [(A1+A2)/2] x 100 where A1+2 = 50 µI of Mab1 + 50 µI of Mab2, 
A1 = 50 µI of Mab1 + 50 µI of blocking solution and A2 = 50 µI of Mab2 + 50 µI blocking solution. 
Index values of greater than 40% were considered significant. Hybridoma clones with significant 
index values were selected and cloned once more by limiting dilution. 
10. 7 lsotyping and purification of antibodies 
Serum-free hybridoma CM from the selected clones were used to determine the isotype of the 
antibodies by a standard ELISA procedure (see A.31 for details; Coligan et al., 1994a). The Mabs 
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from the selected clones were purified from ascites fluid (see A.32 for details) or from 
concentrated serum- and protein-free hybridoma CM (Hybrimax, Sigma) by caprylic acid and 
ammonium sulphate precipitations (see A.33 for details; Reik et al., 1987). The purity and the 
molecular weight of each antibody preparation was verified on a 10% polyacrylamide gel under 
reducing conditions (see A.34-A.41 for details; Laemmli, 1970). 
10.8 Preparation of extra- and intracellular and matrix-associated PAl1 
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HT1080 cells (Laug et al., 1992) were used to prepare PAI 1 from different components of the cell 
culture for immunoblotting. The cells were plated at 5x105 cells per 100 mm dish and were 
allowed to grow for 48 hrs. Serum-free 24-hour CM was collected in 0.1 % BSA, filtered through a 
0.45 µm syringe filter and stored at -80°C as a source of extracellular (secreted) native PA11 
(nPAl1). The cells were dislodged from the culture dish with versene and lysed for 30 mins on ice 
at 5x106 cells/ml lysis buffer (PBS containing 0.5% NP-40, 1 mM phenylmethyl sulfonylfluoride 
[PMSF, Sigma], 2 mM EDTA). The cell nuclei were removed by centrifugation (700 g, 10 mins) 
and the supernatant was stored at -80°C as a source of intracellular nPAI 1. The cell-matrix 
attached to the culture dish was washed with cold PBS containing 0.5% Triton X100, 1 mM 
PMSF and 2 mM EDTA for 5 mins at 4°C to lyse remaining cells. It was then rinsed twice with 
cold TST-buffer (20 mM Tris-HCI pH 7.4, 100 mM NaCl, 0.1 % Tween-80) and solubilized with 
500 µI 1x SOS sample buffer (see A.36 for details; Mimuro et al., 1987). The viscous ECM 
preparation was stored at -80°C as a source of matrix-associated n PAI 1. 
10.9 lmmunoblotting 
PAl1-containing samples were electrophoresed (100 V/cm; 2 hours; 4°C) in a 10% 
polyacrylamide gel (Laemmli, 1970) without boiling the samples and under non-reducing 
conditions (see A.34 - A.41 for details). The separated proteins were electro-blotted onto 
lmmobilon-P polyvinylidene difluoride (PVDF) membrane (Millipore) using a standard electro-
blotting procedure (see A.42-A.43 for details). A cocktail of the selected Mabs was used as the 
primary antibody (5 µg/ml each in PBS containing 0.5% BSA). A biotinylated rabbit anti-mouse lg 
(Dake) was used as a secondary antibody and was followed with peroxidase-conjugated 
streptavidin (Dake). Luminol was used as a chemiluminescent substrate (Boehringer Mannheim) 
to detect peroxidase activity after a 30 second exposure to Cronex-4 X-ray film (see A.44 for 
details). 
10.10 lmmunofluorescence and immunocytochemistry 
HT1080 cells were grown to semi-confluency on glass slides fitted with 8-well (7x7 mm) tissue 
culture chambers (Lab-Tek). The cells were washed with PBS, fixed with 50% methanol/ 50% 
acetone for 90 secs and then transferred to TBS-buffer (50 mM Tris.HCI pH 7.6, 100 mM NaCl) 
for 5 mins. After blocking with 0.1 % BSA in PBS, each well was incubated for one hour with a 
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selected Mab (20 ug/ml). The bound antibody was detected with a fluorescein-conjugated goat 
anti-mouse lgG (Cappel, diluted 1/400). Cell nuclei were counterstained with ethidium bromide 
and viewed under a fluorescent microscope using a blue excitation filter (see A.45-A.46 for 
details; Veenstra & Dowdle, 1992). For immunocytochemistry a similar protocol was used, with 
19 parts methanol I 19 parts acetone / 1 part formaldehyde ( 40%) for 90 secs as the fixative and 
biotinylated rabbit anti-mouse lgG (Dake, diluted 1/500) as the secondary antibody. Bound biotin 
was detected with peroxidase-conjugated streptavidin (Dake, diluted 1/1000) and peroxidase 
activity with the insoluble chromogenic substrate diaminobenzidine (see A.47 for details). The 
nuclei were counterstained for 5 mins with 1 % haematoxylin (in 100% ethanol) and the cells were 
examined microscopically for the presence of brown precipitate. 
10.11 Matrix-associated PAl1 ELISA 
A flat-bottom 96-well tissue culture plate (Cell-Cult) was seeded with 2x104 HT1080 cells per well 
and allowed to grow for 48 hours. In the steps to follow, all reagents were carefully added with a 
Digital Multichannel Pipette (Labsystems for Flow Laboratories) and drained carefully by inverting 
the plate on an absorbent cloth. The plate was washed once with PBS before dislodging the cells 
with versene for 15 mins at 37°C. Residual cells on the cell matrix were removed by washing the 
plate with cold PBS containing 0.5% Triton X100, 1 mM PMSF and 2 mM EDTA. The plate was 
washed once with PBS and twice with TST-buffer and then blocked with 0.1% BSA in PBS. Serial 
ten-fold dilutions were made for each selected Mab, starting at 10 µg/ml and then incubated with 
the HT1080 cell matrices. The SAM, PAP and substrate were added as described under 
Screening assay (see 10.5). The absorbance at 405 nm was read after 20 mins. 
10.12 Matrix-binding inhibition ELISA 
In part 1 of this experiment, the results of the Matrix-associated PA/1 ELISA was mimicked, by 
substituting the endogenous matrix-accociated PAI 1 with exogenous active rPAI 1. The 
experimental design was essentially as described under Matrix-associated PA/1 ELISA (10.11 ). 
Before proceeding with the blocking, endogenous nPAl1 was depleted from the cell matrix with 
glycine-buffer pH 2.5 (200 µI/well) with two incubations at 37°C for 30 mins each (Mimuro et al., 
1987). The plate was washed once with glycine-buffer; twice with TST-buffer and blocked as 
before. Active rPA11 was incubated at 2 µg/ml with the PAl1-depleted cell matrices. Serial two-
fold dilutions for maPA11/C2, -C6 or -C14, starting at 20 µg/ml, were added to duplicate wells. 
The SAM, PAP and substrate were added as described under Screening assay (10.5). The 
absorbance at 405 nm was read after 20 mins. Negative controls were included for each Mab by 
substituting active rPAl1 with latent rPAl1. 
In part 2 of this experiment, PA11-depleted HT1080 cell matrices were prepared as described 
above. Active rPA11 at 1 µg/ml was incubated in the fluid phase with serial two-fold dilutions of 
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maPAl1/C2, -C6 or -C14, starting at 1000 µg/ml. The antibody-antigen complex (100 µI) was then 
incubated with the PAl1-depleted cell matrices. The wells were washed with TST-buffer and 
matrix-bound PAl1 was detected with maPAl1/C2 or -C11 at 1 µg/ml. The SAM, PAP and 
substrate were added as described under Screening assay (10.5). The absorbance at 405 nm 
was read after 20 mins. 
10.13 Vitronectin-binding inhibition ELISA 
A flat-bottom 96-well ELISA plate (Nunc, MaxiSorb) was coated with 2 µg/ml human vitronectin 
(VN, Sigma) in PBS for 1 hr at RT and then blocked with 0.1% BSA in PBS. Active rPA11 at 
1 µg/ml was incubated in the fluid phase with serial two-fold dilutions of maPAl1/C2, -C6 or 
-C14, starting at 100 µg/ml. The antibody-antigen complex (100 µI) was then incubated with the 
VN-coated wells. The wells were washed with TST-buffer and VN-bound PA11 was detected 
with maPAl1/C2 or -C11 at 1 µg/ml. The bound antibody was detected with goat anti-mouse lgG 
conjugated with alkaline phosphatase (Dake, diluted 1 in 2000). PNPP (100 µI per well) was 
used as a substrate for alkaline phosphatase (see A.57 for details). The plate was incubated for 
1 hr at 37°C and the absorbance was read at 405 nm. 
10.14 Activity inhibition assay 
Fifty microliter active rPA11 at 0.2 µg/ml (in RPMI medium supplemented with 3% plasminogen-
depleted FCS) was incubated for 15 mins at RT with 50 µI 10-fold dilutions of each selected Mab, 
starting at 200 µg/ml. An anti-beta galactosidase Mab (lgG1) was included as a negative control. 
The antibody-antigen complex was incubated with an equal volume of 1 IU/ml 2c-tPA (see A.56 
for details) for 30 mins at RT. The residual PA activity of this mixture was measured as the rate 
of plasminogen-dependent release of soluble radioactive fibrin degradation peptides from 
insoluble 1251odine-labelled fibrin adsorbed to Linbro multiwell plates (see A.48-A.53 for details; 
Wilson & Dowdle, 1978). 
10.15 Recognition of latent and active PAl1 by ELISA 
A 96-well polypropylene ELISA plate (MaxiSorb, Nunc) was coated with RaPAl1 at 50 µg/ml in 
PBS for 2 hrs at RT and then blocked with 0.1 % BSA in PBS. This was followed by 100 ng/ml 
latent or active rPAl1 in blocking solution. The plate was washed with TST-buffer before adding 
maPAl1/C2, -C6, -C11, -C12 and -C14 at 1 µg/ml. The bound antibody was detected with goat 
anti-mouse lgG conjugated with alkaline phosphatase (Dake, diluted 1 in 2000). PNPP (100 µI 
per well) was used as a substrate for alkaline phosphatase. The plate was incubated for 1 hr at 
37°C and the absorbance was read at 405 nm. 
CHAPTER 11: RESULTS AND DISCUSSION 
11.1 The expression of rPAl1 in Sf9 insect cells 
The cDNA for PAl1 was cloned into the pBlueBacll vector as was described in Materials and 
Methods (10.3) and placed under the control of the polyhedrin promoter. This results in the 
inactivation of the polyhedrin gene. Sf9 insect cells were then co-transfected with the vector and 
wild type baculovirus. This results in homologous recombination (in 1-5% of cases) between the 
recombination sequences of the vector and the virus. The resulting recombinant virus expressed 
human PAl1 instead of the polyhedrin protein. Putative recombinant plaques were selected by 
overlaying a monolayer cell culture with an agarose-medium containing 5-bromo-4-chloro-3-
indolyl J3-D-galactopyranoside (X-gal) as a substrate for beta-galactosidase. PAl1 recombinant 
plaques expressed simultaneously beta-galactosidase through the ETL promoter (Figure 11.1.A 
and B). 
11.2 Determination of PAl1 recombinant virus titre 
In order to prepare an insect cell suspension culture expressing human PA11 for immunization, it 
was first necessary to determine the titre of the recombinant virus preparation. A standard 
protocol was followed as described in appendix 17. The results are presented in Figure 11.2. In 
this example the virus titre (plaque forming units per ml) was calculated as (1/10-6 x 21 x 1/2) = 
1.05 X 107. 
11.3 Confirmation of PAl1 synthesis by insect cells for immunization 
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Before proceeding with immunization, it was necessary to confirm the synthesis of PA11 by insect 
cells. This was done with immunofluorescence using a commercial anti-PA11 Mab (Figure 11.3). 
A strong immunofluorescent signal for PAI 1 was detected in the cytoplasm of the infected cells. A 
suspension culture positive for PAI 1 synthesis was used to immunize balb/c mice as described in 
Materials and Methods (10.4). 
11.4 Epitope analysis 
The additivity index (Al) is based upon the principle that two Mabs against two different 
epitopes of the same antigen will give a higher optical density reading than each of the 
antibodies alone, providing that there is no steric hindrance involved and that antigen 
sites are saturated by the antibodies. Five hybridoma clones were selected from the 20 
clones since they had Al values greater than 40%. These were named maPAl1/C2, -C6, 
-C11, -C12 and -C14. All five Mabs were of the sub-class lgG1. The Al values of the 
negative controls were less than 10%. 
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(A) 
(B) 
Figure 11.1. The expression of rPAl1 in Sf9 insect cells. A, Wild type viral plaques (40x magnification) with occlusion bodies in the cells containing the virus which is embedded in the polyhedrin protein. B, Recombinant viral plaques (40x magnification) expressing human PAl1 and beta-galactosidase {blue cells) . The photographs for Figure 11.1 are courtesy of Mrs. Debby Clarke. 
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(A) 
(8) 
(C) 
Figure 11.2. Determination of PAl1 recombinant virus titre. Duplicate monolayer Sf9 cultures were infected with the PAl1 recombinant baculovirus using 10-fold dilutions of the virus stock and overtayed with an agarose-medium containing X-gal as a substrate for beta-galactosidase. The blue plaques that formed on the plate with the 10-6 virus dilution were counted in order to calculate the virus titre. (A) 10"7, (8) 10-6 and (C) 10·5 virus dilutions. 
Mabs to PA/1: Resuffs and discussion 61 
(A) 
(B) 
Figure 11.3. lmmunofluorescence of a Sf9 suspension culture infected with the PAI 1 
recombinant baculovirus (400x magnification). A, Normal mouse immunoglobulin as the negative 
control showing background fluorescence. B, Mouse anti-PAl1 Mab (American Diagnostica) 
showing the expression of human PAl1 by insect cells. A fluorescein-labelled goat anti-mouse 
was used as the secondary antibody. The nuclei were counterstained with ethidium bromide. 
Mabs to PA/1: Results and discussion 
11.5 lmmunoblotting 
In order to evaluate whether any of these Mabs would be suitable for immunoblotting, 
each of the antibodies was tested for its ability to detect PAI 1 from different tissue 
compartments. These included PAl1 from the intracellular (cytoplasmic) and extracellular 
(secreted) compartments as well as ECM-bound PAl1. All fractions were prepared from 
the human fibrosarcoma cell line, HT1080. The PAl1 from the HT1080 cells was 
compared with the PAl1 secreted by the insect cells (see Materials and Methods, 10.8). 
The western blotting results, using the maPAl1/C11 Mab, are presented in Figure 11.4. 
A molecular weight (MW) of 45 kD was obtained for recombinant PAl1 (rPAl1, lane 1) 
and corresponds to the expected size as estimated from the 379 amino acid sequence. 
A 52 kD glycosylated native PAl1 (nPAl1) was detected in mammalian cell HT1080 
conditioned medium (CM, lane 5) compared to a 48 kD glycosylated rPAl1 in insect cell 
CM expressing human PAl1 (Sf9/PAl1, lane 2). This clearly indicates differences in the 
glycosylation of human PAl1 by insect cells compared to human cells. The detection of 
PAl1 in Sf9/PAl1 CM confirms that PAl1 is secreted by the infected insect cells. Non-
glycosylated PAl1 (45 kD faint band in lane 5) was also present in the HT1080 CM and 
might be explained by cell lysis over the 24 hour period of CM collection, since non-
glycosylated forms are not expected to be secreted. Two additional bands were 
observed in HT1080 CM (lane 5): these bands are most likely tPA/PA11 (127 kD) and 
uPA/PAl1 (106 kD) complexes, since (a) the MW's of the complexes correspond to 
published data (Laug et al., 1992), (b) HT1080 cells are known to secrete both forms of 
PA and (c) the bands disappear when electrophoresis is performed at RT [It has been 
shown that prolonged incubation of SOS (present during electrophoresis) with PA/PAl1 
complexes will result in their dissociation in a time- and dose-dependent manner 
(Gaussem et al., 1993)]. Antibodies against tPA and uPA should clarify with certainty the 
nature of these two bands. 
The HT1080 ECM-preparation (lane 7) reveals a doublet in the 52-55 kD range. The 55 
kD band is most likely intact, active PAl1 while the 52 kD band is latent PAl1 which, 
owing to a conformational change runs slightly ahead. It is unlikely that the 52 kD band is 
inactive PAl1 since the 52 kD band is the major fraction of PA11 found in HT1080 CM 
(lane 5). This PAl1 from the CM can be activated with guanidine.HCI and thus confirms 
that it is the latent form. Alternatively, the 55kD band could be active PAI 1 bound to a 
fragment of a cell matrix component, for example a fragment from vitronectin (VN). Only 
glycosylated latent PAl1 was observed intracellularly (lane 8) - presumably having 
accumulated in the Golgi-apparatus. The two high MW bands (lane 8) were the result of 
non-specific streptavidin binding as detected on a control blot (results not shown). Lanes 
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3 and 6 were shorter exposures of 10 seconds each to confirm that the heavy bands in 
lanes 2 and 5 were not doublets. 
• 
1 2 3 4 5 6 
Figure 11.4. Western blotting with maPAl1/C11 Mab. 
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Lane 1, rPAl1 (45 kD) from E.coli ; Lane 2, rPAl1 from Sf9/PAl1 CM; Lane 3, the same as lane 2 but a shorter exposure of 10 secs; Lane 4, WT-baculovirus CM as a negative control ; Lane 5, nPAl1 from HT1080 CM; Lane 6, the same as lane 5 but a shorter exposure of 10 secs; Lane 7, nPAl1 from HT1080 ECM; Lane 8, nPAl1 from HT1080 cell lysate. Molecular weight markers are given in kilodaltons. 
Each individual Mab was similarly tested for its use in immunoblotting (results not 
shown). It was concluded that maPAl1/C11 was the most suitable antibody since it was 
the only one that reacted with both free and PA-complexed forms of PA11 . The 
maPAl 1/C6 was found not to be suitable for Western blotting. 
11.6 lmmunofluorescence and immunocytochemistry 
To assess the suitability of the Mabs for immunofluorescence and immunocytochemistry, each of 
the antibodies was tested as described in Materials and Methods (10.10). Strong fluorescence 
was obtained with maPAl1/C11 when methanol/acetone fixation was used (Figure 11 .5.A) . A 
considerable amount of fluorescence was observed intracellularly as well as on the cell matrix 
where PAl1 is deposited in a "carpet-like" manner. Weaker fluorescence was obtained with 
maPAl1/C2, -C12 and -C14 while maPAl1/C6 was completely negative. A similar profile was 
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obtained with immunocytochemistry using methanol/acetone/formaldehyde fixation (Figure 
11 .5.B). 
A1 A2 
81 82 
Figure 11.5. A, lmmunofluorescence (400x magnification) and 8, immunocytochemistry (800x 
magnification) on HT1080 cells. 1, Mouse anti-beta-galactosidase Mab (lgG1) as the negative 
control for background staining. 2, MaPAl1/C11 . A fluorescein-conjugated goat anti-mouse lgG 
was used as the secondary antibody for immunofluorescence. The nuclei were counterstained 
with ethidium bromide. A biotinylated rabbit anti-mouse lgG was used as the secondary antibody for immunocytochemistry. The biotin was detected with peroxidase-conjugated streptavidin. The 
nuclei were counterstained with haematoxylin. 
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11.7 Binding of Mabs to matrix-associated PAl1 
PAl1 is a secreted protein whose activity is stabilized by binding to VN, an adhesive protein 
present in plasma, platelets and the ECM (Declerck et al. , 1988a; Lawrence et al., 1994). It was 
therefore of interest to identify those Mabs which would recognize matrix-accociated PAl1 . Cell 
matrices were prepared by culturing of HT1080 cells on microtiter plates and the Mabs were tested 
as described in Materials and Methods (10.11). MaPAl1/C2 (squares) and -C11 (triangles) 
detected matrix-associated PAl1 with high affinity (Figure 11 .6). MaPAl1/C12 (diamonds) and -C14 
(crosses) gave weaker signals. MaPAl1/C6 (circles) failed to detect matrix-associated PAl1 , 
indicating that this Mab most likely binds to the matrix-binding epitope of PAl1 . 
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Figure 11.6. The recognition of endogenous matrix-associated PAl1 by selected Mabs. 
Decreasing concentrations of maPAl1/C2 (0), -C6 (0 ), -C11 (.1.), -C12 (0) and -C14 (x) were incubated with HT1080 cell matrices starting with 10 µg/ml Mab. The maPA11/C6 failed to detect matrix-associated PAl1 which indicated that this Mab might bind to the matrix-binding epitope of PAl1 . The absorbance at 405 nm was plotted against the logarithm of antibody concentration. The 
results are representative of two independent experiments and are expressed as the mean ± SOM of duplicate determinations. 
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11.8 A Mab against the matrix-binding epitope of PAl1 
Before it was possible to test whether maPAl1/C6 is indeed against the matrix binding epitope of 
PAI 1, it was necessary to mimic the results of the previous experiment by replacing the 
endogenous PAl1 with exogenous active rPAl1. The rationale being that this would clarify 
whether active rPAl1 will bind to the PA11-depleted (acid buffer treatment) cell matrices. When 
endogenous PAl1 was depleted from HT1080 cell matrices and replaced with exogenous active 
rPAI 1 (see Materials and Methods, 10.12), similar results (as portrayed in Figure 11.6) were 
obtained (Figure 11. 7a). As expected, the results were negative when active rPAI 1 was replaced 
with latent rPAl1 since it is not able to bind to the cell-matrix (results not shown). The next step 
was to test the ability of each of the Mabs to block the binding of PAI 1 to the cell matrices. Figure 
11.7b illustrates that complete inhibition of PAl1 binding to cell matrices was obtained when PA11 
was pre-incubated with a 100-fold excess of maPAl1/C6 (squares). None of the other PAl1 
antibodies inhibited PAl1 binding to the cell matrix. This confirms that maPAl1/C6 most likely 
does bind to the VN-binding epitope of PAl1. 
11.9 A Mab against the VN-binding epitope of PAl1 
To confirm that maPAl1/C6 will block the binding of PAl1 to VN and not to another matrix 
component, the Mabs were tested for their ability to block the binding of PAl1 to VN immobilized 
on a microtiter plate. Figure 11.8 illustrates that complete inhibition of PAl1 binding to VN was 
observed when the inhibitor was pre-incubated with a 100-fold excess of maPAl1/C6 (squares). 
MaPAl1/C14 (triangles) moderately inhibited the binding of active rPAI 1 to VN. None of the other 
PAl1 antibodies inhibited PAl1 binding to VN as shown with maPAl1/C2 (diamonds). This 
indicates that maPAl1/C6 either binds to the VN-binding epitope of PA11 or in the vicinity of the 
epitope bringing about an inhibitory effect through steric-hindrance. It was recently shown that 
both the somatomedin B (SMB) domain at the N-terminus and the cluster of basic amino acids at 
the C-terminal moiety of VN contributes to PA11 binding (Gechtman et al., 1997). MaPAl1/C6 
most likely binds, in close proximity to the domain of PA11 that interacts with the SMB domain of 
VN, since the immobilization of VN to plastic surfaces renders its cluster of basic amino acids 
inaccessible for binding of PAl1. The ability of the antibody to effectively block the binding of 
active PAI 1 to immobilized VN suggests an inhibitory effect through steric hindrance since the 
antibody also binds to latent PAI 1 (see 11.11 ). 
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Fig.11. 7a. The recognition of exogenous matrix-associated PAI 1 by selected Mabs when added 
to PAl1-depleted matrices. Decreasing concentrations of mcxPAl1/C2 (0), -C6 (D) and -C14 (~.) 
were incubated with HT1080 cell matrices (starting with 20 µg/ml Mab) of which the endogenous 
PAl1 was replaced with exogenous active rPAl1 . Again, as seen in Figure 11.6, mcxPAl1/C6 failed to detect matrix-associated rPAl1 . The absorbance at 405 nm was plotted against the 
logarithm of antibody concentration. The results are representative of two independent 
experiments and are expressed as the mean ± SOM of duplicate determinations. 
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Fig.11.7b. Inhibition of PAl1 binding to HT1080 cell matrices by ma.PAl1/C6. Decreasing 
concentrations of ma.PAl1/C2 (0), -C6 (D) and -C14 (A), starting at 1000 µg/ml , were pre-
incubated with active rPAl1 (1 µg/ml) in the fluid phase. The antibody-antigen complex was then 
incubated with the PAl1-depleted HT1080 cell matrices. Matrix-bound rPAl1 was detected with 
ma.PAl1/C2 or-C11 (1 µg/ml) . A 100-fold excess of ma.PAl1/C6 completely inhibited the binding 
of active rPAl1 to the HT1080 cell matrix. The absorbance at 405 nm was plotted against the 
logarithm of antibody concentration. The results are representative of two independent 
experiments and are expressed as the mean ± SOM of duplicate determinations. 
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Figure 11.8. Inhibition of PAl1 binding to VN by ma.PAl1/C6. 
Decreasing concentrations of ma.PAl1/C2 (0), -C6 (D) and -C14 (~), starting at 100 µg/ml , were 
pre-incubated with active rPAl1 (1 µg/ml) in the fluid phase. The antibody-antigen complex was then incubated with VN coated on a microtiter plate. VN-bound rPAl1 was detected with 
ma.PAl1/C2 or -C11 (1 µg/ml) . A 100-fold excess of ma.PAl1/C6 completely inhibit the binding of 
active rPAl1 to VN. The absorbance at 405 nm was plotted against the logarithm of antibody 
concentration. The results are representative of two independent experiments and are expressed 
as the mean ± SOM of duplicate determinations. 
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11.10 A Mab which inhibits PAl1 activity 
To establish whether any of the Mabs inhibit the activity of PAl1 , they were tested with a standard 
1251odine-fibrin plate assay as described in Materials and Methods (10.14). The concentration of 
0.05 µg/ml active rPAl1 used in the assay resulted in 18% residual PA activity which was 
considered as the background activity (Figure 11 .9) . PAl1 activity was significantly inhibited 
(78%) with ma.PAl1/C6 at 1000-times excess (bar C6). Lower concentrations of antibody were 
not inhibitory. None of the other Mabs inhibited PAl1 activity significantly (bars C2, C11 , C12 and 
C14). The negative control (1000-times excess anti-beta galactosidase Mab) did not inhibit PAl1 
activity. These results therefore demonstrate that ma.PAl1/C6 not only blocks the binding of PAl1 
to VN but also significantly inhibits the activity of PAl1 . 
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Figure 11.9. Inhibition of PAI 1 activity with selected Mabs. The ability of each selected Mab to inhibit PAl1 activity was measured with the 1251-fibrin plate assay and the results are presented as percentage residual PA activity. PA, 0.5 IU/ml 2c-tPA; PAl1 , 0.05 µg/ml active rPAl1 ; Cont, Negative control with 1000-times excess anti-beta galactosidase Mab; C2, C6, C11 , C12, C14, Individual anti-PAl1 Mabs (1000-times excess). The results are representative of two independent experiments and are expressed as the mean ± SOM of duplicate determinations. 
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11.11 Recognition of latent and active PAl1 by ELISA 
To establish whether any of the Mabs would recognize latent and/or active rPAl1 captured on a 
microtiter plate with a rabbit anti-PAI 1 Pab, they were tested with an ELISA procedure as 
described in Materials and Methods (10.15). MuPAl1/C11, -C12 and -C14 recognized latent and 
active rPAl1 with approximately equal affinities (Figure 11.10). The affinity of muPAl1/C2 was 
two-fold greater for latent PAl1 than for the active molecule. MuPAl1/C6 detected only latent 
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PAl1 with an affinity similar to that of muPAl1/C11 . The absorbance value for the active molecule 
was the equivalent of background levels. It was concluded that muPAl1/C6 and -C11 might allow 
the quantitation of the active fraction of PAl1 in biological fluids by subtracting the amount of 
latent PAl1 (detected with muPAl1/C6) from the amount of total PAl1 (detected with 
muPAl1/C11). 
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Figure 11.10. The recognition of latent (a ) and active PAI 1 (a ) by selected Mabs. A rabbit anti-PAl1 Pab was used to capture latent or active rPAl1 on a MaxiSorb ELISA plate. Each of the selected Mabs, ie. mu PAI 1 /C2, -C6, -C 11, -C 12 and -C 14 was tested for the ability to recognize bound latent or active PAl1 . The results are representative of two independent 
experiments and are expressed as the mean ± SOM of duplicate determinations. 
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CHAPTER 12: SUMMARY AND FUTURE CONSIDERATIONS 
This section of the thesis describes several anti-PAl1 Mabs that were developed by making use 
of baculovirus-expressed rPAl1 as the immunogen in order to study the regulatory roles of this 
inhibitor in cancer progression and invasion. Factors contributing to the success of this approach 
may include the effective post-translation modification of the recombinant molecule and the 
secretion of a more soluble form of rPAl1 compared to E. coli-derived recombinant molecules 
which are often troubled by insolubility. Five hybridoma clones with additivity index values greater 
than 40% were selected from 20 clones. Their individual characteristics are presented in Table 
12.1. The data indicate that the five selected Mabs are against different epitopes of PA11, except 
for maPAl1/C12 and-C14 which are most likely against the same epitope of PAl1. The high 
affinity maPAl1/C11 is suitable for immunoblotting, immunofluorescence and 
immunocytochemistry. This indicates that the epitope is resistant to denaturation by SOS, 
methanol, acetone and formaldehyde. MaPA11/C2 and -C11 can be used in ELISA assays for 
the detection of matrix-associated PAl1. MaPAl1/C6 should be suitable for tissue culture 
experiments to block the binding of PA11 to the ECM (thus destabilizing the activity of PAl1) and 
for the simultaneous inhibition of PA11 activity when added in excess quantities. 
Table 12.1 Summary of individual characteristics of selected Mabs 
Mab characteristic C2 C6 C11 C12 C14 
lmmunoblotting + ++ + + 
I mm unofluorescence + ++ + + 
lmmunocytochemistry + ++ + + 
Recognition of ECM-associated PA11 ++ ++ + + 
Inhibition of PAl1 binding to VN ++ 
Inhibition of PA11 activity + 
Recognition of latent PAl1 with ELISA ++ + + + + 
Recognition of active PAl1 with ELISA + + + + 
(++) Strong reaction, (+) Weaker reaction, (-) Negative reaction 
In addition, maPAl1/C11 allows the quantitation of latent and active PAl1 with an equal affinity on 
a microtiter plate. In contrast, maPAl1/C6 can only detect latent PAl1 on the microtiter plate but 
with a similar affinity as maPAl1/C11 has for latent and active PA11. This allows the quantitation 
of the active fraction of PAl1 in biological fluids by subtracting the amount of latent PA11 (detected 
with maPA11/C6) from the amount of total PAl1 (detected with maPAl1/C11). The application of 
this approach is described and discussed in section B of this thesis. 
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FUTURE CONSIDERATIONS 
It is now eminently clear that PAl1 has regulatory functions in the metastasis and vascularization of 
solid tumors. Increased levels of PAl1 in metastases as compared to the primary tumor, support 
this hypothesis (Sier et al., 1994). In concordance, Fletcher and Dowdle (1994) describe the 
presence of PAl1 in adrenal and lung metastases of the highly metastatic melanoma cell line UCT-
Mel-3 in athymic mice, while the parental cell line had no detectable PAl1 (Fletcher & Dowdle, 
1994). This suggests the existence of PAl1-producing melanoma cells within the parental cell line 
which may preferentially metastazise. The UCT-Mel-3 cell line and the two PAl1-producing clones 
that were obtained from adrenal and lung metastases in athymic mice could be an ideal model 
system for studying the role of PAl1 in tumor cell invasion and vascularization using in vitro 
transwell culture systems. As mentioned before, PAl1 acts as a cell detachment factor (Deng et al., 
1996a) by competing with the uPAR for binding to VN (Figure 12.1). Theoretically, the PAl1-
producing clones should have higher metastatic potentials than the parental cell line in a transwell 
culture system with VN supplied as a cell substratum. It might be possible to use the maPAl1/C6 
Mab in this type of experimental design to block the binding of PA11 to VN and to inhibit its activity. 
This may cause the PAl1-producing clones to become more adhesive to the VN substratum and 
ultimately to become less invasive. 
Cell Cell 
uPAR 0 
~PAl1 
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Cell acllesion Cell release 
Figure 12.1. A model for the regulation of uPAR dependant cell adhesion and release by PAl1 and uPA. Adapted from Deng et al. (1996). 
The above mentioned model system could also possibly be used to explore the role of PAl1 in 
tumor vascularization. It has been shown that the angiogenic inhibitor, angiostatin (O' Reilly et al., 
1994), can be generated from plasmin in HT1080 fibrosarcoma cells by reduction and proteolysis (Stathakis et al., 1997). Physiologically relevant concentrations of reduced glutathione fulfill the role 
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of the reductase. In another study is was demonstrated that human prostate carcinoma cells can 
convert plasminogen to angiostatin (Gately et al., 1997). In this system, plasminogen is first 
converted to active plasmin by uPA, and in the presence of a free sulfhydryl donor, plasmin serves 
as both the substrate and enzyme for the generation of angiostatin (Figure 12.2). It would be 
interesting to explore whether UCT-Mel-3 cells are able to generate angiostatin from plasminogen 
since it is known that these cells secrete tPA (Hoal-Van Heiden et al., 1986). 
PAl1 
Pl.-.minogen 1PA/uPA I Pl.-.min FSD \ Angiost.nin pl.-.min 
Figure 12.2. A model for the generation of angiostatin from plasminogen by tPA or uPA and free 
sulfhydryl donors (FSDs). 
The UCT-Mel-3 parental cell line and its PA11-producing clones could provide an interesting model 
system to study the role of PAI 1 in tumor vascularization, provided that the parental cells are able 
to generate angiostatin from plasminogen (possibly via tPA and a reductase). The cells should 
theoretically inhibit endothelial cell proliferation if they are able to generate angiostatin. In contrast, 
the PAl1-producing clones should theoretically allow endothelial cell proliferation since PA11 will 
block tPA activity and consequently less angiostatin will be generated by these cells. It might also 
be possible to use the maPAl1/C6 Mab to block the binding of PAl1 to VN and to inhibit its activity, 
thereby promoting angiostatin generation and consequently inhibit endothelial cell proliferation. 
In conclusion, it is clear that the Mabs produced in the present study will be most helpful in 
answering various questions related to PAl1 and its interaction with other molecular components. 
In addition, as shown in section B of this thesis, these Mabs provide invaluable tools for carrying 
out clinical studies related to melanoma progression. 
&&&&&&&&&&&&&&&&&& 
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APPENDIX: METHODS AND SOLUTIONS 
A.1 Routine culturing of melanoma cells 
Melanoma cell lines were maintained in RPMI 1640 medium (Sigma) supplemented with 10% fetal 
calf serum (FCS, State Vaccine Institute, Cape Town), 50 U/ml penicillin (Novo Nordisk) and 
20 µg/ml streptomycin (Gibco) at 37°C under 5% C02/95% air and 90% humidity. The complete 
growth medium is abbreviated as RP10 medium. Sub-culture the cells as follows: Wash the 
cultures once with PBS (see A.4 for details) and dislodge the cells with versene-buffer (see A.5 for 
details) for 1 O mins at 37°C. Centrifuge the cells at 700 g for 5 mins at RT. Resuspend the cell 
pellet in fresh RP10 medium and plate 1110th of the original amount of cells on a 100 mm tissue 
culture dish (Falcon). Maintain frozen cell stocks in RP10 medium plus 10% dimethylsulphoxide 
(DMSO) at -80°C or in liquid nitrogen (-196°C). Thaw the cells for 5 mins at 37°C and transfer 
quickly to 1 O ml RP10 medium in order to dilute out the DMSO. Centrifuge for 5 mins at 700 g. 
' 
Resuspend the cell pellet in fresh RP10 medium and culture as described above. 
A.2 RPMI 1640 tissue culture medium 
Dissolve 52.0 g RPMI 1640 powder medium (Sigma) in 4000 ml double distilled water (ddH20). 
Add 10.0 g NaHC03 (BDH), 2.5 x 105 Units penicillin (50 U/ml) and 0.1 g streptomycin sulphate 
(20 µg/ml). Adjust the pH to 7.1 with 1 M HCI and make up to 5000 ml with ddH20. Sterilize the 
solution through a 0.45 µm filter and store in 400 ml aliquots at 4°C. The pH should be 
approximately 7.4. 
A.3 Complement-inactivated fetal calf serum (FCS) 
Heat the FCS for 30 mins at 56°C to inactivate complement factors. Pre-filter the serum (Millipore 
type AP) and sterilize through a 0.45 µm filter. Store in 50 ml aliquots at -20°C. 
A.4 10x Phosphate-buffered saline (PBS) 
Dissolve 80.0 g NaCl (1.37 M), 2.0 g KCI (0.03 M), 14.4 g Na2HP04 (0.08 M) and 2.4 g KH2PQ4 
(0.01 M) in ddH20 and make up to 1000 ml. Sterilize the solution through a 0.45 µm filter and store 
at RT. Dilute the buffer 1 in 10 as a working solution. The pH should be approximately 7.4. 
A.5 1 Ox Versene-buffer 
Dissolve 40.0 g NaCl, 1.3 g Na2EDTA, 1.0 g KCI, 5. 7 g Na2HP04.2H20 and 1.0 g KH2P04 in 
ddH20 and make up to 500 ml. Sterilize the solution through a 0.45 µm filter and store at RT. Dilute 
the buffer 1 in 10 as a working solution. The pH should be approximately 7.4. 
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A.6 RNA extraction 
Add 1.5 ml cold solution A (freshly prepared) to the PBL pellet (1-5 x 107 cells) after erythrocyte 
lysis with TE-buffer. Apply repetitive pipetting to ensure complete cell lysis and dissociation of 
nucleoprotein complexes. Transfer the solution to a sterile 2.2 ml polypropylene tube containing 
200 µI chloroform. Vortex the sample for 30 secs. Separate the solution into three phases at 
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12 000 g for 15 mins at 4°C. Transfer the upper aqueous phase (0. 7 ml) to a sterile 1.5 ml 
polypropylene tube containing 0.7 ml isopropanol. Precipitate the RNA overnight at -20°C. 
Centrifuge at 12 000 g for 15 mins at 4°C and pour off the supernatant. Add 1 ml 75% ethanol to 
the RNA pellet and vortex for 15 secs. Centrifuge at 12 000 g for 5 mins at 4°C and aspirate the 
supernatant. Do not allow the RNA pellet to dry completely. Dissolve the RNA in 60 µI DEPC-
treated water. Use repetitive pipetting to aid solubility. Store in 10 µI aliquots under two drops of 
mineral oil at -80°C. An average yield of 30 µg total RNA (= 0.3 µg mRNA) is obtained from 10 ml 
whole blood. 
0025012eo ratio of 1.8 - 2.0 for pure RNA. 
Ratio < 1.8 is protein contamination. 
Ratio> 2.0 is phenol contamination. 
00260 / 25 x dilution factor = µg/µI total RNA. 
A. 7 Solution B 
Prepare a 4 M guanidinium thiocyanate (Merck) solution by dissolving 25 g in 45 ml dd-H20 at 
65°C. Add 1.67 ml 0.75 M sodium citrate (pH 7) and make up to 50 ml with ddH20. Sterilize the 
solution through a 0.45 µm filter while warm. Store at 4°C for up to one year. The pH should be 
approximately 5.5. 
A.8 Water-saturated phenol 
Melt crystallized phenol (Merck, 99.5% pure) at 65°C (should be a clear solution). Cool down and 
add 0.04% 8-hydroxyquinoline (AnalaR). Add an equal volume of DEPC-treated water (pH 5.5) and 
tumble for 5 mins at RT. Allow the phases to separate overnight at 4°C. Store protected from light 
at 4°C for up to 3 months. 
A.9 2 M Sodium Acetate (pH 4) 
Dissolve 3.3 g sodium acetate (Merck, anhydrous) in 6.5 ml DEPC-treated water. Add 12 ml acetic 
acid (UniLab, 99.5% pure). The pH should be approximately 4.0. 
A.10 DEPC-treated dd-H&_ 
Add 100 µI diethylpyrocarbonate (DEPC, BDH) per one liter ddH20 (0.01%). Shake and incubate 
for 2 hrs or overnight at 37°C. Autoclave to inactivate the residual DEPC. 
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A.11 Solution A 
Mix 1 part water-saturated phenol, 1 part solution B and 0.1 part 2 M sodium acetate (pH 4). 
Supplement with 50 mM 2-mercapto-ethanol (Merck). Prepare a fresh solution just before use. 
A.12 Agarose mini-gel 
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Melt in a microwave oven 0.25 g, 0.5 g or 0.75 g agarose (Hispanagar) in 45 ml ddH20 to prepare 
a 0.5%, 1.0% or 1.5% solutions respectively. Cool the solution to 60°C before adding 5 ml 5x TBE-
buffer and 2.5 µI of a 1 O mg/ml ethidium bromide solution. Pour the solution into a min-gel 
apparatus and allow to solidify at 4°C. 
A.13 Sx Agarose gel-running buffer (TSE-buffer) 
Dissolve 54.0 g Tris.base and 27.5 g boric acid in 900 ml ddH20. Add 20 ml 0.5 M EDTA solution 
(pH 8) and make up to 1000 ml with ddH20. Dilute the buffer 1 in 10 as a working solution. 
A.14 6x Agarose gel-loading buffer (6x AGLB) 
Dissolve 0.025 g bromophenol blue (0.25%) and 0.025 g xylene cyanol FF (0.25%) in 7 ml ddH20. 
Add 3 ml glycerol (30%) and sterilize the solution through a 0.45 µm syringe filter. Store in 1 ml 
aliquots at 4°C. Add 4 µI 6x AGLB to 20 µI PCR product and load on an agarose mini-gel. 
Electrophorese at 100 Volt/cm for 30 mins at RT. 
A.15 Culturing and maintenance of Sf9 cells 
Maintain Spodoptera frugiperda (Sf9) cells (lnvitrogen) as a monolayer in TNMFH10 medium (see 
A.16 for details) under 100% air and 90% humidity at 27°C. Passage the cells twice per week. 
When confluent, dislodge the cells from the dish by pipetting the medium gently over the cells. 
Replate 1/51h of the cell suspension with fresh TNMFH10 medium per 100 mm tissue culture dish 
(Corning). Subculture monolayer cultures for 2 weeks or more before seeding suspension cultures. 
Maintain suspension cultures under the same conditions as described above on a horizontal 
platform with orbital shaking at one rotation per second. Plate 5 x 105 cells/ml in 20 ml TNMFH10 
medium in a 200 ml Ehrlenmeyer tissue culture flask (Corning). Subculture the cells when the cell 
density reach 3 x 106 cells/ml by replacing 80% of the cell suspension with fresh medium. Use only 
one-week-old suspension cultures for virus infections. Maintain frozen cell stocks in liquid nitrogen 
or at -80°C in 90% FCS plus 10% DMSO at 107 cells/ml. Use only cells in the logarithmic growth 
phase (2 x 106 cells/ml) and with a viability of 95-98% (use trypan blue exclusion determination) for 
cryopreservation. A doubling time (TY:z) of 18-22 hrs and a cell viability of 95-98% should be 
obtained during routine subculturing. 
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A.16 TNMFH medium 
Dissolve 18.67 g Grace's powder medium (Highveld Biological) and 2.28 g MgCl2.6H20 in 450 ml 
dd-H20. Dissolve (separately) 3.3 g yeastolate, 3.3 g lactalbumin and 26.68 g sucrose in 450 ml 
ddH20. Mix the two 450 ml solutions. Adjust the pH to 6.2 with 10 M NaOH and make up to 
1000 ml with ddH20. Prefilter (Millipore type AP) and sterilize the medium through a 0.45 µm filter. 
Store at 4°C protected from light. Prepare TNMFH10 medium by adding 50 µg/ml gentamycin 
sulphate and 10% FCS to the TNMFH medium. 
A.17 Determination of recombinant virus titer 
Plate twelve 60 mm tissue culture dishes with 3x106 Sf9 cells per dish and allow the cells to adhere 
overnight. Replace the medium with recombinant virus inoculum in TNMFH medium in 10-fold 
dilutions from 10-2 to 10-1. Add 2 ml virus dilution per plate and incubate for 1 hr at RT on a rocking 
platform (30 secs per oscillation). Turn the dishes 90° every 15 mins. Aspirate the virus and 
overlay with 5 ml of a 1.5% agarose solution (Sea Plaque low melting point) containing 10% FCS, 
1x TNMFH medium, 50 µg/ml gentamycin (Sigma) and 150 µg/ml 5-bromo-4-chloro-3-indolyl f3-0-
galactopyranoside (X-gal, Sigma). Incubate at 27°C until blue plaques appear on the dishes. Count 
the number of plaques of a particular virus dilution and determine the virus titer [plaque forming 
units (PFU) per ml] as 1/virus dilution x number of plaques x 1/ml inoculum per plate. 
A.18 Infecting suspension cultures for immunizations 
Count a suspension culture with a haemocytometer and determine the cell viability with trypan blue 
exclusion. Use only cells with a viability of 97-98% or greater for virus infection. Calculate the 
amount of virus needed as follow: 
Milliliter inoculum needed = 
MOI (PFU/cell) x number of cells 
titer of virus (PFU/ml) 
Resuspend the cell pellet in the calculated amount of virus inoculum. Add TNMFH10 medium to a 
cell density of 1 x 107 cell/ml and incubate for 1 hr at 27°C. Resuspend the cells by adding fresh 
medium to a cell density of 1-2 x 106 cells/ml. Transfer the cell suspension to an Ehrlenmeyer 
tissue culture flask and culture in suspension for 2-4 days as described under A.15 for suspension 
cultures. Monitor the expression of the recombinant protein after 3 days with immunofluoresence 
(see A.44 for details). Collect the culture medium for future inoculums and store at 4°C. 
A.19 Blood collection from the mouse eye 
Anaesthetise the mouse with ketamine/xylazine at 0.00125 ml/g (half the recommended dose) or 
with CO2. Collect blood from the inner corner of the eye with a heparinized capillary tube (60µ1 
each) by twisting the tube to brake the surface capillary vessels. Plug the tube at the one side with 
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clay to prevent the blood from leaking out of the tube. Remove the cell fraction with centrifugation 
(1 min) in a standard microhematocrit. Brake the tube at the erythrocyte/plasma interphase by 
cutting a groove in the glass with a sharp blade. Blow the serum out of the cappillary tube via a 
rubber tube connection. 
A.20 Culturing and maintenance of mouse myeloma cells 
Maintain mouse myeloma cells in culture as described for human melanoma cell lines (see A.1 for 
details). When confluent, dislodge the cells from the dish with 1x versene-buffer at 37°C. Replate 
at 5 x 105 cells per 100 mm dish. Use only sub-confluent myeloma cells with a viability of 95% or 
more for fusions. Cryopreserve myeloma cells as described for human melanoma cells (see A.1 for 
details). 
A.21 Monoclonal antibody production 
On the day of fusion have ready two to three 100 mm tissue culture dishes with mouse myeloma 
cells of good viability. Dislodge the cells with 1x versene-buffer. Resuspend in RPMI medium and 
count the cells with a haemocytometer. Slaughter an immunized mouse with a high antibody titer 
using the cervical dislocation technique. Immobilize the animal on its dorsal side and sterilize the 
abdominal side with 70% ethanol. Remove the spleen with sterile instruments and transport to the 
laboratory in RPMI medium. Squeeze the spleen through a sterile stainless steel sieve with the 
plunger of a 2 ml syringe into a 100 mm tissue culture dish containing 5 ml RPMI medium. Wash 
the sieve with another 5 ml RPMI medium. Pipette the suspension up and down to break up the 
clumps and transfer to a 10 ml centrifuge tube. Allow the large pieces of tissue to settle by gravity 
for a few mins. Transfer the supernatant to a clean 10 ml tube.Wash the cells once with RPMI 
medium and resuspend in 2 ml RPMI medium. Count the spleen cells by making a 1 in 100 dilution 
in white cell diluting fluid (0.01 % gentian violet and 3% acetic acid in ddH20) to lyse the 
erythrocytes. 
Mix the spleen cells with 1/101h the number of myeloma cells in RPMI medium in a 50 ml 
polypropylene tube. Centrifuge at 500 g for 5 mins. Aspirate the supernatant and gently loosen the 
pellet by tapping on the side of the tube. Add 1.5 ml polyethylene glycol (PEG) at 37°C dropwise 
over 2 mins to the cells with gentle mixing. Add 2 ml RPMl-medium (37°C) slowly over 2 min with 
gentle mixing. Add 8 ml RPMl-medium over the next 2 mins. Finally, add RPMl-medium to 45 ml. 
Centrifuge at 500 g for 5 mins. Aspirate the supernatant. Resuspend the cell pellet (with not to 
much pipetting) in HAT10-medium to a concentration of approximately 106 spleen cells/ml medium. 
Use HAT10-medium with FCS if the antigen is present in human serum. Dispense 1 ml aliquots per 
well of a 24-well tissue culture plate. Dispense 105 myeloma cells in one well of the plate for the 
control. These cells should all die within 3 days. Feed the cells with 0.5 ml HAT10-medium per well 
after an one week incubation period. Hybridoma clones should have grown within 10-14 days. 
Remove some of the supernatant when the medium starts to turn yellow and test for antibody. 
Appendix: Methods and solutions 
Expand those hybridomas that tested positive for specific antibody into 60 mm tissue culture 
dishes in HT10-medium (HAT10-medium without aminopterin). Cryopreserve when enough cells 
have been obtained. 
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Clone selected hybridomas by limiting dilution to obtain single cell clones: Prepare a cell 
suspension at a concentration of approximately 10 cells/ml HT10-medium. Plate 200 µI aliquots 
into the wells of a 96-well flat-bottom tissue culture plate (Nunc) to obtain approximately 1-2 cells 
per well. If the culture supernatant was only weakly positive it may be necessary to prepare several 
96-well plates or to clone initially at 10 cells per well. Feed the cells with 100 µI HT10-medium per 
well after 5-7 days of incubation. Prepare to screen for antibody when the clones become 
macroscopically visible and when the medium of some of the clones start to turn yellow. Sample 
the supernatants and test for antibody. Choose 2-3 positive clones for re-cloning. Expand the 
clones and cryopreserve. Repeat the cloning procedure to ensure that the final hybridoma clone 
will be from a single cell. Expand and cryopreserve several clones. Allow the hybridoma clone to 
adapt for growth in RP10-medium (Harlow & Lane, 1988; Pontecorvo, 1975). 
A.22 Polyethelene glycol (PEG) 
Weigh 2 g PEG (Merck, Mr= 4000 daltons) and autoclave. Add 2 ml RPMI at 37°C to the liquid 
PEG before it solidifies. 
A.23 1000x Aminopterin 
Dissolve 17.6 mg aminopterin (Sigma) in 25 ml ddH20 by increasing the pH with 0.5 ml 5 N NaOH 
and neutralizing it again with 0.5 ml 5 N HCI. Make up to 100 ml with ddH20. Sterilize the solution 
through a 0.45 µm filter and store in 10 ml aliquots at -20°C protected from light. Dilute 1 in 1000 in 
RPMI medium to obtain a final concentration of 4 x 10-7 M as the working solution. 
A.24100x HT 
Dissolve 0.34 g hypoxanthine (Sigma) in 125 ml ddH20 by increasing the pH with 2.5 ml 1 O N 
NaOH (add dropwise with stirring). Add 0.0968 g thymidine (Sigma), 0.0055 g glycine and 2.7515 g 
sodium pyruvate and make up to 250 ml with ddH20. Sterilize the solution through a 0.45 µm filter 
and store in 1 O ml aliquots at -20°C. Dilute 1 in 100 in RPMI medium to give final concentrations of 
1 x 10-4 M hypoxanthine, 1.6 x 10-5 M thymidine, 3 x 1 o-s M glycine and 1 x 10-3 M sodium 
pyruvate. 
A.25 HAT10-medium 
Add 0.2 ml 1000x aminopterin, 2 ml 100x HT and 20 ml HUCS or FCS (Flow laboratories) to 
200 ml RPMI medium. 
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A.26 Human umbilical cord serum (HUCS) 
Collect and pool HUCS from different HIV-free patients. Heat-treat the serum, filter and store as 
described for FCS in A.3. 
A.2710x TST 
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Dissolve 60.6 g Tris.HCI (0.5 M), 58.4 g NaCl (1 M) and 5.0 ml Tween 20 (0.5%) in 900 ml ddH20. 
Adjust the pH to 7.6 with 1 M Na OH and make up to 1000 ml with ddH20. Store at RT. Dilute the 
buffer 1 in 10 as a working solution. 
A.28 Sheep anti-mouse lgG (SAM) and mouse anti-beta galactosidase 
A sheep anti-mouse lgG has been produced previously in the Department of Clinical Science and 
Immunology (Heussen-Schemmer et al., 1993). The whole sheep serum was diluted 1 in 200 in 
PBS/0.1 % BSA as a working solution. The mouse anti-beta galactosidase Mab was prepared 
previously in the department with standard monoclonal antibody technology. 
A.29 Mouse anti-peroxidase Mab plus peroxidase (PAP) 
An anti-peroxidase mouse Mab has been produced previously in the Department of Clinical 
Science and Immunology (Heussen-Schemmer et al., 1993). The ascites fluid of mice injected with 
the anti-peroxidase hybridoma cells was diluted 1 in 200 in PBS containing 100 µg/ml horse radish 
peroxidase (Sigma or Seravec), 0.5% BSA and 0.01% thiomersal. The solution was stored at 4°C. 
Dilute 1 in 10 or 1 in 20 for ELISA's or Western blots. 
A.30 ABTS substrate 
Dissolve 2.1 g monohydrate citric acid (0.05 M) in 190 ml ddH20. Adjust the pH to 4 with 1 M 
NaOH and make up to 200 ml with ddH20. Store in 10 ml aliquots at -20°C. Thaw a frozen aliquot 
just before use. Add 100 µI 40 mM 2,2' azino-di (3-ethyl-benzthiazoline) sulfonic acid (ABTS, 
Sigma) and 10 µI 30% H20 2 to obtain a working solution. 
A.31 lsotyping of Mabs 
Coat a 96-well flat-buttom polystyrene ELISA plate (Nunc, MaxiSorp) with 10 µg/ml rabbit anti-
mouse lg (Serotec) in PBS for 2 hrs at RT. Add all the reagents at 50 µI per well for 30 mins at RT, 
except if mentioned differently. Wash five times with TST-buffer and block the plate with PBS/0.1 % 
BSA. Add 24-48 hr serum-free CM from the hybridoma clones to be isotyped. Wash the plate as 
before. Add 20 µg/ml sheep isotyping sera (Serotec) specific for mouse lgG1, lgG2a, lgG2b, lgG3, 
lgM and lgA. Wash the plate as before. Add 20 µg/ml peroxidase-conjugated rabbit anti-goat lg 
(Dako, cross-react with sheep antibodies). Wash the plate 10 times with TST-buffer. Add 100 µI 
per well ABTS in citrate buffer as substrate (see A.29 for details). Measure the absorbance at 
405 nm after 30 mins (Coligan et al., 1994a). 
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A.32 Ascites production 
Prime Balb/c mice with 0.5 ml pristane (2,6, 10, 14-tetramethylpentadecane, Aldrich) 
intraperitoneally (i.p.). Inject 1-5 x 106 hybridoma cells in 0.5 ml PBS per mouse i.p. 1-2 weeks 
after priming. Collect the ascites from the extended abdomen after approximately 2 weeks. 
Centrifuge (800 g, 5 mins) the ascites and use the antibody-containing supernatant to purify the 
antibody with caprylic acid and ammoniumsulphate precipitations. 
A.33 Caprylic acid and ammoniumsulphate purification of antibodies 
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Add 200 ml 0.06 M acetate buffer (pH 4) to 100 ml ascites fluid or 1 Ox concentrated serum-free 
hybridoma conditioned medium. Adjust the pH to 4.8 with 1 M HCI if necessary. Add 3.3 ml 
n-octanoic acid (caprylic acid, Sigma) dropwise with stirring and continue to mix for 30 mins at RT. 
Centrifuge at 10 000 g for 30 mins at 4°C. Keep the supernatant which contains the antibody and 
filter through a 0.45 µm syringe filter. Dialyze twice against 50 volumes of PBS containing 2 mM 
EDTA. Precipitate the immunoglobulin by slowly adding ammonium sulphate crystals to 50% 
saturation (100% saturation = 70.5 g/100 ml). Centrifuge as described before. Dissolve the 
precipitate in PBS and dialyze twice against 50 volumes of PBS. Measure the absorbance at 
280 nm (00280 of 1.38 = 1 mg/ml lgG). Store in suitable aliquots at -20°C. 
Polyclonal antibodies can also be purified with this method. Add 200 ml 0.06 M acetate buffer 
(pH 4) to 100 ml serum. Adjust the pH to 4.8 with 1 M HCI if necessary. Adjust the amount of 
caprylic acid added according to the species, ie. 8.2 ml for rabbit, 7.6 ml for horse and human, 6.8 
ml for bovine, 8.0 ml for goat and 7.6 ml for sheep (Reik et al., 1987). 
A.34 5x Tris-glycine reservoir buffer 
Dissolve 15.1 g Tris.base and 94.0 g glycine in 900 ml ddH20. Add 50 ml 10% SOS and make up 
to 1000 ml with ddHzO. Dilute the buffer 1 /5 as a working solution for mini-gels and 1 /1 O for large 
gels. 
A.35 30% Acrylamide mix 
Dissolve 29.2 g acrylamide (Sigma) and 0.8 g N,N'-methylene-bis-acrylamide (BDH) in 90 ml 
ddH20 and make up to 100 ml. The pH should be approximately 7. Sterilize the solution through a 
0.45 µm filter and store at 4°C protected from light for up to 6 months. 
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A.36 SOS sample buffer 
Reagent 2x 6x 
4x Tris/SOS, pH 6.8 2.5ml 7.0 ml 
sos 0.4 g 1.0 g 
Bromophenol blue _ 2mg 6mg 
Glycerol 2.0 ml 3.6 ml 
Dissolve the above mentioned reagents in 4x Tris/SOS, pH 6.8 buffer and make up to 10 ml with 
ddH20. Sterilize through a 0.45 µm syringe filter and store in 0.5 ml aliquots at -20°C. 
A.37 4x Tris/SOS, pH 6.8 
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Dissolve 6.05 g Tris.base in 90 ml ddH20. Adjust the pH to 6.8 with 1 M HCI. Correct the pH to 6.8 
after 30 mins and make up to 100 ml with ddH20 . Sterilize through a 0.45 µm filter. Add 0.4 g SOS 
and store at 4°C. 
A.38 4x Tris/SOS. pH 8.8 
Dissolve 36.4 g Tris.base in 150 ml ddH20. Adjust the pH to 8.8 with 1 M HCI. Correct the pH to 
8.8 after 30 mins and make up to 200 ml with ddH20. Sterilize through a 0.45 µm filter. Add 0.8 g 
SOS and store at 4°C. 
A.39 Separating (running) gel 
Mix in the following order: Final acrylamide cone. in the running gel(%) 
Stock solutions 5 10 12 15 
8.75 6.25 5.25 3.75 
30% Acrylamide mi>_e . 2.5 5.00 6.00 7.50 
.. 
4x Tris/SOS, pH 8.8 · 3.75 3.75 3.75 3.75 . . . 
10% Ammonium persulphate 0.05 0.05 0.05 O:os 0.05 
,. 
TEMEO* 0.01 O.Q1 0.01 0.01 0.01 
* N,N,N',N'-tetramethylethylenediamine (Sigma) 
Pipette the solution between two pre-sealed (use 1 % agarose) glass plates of the gel apparatus. 
Overlay the solution with water-saturated iso-butanol to prevent the inhibition of polymerization by 
oxygen. Allow the polymerization reaction to complete for 1 hr at RT. Note: Prepare fresh 
ammonium persulphate daily. 
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A.40 4% Stacking gel 
Mix in the following order: 3.05 ml ddH20, 0.65 ml 30% acrylamide mix, 1.25 ml 4x Tris/SOS (pH 
6.8), 0.025 ml 10% ammonium persulphate and 0.005 ml TEMED. Pour the stacking gel 
immediately and place the teflon comb into position. Allow the polymerization reaction to complete 
for 15 mins at RT. 
A.41 Gel electrophoresis 
Remove the comb from the gel and rinse the wells with 1x Tris-glycine reservoir buffer to remove 
any unpolymerized acrylamide. Run the protein samples in 1 x SOS sample buffer under reduced 
(200 mM dithiothreitol, OTT, Sigma) or non-reduced conditions. Boil samples for 3-5 mins prior to 
electrophoresis unless proteolytic activity or protein complexes are of importance. Electrophorese 
mini-gels at 100 V/cm or at constant current of 10 mAmps for 2 hrs at RT or at 4°C. Stain gels with 
0.1 % Coomassie brilliant blue (Sigma) solution in 30% methanol and 10% glacial acetic acid for 
1 hr at RT. Destain with 30% methanol and 10% glacial acetic acid solution for several hours. 
A.42 Western blot 
Cut a piece of lmmobilon-P PVDF membrane (Millipore) to the size of a mini-gel. Pre-wet for a few 
seconds in 100% methanol and then for 1 min in transfer buffer. Cut two pieces of Whatmann filter 
paper (3 mm chr) to the same size as the PVDF membrane and pre-wet in transfer buffer. Use two 
carbon blocks (20 x 15 x 2 cm) as electrodes and two pieces of absorbant material (20 x 15 cm) as 
reservoirs for the transfer buffer. Prepare the western blot sandwich as follows (from bottom to top) 
and place in a plastic container: 
• Carbon block (negative electrode, top) 
• Absorbant pad 
• Filter paper 
• Polyacrylamide gel 
• PVDF membrane 
• Filter paper 
• Absorbant pad 
• Carbon block {positive electrode, bottom) 
Blot a 12 x 6 x 1 mm mini-gel for 1 hr at 220 mAmps. 
A.43 Transfer buffer 
Dissolve 6.05 g Tris.base (0.05 M) and 14.4 g glycine (0.2 M) in 200 ml methanol and make up to 
1000 ml with ddH20. Store at 4°C. The pH should be approximately 8.3. 
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A.44 Enhanced chemiluminescence (ECL) 
Use the chemiluminescent western blot detection system from Boerringer and Mannheim to 
enhance the peroxidase signal on a blot. Dilute solution B (H202) 1 in 100 in solution A (luminol 
and 4-iodophenol) and incubate for 30 mins at RT. Add 125 µI of the detection reagent per cm2 
membrane for 1 min. Drain excess detection reagent from the blot. Seal the blot with "Cling Wrap" 
and expose immediately to Cronex 4 X-ray film for 10 secs to 5 mins. Determine the exposure time 
experimentally. Develop the film with Kodak X-ray developer for 5 mins. Stop development with 2% 
acetic acid solution for 1 min and fix with Kodak fixative for 5 mins. Rinse the X-ray film thoroughly 
with running tap water and air dry. 
A.45 Multi-well cell monolayers for immunocytochemistry 
Prepare teflon-coated, 8-well (6 mm diameter) slides with double-sided sellotape (2.5 cm wide) and 
Whatman no.50 filter paper according to a standard method (Veenstra & Dowdle, 1992). Pipette 
20 µI of a cell suspension (1x106 cells/ml in RP10 medium) unto each well of a prepared slide. 
Allow the slide to dry overnight at RT before removing the tape and filter paper. Store the slides for 
up to one week in a dessicator or wrap the slides in alminium foil and store for an indefinite period 
at -20°C. 
Fix the cells with 50% methanol/SO% acetone for 90 secs at RT and transfer immediately to 1 x 
TBS for 3-5 mins (use Coplin-jars). Block with 0.1 % BSA in PBS for 15 mins. Add 20 µI of the 
primary antibody (1 O µg/ml in PBS/0.1 % BSA) to the appropriate wells and incubate for 30 mins in 
a moist chamber. Wash the slide twice with PBS. Flood the slide (500 µI) with a fluorescein-
labelled secondary antibody and incubate for 30 mins. Wash the slide twice with PBS. 
Counterstain the cell nuclei with ethidium bromide (1 µg/ml in PBS) for 1 min and wash twice with 
PBS. Mount the cells temporally in PBS/30% glycerol or permanently in Mowiol mounting medium. 
View under the fluorescent micropscope using a blue excitation filter. 
A.46 Mowiol mounting medium 
Add 2.4 g Mowiol 4-88 (polyvinylalcohol, Hoechst) to 6 ml glycerol. While stirring, add 6 ml ddH20 
and leave for several hours at RT. Add 12 ml 0.2 M Tris (pH 8.5) and incubate for 1 hr at 50°C with 
occasional stirring. Add 1,4-diazobicyclo-[2.2.2]-octane (Dabco) to 2.5% to reduce 
immunofluorescence fading. Store in 2 ml aliquots at -20°C. Centrifuge at 12 000 g for 5 mins to 
remove insolubles before using the mounting medium. 
A.47 DAB substrate 
Prepare 25 mg/ml diaminobenzidine (Sigma) as a stock solution in ddH20 and store in 1 ml 
aliquots at -20°C. Dilute 1 in 50 in PBS containing 0.03% H20 2 and 0.03% CoCl2 as a working 
solution. 
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A.48 Purification of human plasminogen (Pig) 
Collect 1 liter fresh citrated blood. Centrifuge the blood at 700 g for 10 mins at RT. Sterilize the 
plasma through a 0.45 µm filter and dilute with 2 parts PBS. Apply the diluted plasma at a flow-rate 
of 1.5 ml/min to a lysine-Sepharose column (Pharmacia) equilibrated with PBS at 4°C. Wash the 
column once with PBS and then with 1 M KCI in PBS (pH 7.4) containing 40% ethylene glycol. 
Wash the column with PBS containg 3 mM EDTA until the baseline OD280 is stable. Elute the Pig 
as a single peak (OD280) with 0.2 M E-aminocaproic acid (c-ACA) in PBS (pH 7.4). Collect 2 ml 
aliquots and pool the Pig-containing fractions. Mix an equal volume of chloroform with the eluant. 
Remove the aqueous phase and dialyse 3x against PBS. Determine the Pig concentration by 
measuring the absorbance at 280 nm (OD2ao of 1. 7 = 1 mg/ml). The method yields more than 99% 
pure Pig (Castellino & Powell, 1981; O'Reilly et al., 1996). Use the same protocol to prepare Pig-
free FCS which is collected as the flow-through. 
A.49 Preparation of Pig-free human fibrinogen (Fg) 
Dissolve 1 g of human Fg (Kabi) in 50 ml 0.1 M KP04-buffer (pH 6.4, mix 72.2 ml 1 M KH2P04 and 
27.8 ml 1 M K2HP04 and make up to 1000 ml with ddH20). Make up to 100 ml with ddH20 and 
tumble overnight at 4°C. Centrifuge at 1000 g for 10 mins at RT and discard the pellet. Precipitate 
the supernatant by adding slowly 1/3 the volume saturated ammonium sulphate at RT. Allow to 
stand for 1 hr (stir occasionally with a glass rod) and centrifuge as before. Dissolve the "gummy" 
pellet in 20 ml 0.6 M NaCl (with gentle stirring at 37°C) and adjust the pH to 7.4 with ammonium 
hydroxide. Dialyse the solution overnight at RT against 0.6 M NaCl containing 106 U/ml penicillin 
and 0.2 g/1 streptomycin sulphate. Determine the Fg concentration by measuring the absorbance at 
280 nm (OD2ao of 1.3 = 1 mg/ml). Adjust the concentration to 10 mg/ml with 0.6 M NaCl. Dilute one 
part Fib with 5 parts 0.12 M lysine-HCI in 0.005 M NaP04-buffer (pH 7). Bring the solution to 0°c in 
a salt-ice bath. Discard any precipitate that may form. Add 8 ml 95% ethanol to every 100 ml 
solution (at 0°C) and stir constantly with a glass rod to prevent the Fg from solidifying. Centrifuge 
the solution as before and redissolve the precipitate in 10 ml 0.6 M NaCl at 37°C. Dialyse overnight 
at RT against PBS (containing antibiotics). Pre-filter (Millipore type AP) and sterilize through a 5.0 
and 0.45 µm filters. Measure the absorbance at 280 nm and adjust the concentration to 5 mg/ml. 
Store at -20°C (Mosesson, 1962). 
0.12 M Lycine-HCI in 0.005 M NaP04-buffer 
Dissolve 10.96 g lysine-HCI and 0.45 g Na2HP04.2H20 in 500 ml ddH20. Dissolve 10.96 g lysine-
HCI and 0.34 g NaH2P04.H20 in 500 ml ddH20. Combine the two solutions to obtain a pH of 7. 
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A.50 Labelling of Fg with 1251odine (Salacinski et al., 1981) 
Dissolve 1 mg lodogen (1,3,4,6-tetrachloro-3',6',-diphenylglycoluril, Pierce) in 50 ml chloroform. 
Prepare 1 ml aliquots and allow the chloroform to evaporate overnight at 4°C. Store at -80°C and 
thaw just before use. 
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Prepare a Sephadex-G10 column in PBS. Wash the column once with FCS and 10x with PBS. 
Block the column with 2 ml cold Fg (5 mg/ml) and wash finally once with PBS. Incubate 5 mg cold 
Fg in 400 µI PBS with 2.5 mCi 1251odine (Amersham) in a pre-prepared lodogen tube for 4 mins at 
RT. Separate the hot Fg from the free 1251odine on the Sephadex-G10 column. Collect fractions of 
7 drops per tube and count 5 µI of each fraction on a Gamma-counter. Pool the hot Fg from the 
first peak which will be followed by a higher peek of free 1251odine. Filter the hot Fg through a PBS-
saturated 0.45 µm syringe filter. Dilute the hot Fg 1 in 100 in 500 µI PBS and count three 5 µI 
aliquots on the Gamma-counter. Calculate the mean cpm/ml as the (mean cpm of the three 
aliquots) x 100 x 200. 
Incubate 900 µI RP10 with 100 µI trichloro-acetic acid and 5 µI hot Fg for 30 mins on ice. 
Centrifuge at 12 000 g for 1 min. Count the protein pellet and supernatant separately and estimate 
the efficiency of 125lodine-incorporation as follows: (cpm of pellet)/ (cpm of pellet+ cpm of 
supernatant) x 100. Determine the hot Fg concentration by measuring the absorbance at 280 nm. 
A.51 Preparation of 1251odine fibrin plates (Strickland & Beers, 1976) 
Require 6.5 x 105 cpm/ml of hot Fg to prepare plates. Calculate the volume (µI) of hot Fg needed 
as (6.5 x 105 cpm/ml) / (cpm/ml of hot Fib). Calculate the amount (µg) of hot Fg needed as 
(mg/ml hot Fg) x (µI hot Fg). Need 150 µg/ml Fg in total. Calculate the amount of cold Fg needed 
as (total amount) - (hot amount). Calculate the volume of cold Fg needed as (cold amount)/ 
(mg/ml cold Fg). Need 5 ml Fg per 24-well plate (Linbro or Cell-Cult). Make up the calculated 
amounts of hot and cold Fg with ddH20 (37°C) and add 200 µI per well. Incubate the plate for 4 
days at 37°C to dry. Store the plates for up to 3 months at RT in a fume hood behind lead bricks. 
A.52 Fibrin plate assay (Wilson & Dowdle, 1978) 
The principle of the assay is the conversion of insoluble Fg to soluble fibrin peptides by plasmin, 
which in turn is generated by the activation of Pig by PAs. PA activity can thus be measured 
indirectly by counting the amount of 1251-labelled fibrin peptides that are released from the plate. 
Incubate a 1251-fibrin plate for 1-2 hrs at 37°C with 1 ml RPMI per well. Wash the plate twice with 
1 ml PBS per well and then with 1 ml 0.1 M Tris-buffer (pH 8.1) per well. Dry the plate with suction 
and keep at 4°C. 
Prepare a Pig-cocktail by mixing 250 µI 0.1 M Tris-buffer (pH 8.1) with 20 µI 0.1 mg/ml PIF Pig and 
10 µI 8 mg/ml PIF BSA Prepare a PA standard (tPA or uPA) starting at 2.5 IU/ml PA with 12 
doubling dilutions. Add 20 µI of each dilution to 280 µI Pig-cocktail per well to generate a PA 
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standard starting at 0.05 IU per well. Add 20 µI of each sample to be tested (neat or diluted) to 280 
µI Pig-cocktail per well. Dilute all samples in RPMI medium containing 3% Pig-free FCS (RP3, see 
A.47 for details). Control wells include (a) 300 µI 0.25% trypsin solution in PBS to give the total 
radioactivity present in each well, (b) 280 µI Pig-cocktail plus 20 µI RP3 to detect background lysis 
due to plasmin contamination of Pig, (c) as control b, but without Pig to detect protease 
contamination of the other reagents, (d) the sample, but without Pig to detect Pig independent 
protease activity. Include two test-wells containing 0.05 IU per well PA and two extra wells with 
trypsin on the plate. 
Incubate the plate for 1 hr in a 37°C incubator with 90% humidity. Remove 50 µI time-points from 
the test-wells and from the extra trypsin-wells and count for 1 min in the gamma-counter. Take only 
the full time-point when the test-wells give cpm of between 25-30% of the trypsin-wells. Continue 
incubation if less than 25%. Take three time-points (30-60 mins each). Plot the standard curve for 
PA with the log(%trypsin) on the y-axis and mUnits PA on the X-axis. Convert each sample to 
mUnits PNml and express as mUnits PN106 cells for tissue culture supernatants. 
A.53 Protease and inhibitor free (PIF) BSA 
Subject a 20 mg/ml BSA solution (Boehringer Mannheim) to acid-treatment to destroy protease 
inhibitors by adjusting the pH to 3 with 2 M HCI for 2 hrs at RT and then restore the pH to 7.4 with 
2 M NaOH. Treat the BSA solution with 0.01 M di-isopropyl fluorophosphate (DFP, Sigma) for 2 hr 
at 40°C to inactivate proteases. Dialyse the solution overnight against 0.1 M Tris (pH 8.1) at 4°C. 
Pre-filter with a Millipore type AP and sterilize through a 0.45 µm syringe filter. Measure the 
absorbance at 280 nm (OD2ao of 6.15 = 10 mg/ml) and adjust the concentration to 8 mg/ml. Store 
the PIF BSA in aliquots at -20°C. Obtain PIF Pig using the same protocol. 
A.54 Activation of Sepharose CL-48 with Cyanogen bromide (CNBr). 
Dissolve 0.5 g CNBr (Sigma) in 1 ml acetonitrile (62.5% solution, wt/vol). Use a fume hood to 
perform all the steps. Wash 25 ml Sepharose CL-4B (Pharmacia) in a sintered-glass funnel with 
10 volumes ddH20. Transfer the beads to a 50 ml polypropylene tube and resuspend in 25 ml 
0.2 M Na2C03-buffer. Activate the sepharose by adding the 1 ml CNBr-solution dropwise over 
1 min with slow stirring. Stir the slurry for another 7 mins. Transfer immediately to a sintered-glass 
funnel and wash with 10 volumes ice-cold 1 mM HCI. Wash with 2 volumes ice-cold 0.1 mM HCI 
and finally with 2 volumes coupling buffer (0.1 M NaHC03, 0.5 M NaCl, pH 8.3). Transfer the 
activated sepharose immediately to an equal volume of coupling buffer containing the antibody or 
protein (5-10 mg/ml) to be coupled (Coligan et al., 1994b). 
A.55 Immobilization of antigens or antibodies to sepharose 
Dialyze the antibody or antigen that must be coupled to the activated sepharose against coupling 
buffer. Adjust the concentration to 5-10 mg/ml. Incubate (with tumbling) equal volumes of activated 
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sepharose with the antibody or antigen for 2 hrs at RT or overnight at 4°C. Determine the coupling 
efficiency by measuring the absorbance of the supernatant at 280 nm. The OD2ao reading should 
be significantly less compared to what was obtained before the coupling procedure. Block the 
remaining active groups with 0.2 M glycine-buffer (pH 8) for 2 hrs at RT. Wash excess adsorbed 
antibody or antigen away with three consecutive washes coupling buffer (pH 8.3) alternating with 
acetate buffer (0.1 M sodium acetate, 0.5 M NaCl, pH 4). Equilibrate the antibody or antigen 
coupled beads in PBS and store at 4°C with 0.05% sodium azide as an anti-bacteriostatic agent. 
Use a suitable syringe fitted with a porous polyethylene disk to prepare a column. Prepare a 
precolumn by blocking activated sepharose with 0.2 M glycine-buffer (pH 8) for 2 hrs at RT and 
then equilibrate the beads in PBS. Use the precolumn to remove non-specific binding to 
sepharose beads (Coligan et al., 1994b ). 
A.56 Preparation of 2c-tPA 
Prepare Plg-sepharose as described in A.48 and A.53 - A.54 and equilibrate the beads in 0.1 M 
Tris (pH 8) containing 0.02% Triton X100. Mix 1 mg/ml recombinant tPA in 0.1 M Tris (pH 8) 
containing 0.02% Triton X100 with an equal volume of Plg-sepharose and tumble at RT. Remove 
50 µI aliquots every 60 mins and assay the supernatant (1 in 100 dilution) with a chromogenic 
assay (American Diagnostica) for plasmin activity. The reaction is completed when a plateau is 
reached (approximately after 3 hrs). Record the protein concentration with the BCA protein assay 
(Pierce) using BSA as the standard. Assay the activity of 2c-tPA by recording the rate of hydrolysis 
of the chromogenic substrate CH3SOrD-cyclohexyltyrosyl-Gly-Arg-p-nitroanilide (American 
Diagnostica). Measure the absorbance of released nitroanilide at 405/680 nm. Use 2c-tPA with a 
known activity as the standard and express the activity as IU/ml and as IU/mg. 
A.57 p-Nitrophenyl phosphate (PNPP) soluble substrate for ELISA 
Mix 97 ml diethanolamine (liquefy at 50°C, Merck) with 700 ml ddH20 and 100 mg MgCl2.6H20. 
Adjust the pH to 9.8 with 1 M HCI and make up to 1000 ml with ddH20. Store protected from light 
at 4°C. Dissolve 10 mg/ml PNPP (Boehringer Mannheim) in the above buffer and store in 1 ml 
aliquots at -20°C. Dilute an aliquot 1 in 10 in the above buffer just before use. 
Appendix: Methods and solutions 90 
A.58 PAl1 data for controls 
n = 38 ng/ml ng/ml ng/ml % 
Controls Total PA11 Latent PAl1 Active P Al 1 active PAl1 Gender Age 
1 38 13 25 66 F 48 
2 17 9 8 47 F 50 
3 11 5 6 55 F 38 
4 87 27 60 69 F 51 
5 43 17 26 60 F 34 
6 18 10 8 44 F 40 
7 17 8 9 53 F 52 
8 29 14 15 52 F 53 
9 64 21 43 67 F 78 
10 20 7 13 65 F 29 
11 18 8 10 56 M 31 
12 16 10 6 38 F 49 
13 14 6 8 57 F 26 
14 14 7 7 50 F 27 
15 271 54 217 80 F 48 
16 66 22 44 67 M 28 
17 10 3 7 70 F 45 
18 64 10 54 84 M 25 
19 43 15 28 65 M 39 
20 25 8 17 68 M 51 
21 82 18 64 78 M 53 
22 32 13 19 59 M 60 
23 41 14 27 66 F 39 
24 80 22 58 73 F 37 
25 33 14 19 58 F 43 
26 15 7 8 53 F 54 
27 70 24 46 66 M 32 
28 326 69 257 79 M 34 
29 29 11 18 62 F 42 
30 67 18 49 73 F 56 
31 81 26 55 68 F 48 
32 23 9 14 61 F 35 
33 86 45 41 48 M 23 
34 60 26 34 57 M 29 
35 35 12 23 66 F 31 
36 26 6 20 77 F 50 
37 32 13 19 59 F 27 
38 162 75 87 54 F 36 
Min 10 3 6 38 M = 11 23 
Max 326 75 257 84 F = 27 78 
Mean 57 18 39 62 41.3 
SD 66 17 52 10.5 11.9 
Median 34 13 22 64 39.5 
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A.59 PA11 data for patients with PM 
n = 21 ng/ml ng/ml ng/ml % 
PM Stage Total PA11 Latent PAl1 Active active Gender Age 
PAl1 PAl1 
1 1 40 14 26 65 M 64 
2 1 39 28 11 28 F 50 
3 2 45 21 24 53 M 59 
4 2 43 17 26 60 M 58 
5 2 22 13 9 41 F 60 
6 2 53 25 28 53 M 62 
7 1 32 15 17 53 M 48 
8 2 60 23 37 62 M 62 
9 1 69 24 45 65 M 56 
10 2 31 14 17 55 M 54 
11 2 196 49 147 75 M 56 
12 1 16 7 9 56 F 45 
13 2 694 279 415 60 F 63 
14 1 46 24 22 48 M 64 
15 2 1257 797 460 37 M 69 
16 2 45 29' 16 36 F 71 
17 1 120 29 91 76 M 51 
18 2 29 13 16 55 F 63 
19 2 15 5 10 67 F 57 
20 2 41 23 18 44 M 73 
21 2 22 9 13 59 M 80 
Min 15 5 9 28 M = 14 45 
Max 1257 797 460 76 F=8 80 
Mean 139 69 69 55 60.2 
SD 295 176 127 12.4 8.5 
Median 43 23 22 55 60 
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A.60 PAl1 data for patients with AM 
n = 18 ng/ml ng/ml ng/ml % 
AM Stage Total PAl1 Latent PAl1 Active Active PAl1 Gender Age 
PAl1 
1 3 528 227 301 57 M 43 
2 4 78 21 57 73 M 70 
3 4 135 62 73 54 F 63 
4 4 83 60 23 28 M 59 
5 4 37 21 16 43 F 64 
6 3 181 140 41 23 F ? 
7 3 49 31 18 37 F 58 
8 3 12 6 6 50 F 50 
9 3 24 11 13 54 M ? 
10 4 36 14 22 61 F 83 
11 4 25 17 8 32 M 85 
12 3 15 11 4 27 F 36 
13 3 189 112 77 41 F 59 
14 4 110 70 40 36 F 79 
15 3 40 28 12 30 M 58 
16 3 9 5 4 44 F 38 
17 3 11 4 7 64 M 21 
18 4 27 9 18 67 M 88 
Min 9 4 4 23 M=8 21 
Max 528 227 301 73 F = 10 88 
Mean 88 47 41 46 59.6 
SD 124 59 69 15.1 19 
Median 39 21 18 44 59 
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